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OBJECTIVES 1  
1 Objectives 
 
The human matrix metalloproteinases 19 and 28 (MMP-19 and -28) are abundantly 
expressed in epithelial tissues. However, their functions in this compartment and their 
functional overlap have not been elucidated so far. MMP-19 contributes to IGF-signaling, 
cell proliferation, and migration and is able to cleave several soluble proteins and 
components of extracellular matrix, including those found in the basement membrane. 
MMP-28 was shown to be important in wound healing. 
Functional studies on MMP-19 and -28 were performed mainly in vitro, but their role in 
vivo is largely unknown. Mouse models are commonly used to establish functions of 
molecules in a living organism, which then enables us to draw conclusions to the human 
system. Mice with a functional deletion of a specific gene, so called knockout mice, are 
widely used to determine the in vivo role of the gene. Thus, the phenotype of such mice 
can characterize the function of the targeted molecule. 
To study the function of both MMPs in vivo, mice with targeted disruption of the Mmp19 
and Mmp28 genes were generated. Since little is known about the role of MMPs in 
inflammation, and as both MMP-19 and -28 show constitutive expression in the 
epithelium, the main goal of the work presented here was to reveal the impact of 
deletion of these MMPs in inflammatory reactions of the colon.  
In order to delineate the role of MMP-19 and MMP-28 in the pathogenesis of induced 
colitis and, in a wider context, in the innate immunity of the intestine, the following aims 
were defined:  
1. To establish the DSS-induced colitis model. 
2. To elucidate MMP-19 and -28 functions in acute inflammation in the colon, so called 
acute colitis. 
3. To analyze the influence of MMP-19 and -28 during the healing phase, so called 
recovery phase after an acute colonic inflammation. 
4. To determine long-term effects of MMP-19 deficiency in chronic inflammation. 
Analyzing the function of MMP-19 and MMP-28 in the colon using single and double-
deficient mice can provide new insights into the pathophysiological role of these 
proteases in maintaining the epithelial barrier, especially in inflammatory reactions and 
immune responses. Furthermore, these studies can improve the understanding of MMP 
activity in healthy and inflamed colonic tissue and define a role of these proteolytic 
enzymes in inflammatory bowel disease (IBD).   
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2 Introduction 
 
 
2.1 Intestine and epithelial barrier function 
 
2.1.1 Intestine – a brief overview 
 
The gut consists of the small and large intestine. The small intestine of vertebrates follows 
the stomach and is followed by the large intestine. It consists of three parts: the 
duodenum, the jejunum, and the ileum. The primary function of the small intestine is the 
digestion and absorption of nutrients and minerals found in food. The large intestine also 
comprises three parts: the caecum, the colon, and the rectum. 
As the colon is central for the analyses in this work, this part of the large intestine will be 
described in more detail. In mammals, the colon consists of four sections: the ascending 
colon, the transverse colon, the descending colon, and the sigmoid colon. The colon is the 
last part of the digestive system; it extracts water and salt from solid wastes before they 
are eliminated from the body, and is the site, in which flora-aided (largely bacterial) 
fermentation of unabsorbed material occurs. Unlike the small intestine, the colon does 
not play a major role in absorption of foods and nutrients. However, the colon does 
absorb water, potassium and some fat soluble vitamins [1]. 
 
2.1.2 Architecture of the colonic wall 
 
The large intestine of all mammals consists of several concentrically arranged layers, as 
the other organs of the digestive tract: lamina mucosa, lamina propria, lamina muscularis 
mucosa, lamina submucosa, lamina muscularis externa, subserosa, and serosa. 
 
Figure 2-1: Schematic representation of the general structure and layers of the colon.  
Taken from http://www.aboutcancer.com. 
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The mucosa lines the large intestinal lumen and lies at the critical interface between the 
external environment and the body’s internal milieu. This is reflected in the mucosa being 
one of the most dynamic tissues in the body. The mucosa is comprised of an epithelium 
and a basement membrane, supporting connective tissue called the lamina propria, and a 
sheet of smooth musculature, the lamina muscularis. The luminal surface of the ceacum 
and colon wall is rich in microflora that is important for digesting complex carbohydrates 
and synthesizing products, such as vitamins and amino acids. Therefore, a barrier that 
avoids invasion by bacteria but is also permeable for water and ions, is essential. A simple 
epithelium lines the lumen and includes absorptive and secretory cells as well as varying 
numbers of goblet cells that produces mucin. The mucin coats the epithelium and is an 
integral and important part of the innate barrier against penetration of foreign 
substances. In addition, some lymphoid cells can be found in the epithelium, the 
intraepithelial leukocytes (IEL). It has been reported that IELs might be involved in the 
downregulation of the local immune response, preventing an over-reaction against 
luminal antigens crossing the epithelium. At the bottom of the crypts, a pool of 
undifferentiated cells (stem cell-like cells) persists in the so called proliferative area, 
which generates new cells that migrate to the epithelial layer. The turnover of the cells in 
the intestine is one of the fastest in the body. The basement membrane of the epithelium 
is supported by connective tissue elements, called lamina propria. In this layer, fibroblasts, 
endothelial cells, some smooth muscle cells, and a large number of immune cells 
(lymphocytes, plasma cells, macrophages, mast cells, eosinophils, and dendritic cells) are 
located. The numbers of immune cells vary with the state of inflammation in that area [2; 
3]. The outer boundary of the mucosa is formed by a thin layer of smooth muscle cells, 
the lamina muscularis mucosa. This sheet only consists of two to six layers of cells [4]. The 
submucosa consists of connective tissue bordering the lamina muscularis mucosa and the 
outer two layers of smooth musculature (lamina muscularis externa). Cell types present in 
this area are mainly fibroblasts, some macrophages, mast cells, few eosinophils, and 
plasma cells. All cells are embedded in a matrix of loosely packed collagen bundles and 
some elastin fibres. There are also large arteries and veins present that branches to both 
the lamina mucosa and the lamina muscularis externa [5].  
 
2.1.3 The epithelium – barrier function and interface to the gut lumen 
 
Mucosal surfaces are lined by a simple epithelium. Epithelial cells establish and maintain a 
barrier between the external environment and the internal milieu. The mammalian 
intestine is covered by a single layer of epithelial cells that is renewed every 2–3 days. The 
function of the epithelium is enhanced by protective effects of products of goblet cells 
(mucins, trefoil peptides) in the intestine, which are secreted onto the mucosal surface. 
Functionally, the barrier results from tight junctions connecting the epithelial cells. 
Transmembrane proteins such as claudins play a crucial role in building and determining 
the function of tight junctions; claudins are regulated by several cytokines (e.g. TNF-α) 
and occludins, transmembrane proteins that can regulate the barrier. These proteins may 
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be a link between barrier function and inflammatory and immune response. Just as 
important as knowing how the epithelium is forming an effective barrier is the analysis of 
the epithelium playing an active role in the mucosal immune response. The epithelium 
mediates innate immune responses by expressing a large number of Toll-like receptors 
(TLRs) that serve as a pattern recognition receptors (PRRs) for microbial products such as 
LPS (binding to TLR-4), bacterial DNA (TLR-9) and viral replication intermediates (TLR-3) 
[6; 7]. These receptors enable epithelial cells to sample and monitor the intestinal flora 
and react on the luminal bacterial changes with an appropriate output of chemokines and 
cytokines. There are further PRRs expressed by the epithelium, including the NOD 
proteins, which serve as a signal transduction unit sensing contents of the lumen and co-
ordinating a mucosal response to potential pathogens. Key cellular components 
mediating the mucosal immune response are antigen-presenting cells such as dendritic 
cells (DCs) and mucosal lymphocytes. DCs can be primed by antigens that permeated the 
epithelial barrier or been obtained by direct luminal sampling. They stimulate Th1 
lymphocytes, which produce cytokines (mainly IL-2 and IFN-γ, also others) that results in 
the activation of macrophages. Active macrophages produce a broad spectrum of 
cytokines and other mediators, including IL-12, IL-18 and more IFN-γ, which further 
stimulates Th1 lymphocytes to create a feedback cycle. IL-1, IL-6, and TNF-α are also 
released by macrophages, which leads to the amplification of the inflammatory response 
by stimulating other, diverse cell types. Several chemokines are involved as well, for 
example MIF (macrophage inhibitory factor) that enhances the expression of TLR-4. The 
main signaling pathways involved in this activation of key immune and inflammatory cells 
are the NF-κB (nuclear factor-kappaB), the MAP (mitogen-activated protein) kinase and 
the PI3 (phosphotidyl inositol) kinase pathways [8; 9; 10].  
 
 
Figure 2-2: Barrier function of the intestinal epithelium. 
In case of defective barrier bacterial contents can enter the tissue, activate macrophages and T 
cells, which then produce pro-inflammatory cytokines such as TNF-α. Taken from [11]. 
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As the epithelium of the intestine is a very dynamic area with a very short turn-over in 
comparison to other tissues, repair and healing processes also occur fast under normal 
conditions. Such processes start with an initial phase called restitution [12; 13] in which 
the continuity of the surface epithelium is re-established. This is done by extension and 
migration of the epithelial cells from the edge of the wound (mucosal ulceration), cell 
proliferation, the production of extracellular matrix components, and finally remodelling 
to rebuild the normal intestinal architecture. Restitution provides a rapid mechanism for 
covering a defect in the barrier and does not involve proliferation of epithelial cells [12; 
14]. It results in an area that, while protected, is not physiologically functional. Healing 
requires that the epithelial cells on the margins of the defect proliferate, differentiate, 
and migrate into the damaged area to restore the normal cellular architecture and 
function. These events are regulated by cytokines, growth factors (EGF, TGF-α) and trefoil 
factors [15; 16]. Remodelling is also dependent on the balance between the production of 
extracellular matrix (ECM) components, matrix metalloproteinases (MMPs) and their 
inhibitors, the tissue inhibitors of metalloproteinases (TIMPs)[17]. 
To know about the function of the epithelium is important to understand the 
susceptibility to IBD, as there are several mouse mutant lines deficient in the expression 
of epithelial-specific proteins (e.g. keratin-8, intestinal trefoil factor (ITF)) that 
spontaneously develop colitis [18]. A better knowledge of mucosal physiology would 
provide important insights into the pathology of IBD, which is still incompletely 
understood. Also, the impact of MMPs on the development, onset, and recovery of the 
disease remains elusive. 
 
 
2.2 Inflammatory Bowel Disease (IBD) 
 
Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders of the 
gastrointestinal tract. In the Western World about 1 in 1000 people is affected by this 
relapsing and remitting disease, which is still incurable. Genetic, psychosomatic, and 
environmental factors such as gut flora and nutrition are known to be involved in the 
onset as well as progression of the disease. The onset of IBD typically occurs in the second 
and third decades of life and a majority of affected individuals progress to relapsing and 
chronic disease. Family aggregation has long been recognized. The inheritable component 
seems stronger in Crohn’s disease than in ulcerative colitis [19; 20]. 
The two major types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). There are 
also other forms of IBD that are less prevalent, e.g. collagenous colitis or lymphocytic 
colitis [21; 22; 23]. The main difference between Crohn’s disease and ulcerative colitis is 
the site of inflammation: UC is restricted to the large intestine whereas CD can occur in 
the small and/or the large intestine (Figure 2-3). 
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Figure 2-3: Schematic representation of the affected areas of patients suffering from IBD.  
Both CD and UC are characterized by mucosal ulceration, which is continuous and restricted to 
the colon in UC but patchy and possibly spread through the whole intestinal tract in CD. Taken 
from http://www.hopkinsmedicine.org. 
 
Histologically, ulcerative colitis is restricted to the mucosa, while Crohn’s disease is 
affecting the whole bowel wall. Key features of UC include diffuse mucosal inflammation 
extending proximally from the rectum to different intensities. Together with severe 
inflammation and the associated production of a complex mixture of inflammatory 
mediators, extensive superficial mucosal ulceration develops [19]. Histopathological 
features include the accumulation of neutrophils within the lamina propria and the crypts, 
where they form micro-abscesses (Figure 2-4). Depletion of goblet cell mucin is also 
common. In contrast, CD is rather characterized by the aggregation of macrophages that 
frequently form granulomas (Figure 2-4). Although any site of the gastrointestinal tract 
may be affected, involvement of the terminal ileum is most common [19; 23].           
                      
                                         Crohn’s disease                                  ulcerative colitis 
 
Figure 2-4: Histological features of IBD: CD versus UC.  
Crohn’s disease-biopsy from a terminal ileum with active disease. The picture shows a granuloma 
composed of compact macrophages, giant cells, and epithelioid cells. The nodule is surrounded by 
marked infiltration of lymphoid cells, plasma cells and other inflammatory cells. Ulcerative colitis-
colonic mucosal biopsy was taken from a patient with active disease as well. The crypt abscess is 
composed of transmigrated neutrophils and the surrounding epithelium exhibits features of acute 
mucosal injury. Adapted from [23].  
CD UC 
IBD 
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The main clinical features of IBD are diarrhoea, abdominal pain, blood loss, loss of 
peristaltic function, and bowel obstructions. Both diseases are associated with several 
extra-intestinal manifestations such as liver problems, arthritis, skin manifestations and 
eye problems [24; 25]. In general, people suffering from IBD have a higher risk of 
developing colon cancer, especially those with UC [26]. 
Concerning the cytokine secretion by activated lymphocytes, a typical and strong T helper 
type 1 (Th1) cytokine profile (increased secretion of tumor necrosis factor (TNF)-α, 
interleukin (IL)-2, interferon (IFN)-γ, IL-12, IL-18) was described in individuals suffering 
from CD, in contrast to much weaker support for a T helper type 2 (Th2) pathogenesis 
(increased secretion of IL-4, IL-5, IL-10) in UC patients [27; 28; 29; 30; 31; 32]. While Th1 
cytokines are not raised in UC, there is only little evidence for increased Th2 cytokine 
levels. However, the presence of autoantibodies, such as the anti-neutrophil 
cytoplasmatic antibody, is suggestive of a Th2 pathogenesis in UC [33]. A massive 
overexpression of matrix-degrading enzymes was also found in fibroblasts in UC. These 
cells are ultimately responsible for ulceration and fistula formation [34; 35]. 
 
2.2.1 Factors leading to IBD 
 
Genetic and environmental factors act together to cause inflammation in IBD. In 
susceptible individuals, the luminal microflora can provide antigens and adjuvants that 
stimulate either pathogenic or protective immune responses. Environmental triggers are 
necessary to initiate or reactivate the disease (Figure 2-5). 
 
 
 
Figure 2-5: Interaction of various factors influencing IBD. 
The main factors contributing to the development of IBD are a genetic susceptibility and an 
impaired immune response; both are influenced by the luminal bacteria. Several environmental 
triggers are necessary to initiate the disease. Adapted from [36]. 
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Concerning environmental factors, it has to be stated that both UC and CD are 
predominantly associated with industrialized temperate regions and are rare in tropical 
countries with poor sanitation and a low level of overcrowding. The highest incidence 
rates and prevalence of UC and CD have been reported from northern Europe, the UK, 
and North America. Low incidence areas can be found in southern Europe, Asia, and most 
developing countries [37]. Interestingly, migration to developed countries leads to an 
increased risk of coming down with IBD [38; 39; 40], further supporting the hypothesis 
that genetic factors are not solely responsible for the disease. Various environmental 
factors have been proposed to contribute to the enhanced risk of IBD in industrialized 
countries; including nutrition, infections [41; 42], smoking status [43; 44; 45; 46; 47], and 
the level of stress experienced [48; 49; 50]. 
Ulcerative colitis and Crohn’s disease are polygenic diseases (Figure 2-6). Genetic 
predisposition was further substantiated by the discovery of susceptible regions on 12 
chromosomes so far. Susceptible loci for UC were found on chromosome 12, for CD on 
chromosome 5, 14, and 16, and on chromosome 1, 6, and 19 for both UC and CD [21; 51; 
52]. Alterations in genes of the immune system such as NOD2, IL23R and ATG16L1 are 
specifically associated with CD in white populations but are not observed in patients 
suffering from UC [53; 54; 55]. 
Concerning NOD2, three major polymorphisms in or around the external leucine-rich 
repeat within the recognition region of the nucleotide-binding oligomerization domain 
molecule 2 (NOD2) on chromosome 16 were detected [54; 56]. Nod molecules (NOD1 and 
NOD2) together with Toll-like receptors (TLR1 to 9) belong to the pattern recognition 
receptor family, which are expressed by gut epithelial cells, monocytes, and particular 
dendritic cells (DCs) in the intraepithelial and subepithelial layers. These cells are 
specialized for sampling microbial and other luminal antigens [57; 58] already within the 
gut by sending long dendrites into the lumen.  
Therefore, a genetically determined disturbance in recognizing the conserved pathogen 
associated molecular patterns (PAMPs) of these microbial antigens and/or subsequent 
signaling may result in decreased activation of nuclear factor κB (NF- κB), which is a 
pivotal transcriptional factor controlling proinflammatory cytokines. A consequence of 
mutations in NOD2 may therefore be a decreased ability to kill pathogenic gut bacteria 
[59; 60]. In addition, there is a possible role for TLR4 polymorphisms in IBD suggested by 
the observation that mice with a missense mutation of the Tlr4 gene have a high 
incidence of spontaneous colitis [61; 62]. Altogether, mutations in PAMP signaling seem 
to be generally associated with IBD, and diminished PAMP signaling itself may be a 
contributing factor to the development of the disease [63]. Interestingly, NOD2 has not 
been found to be associated with CD in Japan [64], highlighting the complex nature of this 
disease. 
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Figure 2-6: IBD immune network. 
Genes specific for both CD and UC (orange ellipses), for CD (green ellipses) and for UC (pink 
ellipses) have been identified. Previous and current data from animal models indicate that IBD-
associated genes are positively (blue lines) or negatively (red lines) linked together, making a 
complicated network. For example, both NOD2 and autophagy, which are primarily involved in 
epithelial defense against commensal microbiota, are controlling IL-23/Th17 axis through antigen 
presentation. The IL-23/Th17 axis can directly activate epithelial defense through IL-22 and also 
represent a key determinant of differentiation of effector versus regulatory immune responses. 
Regulatory immunity can modify the IL-23/Th17 axis and also influence epithelial defense. Taken 
from [65]. 
 
It is also known that the gut microbial flora plays an important role in the induction of IBD. 
Multiple bacterial strains as well as special bacterial products (e.g. flagellin, LPS) are able 
to induce proinflammatory cytokines like TNF-α and interleukin-8 (IL-8) in macrophages 
and epithelial cells in the gut [66]. In general, it was shown that experimental colitis 
cannot develop when mice are kept in a germ-free environment [67; 68]. This suggests 
that the normal intestinal microflora is required to initiate or maintain the inflammatory 
process of IBD. A dysregulation of the gut flora could be one of the causes of IBD. There is 
also some indication that IBD could be considered an autoimmune disease as antigens 
(bacteria) are present in the body from birth onwards and, to some degree, have always 
access to the internal milieu. Thus, in case the immune system fails to differentiate 
between self and foreign antigens, an autoimmune reaction against the normal intestinal 
flora might be the consequence [69; 70]. 
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2.2.2 Animal models of IBD 
 
Several animal models have been developed to mimic IBD. In an ideal model, the key 
characteristics like morphological alterations, inflammation, symptoms, pathophysiology, 
and course of disease are similar to human IBD. Treatments applied should exhibit the 
same effects. The genetic background of the animal should be well defined and the 
immune system well characterized. Environmental factors, especially nutrition and 
enteric flora, should be controllable, and the induction of colitis should be stable, 
reproducible, and predictable.  
Mice are relatively easy and cheap to maintain compared to other mammals, have a short 
reproduction cycle, and allow genetic manipulation, including the cell type specific 
deletion of genes. The mouse genome is 95% identical to that of humans. Inbred strains 
provide a stable and characterized genetic background. Furthermore, mice, if bred in 
animal facilities equipped with individually ventilated cages (IVC), environmental factors 
and microflora can be controlled (reviewed in [71]). 
Commonly used animal models for IBD include gene knock-out, chemically induced, and 
adoptive transfer models (Figure 2-7). The IL-2 knock-out [72] and IL-10 knock-out [73] 
mouse models are examples for gene knock-out models of IBD; in both models colitis is 
most probably due to an increased Th1 immune response accompanied by a lack of 
regulatory T-cells. Inducible colitis models include the induction by 2,4,6-trinitrobenzene 
sulfonic acid (TNBS) enema or dextran sulfate sodium (DSS) [74; 75; 76; 77; 78; 79; 80]. 
TNBS and DSS are thought to induce colitis by damaging the mucosal barrier [77; 78; 81; 
82]. Frequently applied adoptive transfer models use the transfer of CD4+ T-cells 
expressing high levels of CD45RB (CD45Rbhigh) [83] or the marker for naive T-cells CD62L 
[84] into mice with severe combined immunodeficiency (SCID). 
A shared characteristic of the described models (Figure 2-7) is the combined impact of 
genetic factors, intestinal flora and other environmental triggers on the severity of the 
inflammation [85; 86; 87; 88] 
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Figure 2-7: Overview of Mouse Models of Inflammatory Bowel Disease. 
Several mouse models for IBD are known, including various gene-deficient mice as well as 
chemical models, and T cell transfer models, which allow studying different aspects of the disease. 
Taken from [89]. 
 
2.2.2.1 Induction of colitis by dextran sulfate sodium (DSS) 
Dextran sulfate sodium (DSS) is a heparin-like polysaccharide containing up to three 
sulfate groups per glucose molecule (Figure 2-8). Induction of colitis in rodents by 
application of DSS in the drinking water is a widely used and well characterized model of 
colitis in mice, first described by Okayasu et al. 1990 [80]. Morphological changes are 
similar to human ulcerative colitis [80]. Additionally, anti-colitis drugs applied in human 
ulcerative colitis such as sulfasalazine, olsalazine and mesalazine have a therapeutic effect 
in DSS colitis [90; 91]. The inflammation is restricted to the large intestine [80; 92]. 
Erosion and inflammation of the mucosa are both most frequent and severe in the distal 
part of the colon [74; 80; 92]. Its severity is dependent on the concentration of DSS [93], 
but also on the molecular weight [75]. Concentrations described in the literature range 
between 1% and 7%. The most commonly used molecular weight is 40,000 Da. 
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Figure 2-8: Chemical structure of dextran sulphate sodium (DSS). 
The picture was taken from www.sigmaaldrich.com/fluka/product. 
 
The exact mechanism of colitis induction by DSS remains unknown. A direct toxic effect 
on the epithelium could lead to the inflammation [94]. In the acute phase (from day 3 to 
7), prior to the appearance of inflammatory processes, an increased permeability of the 
intestinal mucosa has been shown [81]. Due to the damage of the epithelial barrier, toxic 
products of luminal bacteria such as endotoxin or peptidoglycans might permeate into 
the mucosa causing damage to the epithelial cells of basal crypts and thereby inducing an 
inflammatory reaction. As DSS is taken up by macrophages, inhibition of phagocytic 
capacity is another possible mechanism rendering the intestinal epithelium more 
susceptible to bacterial infection [74]. 
The role of lymphocytes in the induction and maintenance of the disease is a matter of 
debate and published results have so far been contradictory. Acute DSS-induced colitis 
occurs in SCID-mice, lacking B- and T-lymphocytes [95; 96], though in Rag-1 knock-out 
mice, lacking lymphocytes in general, severity of DSS-induced colitis is decreased 
dramatically [97]. While acute DSS-induced colitis is characterized by proinflammatory 
cytokines e.g. IL-1 and TNF-α accompanied by the Th1 immune response through the 
expression of IL-12 and IFN-γ [93], chronic DSS-induced colitis shows a mixed Th1/Th2 
cytokine profile [98]. 
Another controversy in the DSS model is the effect of enteric bacteria: On one hand, it 
was shown that DSS treatment of germfree IQI/Jic mice leads to an even more severe 
colitis compared to SPF mice [99]. On the other hand, it was reported that the molecular 
weights of DSS in the feces were the same as those of the DSS in the drinking water [75], 
suggesting that the chemical cannot be degraded by gut bacteria in the intestinal lumen . 
Antibiotic treatment improves acute DSS colitis but has no effect on established chronic 
colitis [100]. 
Several studies using mouse models to analyze Toll like receptor (TLR) signaling have 
suggested a role of this pathway in DSS-induced colitis. While MyD88 knock-out mice 
showed severe colitis after DSS treatment that is refractory to antibiotic treatment [101], 
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colitis in TLR9 knock-out mice was reduced compared to wildtype mice [102], indicating 
that disturbance of multiple TLR-pathways is detrimental for the homeostasis of the 
intestinal epithelium, while CpG-motifs of the bacterial flora might trigger DSS-induced 
colitis. Recently, probiotic bacteria, such as Proprionibacterium freudenreichii, 
Bifidobacterium infantis and Bifidobacterium adolescentis have been reported to be able 
to attenuate DSS colitis [103; 104; 105]. Mähler et al. described the influence of inbred 
background on the extent and severity of colitis after exposure to DSS: significant 
differences for all parameters scored have been found for all strains. Susceptibility to 
caecum lesions decreased from C3H/HeBir, C3H/HeJ, C57BL/6J to 129S2/SvPas. 
Concerning lesion formation in the colon, C3H/HeBir, C3H/HeJ, C57BL/6J and 
129S2/SvPas mouse strains were highly susceptible whereas, DBA/2J was less susceptible 
to DSS [86; 102]. Melgar et al. found that five days of treatment with 3% for C57BL/6 and 
5% for BALB/c strains revealed similar symptoms in the acute phase. However, disease 
resolved in BALB/c mice but became chronic in C57BL/6, indicating that BALB/c are more 
resistant to DSS than C57BL/6 mice [106]. 
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2.3 Matrix metalloproteinases (MMPs) 
 
 
MMPs, also known as matrixins, build a large family of highly homologous zinc-dependent 
endopeptidases, which are widely distributed in all kingdoms of life [107]. They belong to 
the superfamily of metzincin proteases, together with a disintegrin and 
metalloproteinases [108] [108] and ADAM proteases with thrombospondin motifs 
(ADAMTSs) [109]. MMPs play important roles in many physiological processes such as 
embryonic development, wound healing, and tissue repair. However, they also show 
unwanted activities in a variety of disorders, including cancer, arthritis, and cardiovascular 
diseases [110; 111; 112; 113; 114]. Although they are best known for their capacity to 
degrade extracellular matrix (ECM) components, they have become increasingly 
recognised for their functions in processing of cell surface receptors, chemokines and 
signaling molecules [115]. 
 
2.3.1 Classification and substrate specificities 
 
The 24 MMPs that have been identified in humans to date can be classified in two main 
groups based on their structural characteristics: secreted-type and membrane-anchored 
or membrane-type (MT)-MMPs (Figure 2-9). Domain organisation and substrate 
specificity are criteria for further division [116]. The molecular structure shared by most 
MMPs consists of four functional domains: a signal peptide that targets them for 
secretion, a propeptide of around 10 kDa containing the conserved cysteine switch motif 
PRCGXPD, a catalytic domain of around 20 kDa featuring the conserved zinc-binding motif 
HEXXHXXGXXH, and a C-terminal hemopexin-like domain of around 30 kDa that mediates 
substrate and inhibitor interactions. A linker peptide of variable length, also called the 
‘hinge region’, separates the catalytic domain from the hemopexin-like one. Divergence 
from this basic core design reflects the evolution of MMPs into distinct subgroups. The 
secreted-type MMPs can be further divided into collagenases, stromelysins, gelatinases, 
matrilysins, and other MMPs, according to differences in structure as well as substrate 
specificity (Figure 2-9). MMP-1, MMP-8 and MMP-13 are designated as collagenases and 
have the ability to cleave collagens I, II and III at a specific site three-fourths of the 
distance from the N-terminus [17; 107]. In addition, they are also able to proteolytically 
process other ECM proteins as well as certain cytokines such as IL-8 [117] and TNF [118]. 
Stromelysins, which share their structural design with the collagenases, degrade a variety 
of ECM components but are not able to cleave native collagen. Other substrates of the 
stromelysins include stromal-cell derived factor-1, E-cadherin, and pro-interleukin-1 beta 
[119]. The gelatinases comprise two members, MMP-2 (gelatinase-A) and MMP-9 
(gelatinase-B). They feature three fibronectin type II repeats located inside the catalytic 
domain which facilitate binding and digestion of denatured collagens (gelatines). Collagen 
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types I, IV, V, VII, X, IX, elastin, fibronectin, aggrecan, vitronectin, and laminin are among 
the substrates for gelatinases as well as various non-ECM molecules like pro-TNF, TGF-β, 
pro-IL-1β, pro-IL-8, and monocyte chemoattractant protein (MCP)-3 [118; 119; 120; 121]. 
MMPs with the simplest domain arrangement of all are the matrilysins (MMP-7 and 
MMP-26) as they lack the hinge region and the hemopexin domain. Whereas both family 
members share the ability to degrade ECM proteins like type IV collagen, laminin, and 
entactin, they also exhibit differential activities: MMP-7 mediates the ectodomain 
shedding of several cell surface molecules like Fas ligand [122], E-cadherin [123], and 
syndecan-1 [124], and MMP-26 has been shown to activate proMMP-9 (see 1.2 
Regulation of MMP activity). In comparison, only little is known about other secreted-
type MMPs which diverge too much in sequence and substrate specificity to be classified 
in one of the previous subgroups. MMP-11 shows weak proteolytic activity against a 
number of ECM components such as collagen type VI, gelatine, and laminin but it also 
digests α1-proteinase inhibitor and insulin-like growth factor binding protein-1 (IGFBP-1). 
MMP-12 or metalloelastase is a very potent enzyme for degradation of the fibrous ECM 
protein elastin [17; 107; 116]. 
The group of MT-MMPs includes type I and type II transmembrane MT-MMPs as well as 
GPI-anchored MT-MMPs (Figure 2-9). The type I transmembrane proteases comprise 
MT1-MMP (MMP-14), MT2-MMP (MMP-15), MT3-MMP (MMP-16) and MT5-MMP 
(MMP-24). They are characterized by a long hydrophobic sequence followed by a short 
cytoplasmic tail that is involved in numerous cellular events, such as activation of 
MERK/ERK and src-tyrosine pathways. Besides their capacity to cleave a variety of 
substrates including ECM components, they are the major physiological activators of 
proMMP-2. MT4-MMP (MMP-17) and MT6-MMP (MMP-25) belong to the GPI anchored 
MT-MMPs. In contrast to the low enzymatic activity of MT4-MMP against ECM proteins, 
MT6-MMP potently processes gelatin, collagen IV, fibronectin, fibrin, and proteoglycans. 
The two members of the type II transmembrane MT-MMPs, MMP-23A and MMP-23B, 
have identical amino acid sequence, but are encoded by distinct genes. They are unique 
among the matrixin family as they lack the signal peptide, the cysteine-switch motif and 
the hemopexin domain. Instead, they contain cysteine array and immunoglobulin 
domains in their shortened cytoplasmic tail. So far, no substrate for the MMP-23 enzymes 
has been identified [17; 107; 116].  
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Figure 2-9: Classification of MMPs based on structural characteristics. 
Adapted from [107]. 
 
2.3.2 Regulation of MMP activity 
 
MMP activity is regulated at three main levels: gene transcription, posttranslational 
activation of zymogens, and interaction of MMPs with inhibitors [110; 113]. Additional 
mechanisms that fine-tune MMP activity include mRNA stability, cell-surface recruitment, 
and autolysis [113] (Figure 2-10).  
 
2.3.2.1 Transcriptional regulation 
Transcription is considered as key regulatory step for most MMPs (excluding MMP-2) 
[107; 110; 113]. Whereas under normal physiology, the majority of MMPs is expressed at 
low or non-detectable levels, their gene transcription can be induced in a highly cell and 
tissue specific manner by a variety of signals. These include pro-inflammatory cytokines 
such as TNF-α, IL-1, and IFNs, growth factors such as EGF, KGF, and VEGF, and ECM 
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proteins or cell-cell interaction [113] (Figure 2-10). The main signaling pathways involved 
are the p38 mitogen activated protein kinase (MAPK, ERK1/2) pathways, the NF-κB, and 
the JAK-STAT pathways [107; 113]. MMP-1 transcription, for example, is induced in 
dermal fibroblasts in response to IL-1 via MAPK signaling. This pathway activates 
members of the Jun and Fos families of oncoproteins, which bind to the AP-1 
transcription-factor binding site. The AP1-site is thought to be the major mediator of 
MMP gene regulation and is present in most MMP promoters. The polyomavirus 
enhancer-A binding protein-3 (PEA3) site, which binds oncoproteins of the ETS family, is 
another important transcription-factor binding site shared by many MMPs. It is thought 
to act cooperatively with the AP-1 site to promote MMP production in cancer cells. 
Transcription of MMP-1, -3, -9, -13 and -14 can be induced by TNF-α through NF-κB 
signaling, and the effect of interferons on MMP expression are mediated by STAT sites 
[107; 113; 125]. Constitutive expression, as observed for MMP-2, MT1-MMP, and MMP-
28, is associated with the lack of a TATA box and the presence of the GC cis-element, 
which binds the ubiquitous Sp1 family of transcription factors [125].  
MMP transcription can also be influenced by genetic variation in the promoter region of 
MMP genes, which affects affinities for transcription factors or creates or abolishes 
transcription factor binding sites. Such functional polymorphisms have been 
demonstrated in various MMP genes, for example MMP-2, MMP-3, MMP-9, and MMP-12, 
and are often associated with disease susceptibility [125].  
 
2.3.2.2 Activation of zymogens 
MMPs are initially synthesized as inactive zymogens (proMMPs) with a pro-peptide 
domain that must be removed to activate the enzyme (Figure 2-10) [17; 116]. In its 
inactive conformation, the cysteine in the propeptide (the ‘cysteine switch’) ligates the 
catalytic zinc to maintain latency of the proMMP. For activation, the prodomain of MMPs 
is removed in an autocatalytical manner or by other proteases, and the cysteine is 
replaced by a water molecule to allow enzyme catalysis to proceed. Dependent on the 
type of MMP, this process takes place either in the pericellular space, intracellularly or at 
the cell surface. Most MMPs are secreted as proMMPs and activated by other active 
MMPs or serine-proteases. For example, MMP-1, MMP-2, and MMP-26 are able to 
activate proMMP-9, and MMP-7 activates proMMP-1, proMMP-2, and proMMP-9. 
Plasmin is thought to be a major contributor to initiate extracellular proMMP activation 
via the cysteine switch. Some MMPs (MMP-11, MMP-28, and the MT-MMPs) can also be 
activated intracellularly. These proteases contain a conserved RXRXKR furin-like enzyme 
recognition motif between their pro- and catalytic domains and, thus, can be activated by 
furin, a serin protease, within the Golgi network [17]. MMP-2 is activated at the cell 
surface through a unique multistep pathway that involves MT1-MMP and the tissue 
inhibitor of metalloproteinases 2 (TIMP-2): The C-terminal domain of TIMP-2 facilitates 
non-inhibitory binding to the proMMP-2 C-terminal domain via electrostatic interactions 
to allow an adjacent free, active MT1-MMP to process proMMP-2 into an active enzyme. 
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More recently, it has also been suggested that proMMP-2 can be activated by coagulation 
factors such as protein C, thrombin, and factor Xa via an MT-MMP independent route [17; 
110; 113]. 
 
2.3.2.3 Interaction with inhibitors 
MMP activities are blocked by two major types of endogenous inhibitors: general 
inhibitors, such as α2-macroglobulin that are present in the plasma and tissue fluids, and 
by more specific inhibitors, such as TIMPs (Figure 2-10) [17; 126]. α2-macroglobulin is a 
glycoprotein, consisting of four identical subunits of 180 kDa. It inhibits most proteases by 
entrapping the proteinase within the macroglobulin, followed by clearance of the 
complex through receptor-mediated endocytosis (by Low density lipoprotein receptor-
related protein 1, LRP-1 (CD91)). Four human TIMPs (TIMP-1, -2-, -3- ,-4) have been 
identified; they are anchored in the ECM or secreted extracellularly. TIMPs consist of 184 
- 194 amino acids. The N-terminal region binds to the MMPs’ catalytic domain and 
inhibits MMP activity, whereas the C-terminal region interacts with the hemopexin 
domain of proMMP-2 and proMMP-9 to stabilize the proenzyme inhibitor complex. TIMPs 
inhibit all MMPs tested so far, although TIMP-1 is a poor inhibitor for most type I MT-
MMPs [17]. TIMP-3 has been shown to potently block MMP-2 and MMP-9 as well as the 
majority of ADAMs. TIMP-2 is unique in that it also functions as activator of MMP-2 by 
specific interaction with MT1-MMP and proMMP-2 at the cell surface (see above, 
Activation of zymogens) [17; 127]. 
Several other proteins have been described to inhibit MMPs: RECK, a GPI-anchored 
glycoprotein that suppresses angiogenesis, inhibits MMP-2, MMP-9, and MMP-14 [128]. 
Other molecules that can block MMP activity include TFPI2, a serine protease inhibitor, 
and PCPE, a C-terminal proteinase enhancer [17; 127]. 
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Figure 2-10: Levels of regulation of MMP expression and activity.  
Diverse regulatory signals, such as soluble factors, extracellular matrix (ECM)-cell interactions or 
cell-cell contacts interact with specific receptors at the cell surface and initiate a cascade of events 
that lead to the generation of functional matrix metalloproteinases (MMPs), which are localized 
to the cell surface (MT-MMPs) or secreted to the extracellular space (proMMPs). ProMMPs are 
activated in an autocatalytical fashion or by other activated MMPs. MMP activity can be inhibited 
by diverse endogenous inhibitors. Adapted from [113].  
 
2.3.3 MMP functions in health and disease 
 
MMPs play a primary role in many aspects of normal physiology, including embryonic 
development, cell migration, wound healing, and tissue resorption. At the same time, 
MMP deregulation is implicated in diverse human pathologies, like cardiovascular 
diseases, rheumatoid arthritis, neurological disorders, cancer, and other [107; 110; 113].  
Early characterisation of MMP knockout mouse models has provided insight into the role 
of some of the proteases: MMP-14 deficiency, for example, caused multiple abnormalities 
in the remodelling of skeletal and connective tissues, as well as impaired angiogenesis. 
Mice lacking MMP-20 had defects in tooth development and Mmp3-null mice showed 
altered mammary gland morphogenesis. However, the vast majority of MMP single-
knockout mice displayed no major physiological alterations, pointing towards 
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mechanisms of enzymatic compensation and redundancy. Transgenic mouse models 
overexpressing different members of the MMP family validated the contribution of the 
proteases to tumour progression, since high levels of MMPs often correlate with poor 
clinical outcome in cancer patients [107]. 
Several activities of the proteases can be linked to tumour growth: first, MMPs can 
support vascularisation by mobilising proangiogenic factors, such as basic fibroblast 
growth factor (bFGF), vascular endothelial growth factor (VEGF) or transforming growth 
factor-β (TGF-β) [115]; they can also process cell-adhesion molecules, thereby promoting 
cancer metastasis. MMP-7 has been shown to cleave the proapoptotic FAS ligand, 
allowing tumour cells to become resistant to apoptosis signals [113; 115]. Nevertheless, 
early clinical studies involving synthetic MMP inhibitors (MMPIs) have not shown the 
desired efficacy. In fact, MMPIs even promoted cancer progression in some cases by 
enhancing tumour vascularisation or expression of MMPs, such as MMP-9 in human 
fibrosarcoma cells. With hindsight, these results are not surprising as MMP function has 
turned out to be far more complex than previously thought. MMP-8, -12, and -19, for 
example, have been shown to act as tumour suppressors [129], and the sheddase 
activities of some MMPs has been linked to angiogenesis inhibition rather than promotion. 
MMP-2, -7, -9, and -12, for instance, can process plasminogen to release the potent 
angiogenesis inhibitor angiostatin [115]. Furthermore, MMPs have recently been 
demonstrated to be able to activate or degrade chemokines and cytokines [115]. In 
summary, MMPs exhibit functions that exceed their well-accepted role in extracellular 
matrix remodelling. Future therapeutic strategies for intervention with MMP activity 
need to consider their emerging roles as regulators of inflammation and cell signaling.  
 
2.3.4 MMPs in healthy and diseased colon 
 
2.3.4.1 MMP and TIMP protein expression in healthy colon 
Under normal conditions, MMPs are present at low levels, usually in the inactive form, 
and are responsible for normal tissue homeostasis. MMP-2 expression was observed in 
subepithelial and pericryptal fibroblast/myofibroblasts, in lamina propria mononuclear 
cells (macrophages and lymphocytes), and in vascular endothelial cells. Also some 
expression was seen in the laminar muscularis mucosa. In contrast, only a few cells in the 
lamina propria were found to express MMP-3 and MMP-9. Neither MMP-1 nor MMP-7 
was expressed in normal colon. MMP-10 expression was detected at low levels in colonic 
epithelial cells. Expression of their inhibitors TIMP-2 and -3 were observed in the 
epithelium of the colon as well as in few lamina propria mononuclear cells [130]. In 
addition, also MMP-19, -26, and -28 expression was shown in normal intestine [131]. 
Normal colonic epithelial cells express transcripts for MMP-1, -3, -7, -10, and -12. Weak 
expression for MMP-2, -8, and -9 could be found, whereas MMP-11, -13, and -14 were 
not detected at RNA level [132]. The inconsistence in detecting MMPs in healthy colon 
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tissue can be explained by using different methods for detection – immunostaining [130] 
versus mRNA analysis [132]. MMPs released by intestinal epithelium may be involved in 
the pathogenesis of IBD by promoting local mucosal damage. 
 
2.3.4.2 MMP and TIMP expression in intestinal epithelial cell lines 
MMP expression has been detected so far in several cell types of the intestinal mucosa, 
like myofibroblasts, smooth muscle cells, activated T cells, and macrophages. However, 
only little is known about expression pattern, regulation, and function of these 
proteinases in the epithelium of the gut. Spontaneous expression of MMP-1, -3, -7,-10,     
-11, and -13 was detected in several intestinal epithelial cell lines (HT-29, DLD-1), whereas 
other MMPs were undetectable [132]. After stimulation with TNF-α, levels of MMP-3, -10, 
and -13 were increased. MMP-12 mRNA, which was not expressed in unstimulated cells, 
could be induced by TNF-α treatment. By contrast, MMP-2, -8, -9, -14 mRNA remained 
undetectable even after cytokine exposure. TIMP mRNA levels remained unchanged as 
well. 
 
2.3.4.3 MMPs and TIMPs in IBD 
The expression and functional activity of several MMPs are increased in epithelial cells 
from patients with active IBD. Ulceration is a main feature of IBD. High levels of both 
MMP-1 and MMP-3 were detected in the granulation tissue around ulcers in specimens 
of IBD patients. Fibroblasts in these ulcers expressed MMP-13 and TIMP-3 [133]. The 
epithelium at the edge of the ulcers expressed MMP-7, which appeared to be important 
for re-epithlization after injury [134]. Myofibroblasts in the mucosa expressed high levels 
of MMP-1, -3 and -9 in IBD [135], whereas MMP-2 and -10 expression was increased in 
the epithelium [133; 136]. MMP-12 and MMP-14 were overexpressed in macrophages 
and myofibroblasts in the lamina propria of the inflamed gut. 
Similar to healthy colon, abundant MMP-2 expression was found in fistulae of Crohn’s 
disease samples. Differences could be seen between acute inflammation with granulation 
tissue and chronic inflammation characterized by fibrosis. In case of acute inflammation 
MMP-2 was detected in large mononuclear macrophage-like cells, and in endothelial cells, 
whereas during chronic inflammation the proteinase was localized in fibroblasts and large 
mononuclear macrophage-like cells. High levels of MMP-3 expression were detected in 
both types of inflammation and in the same cell types that expressed MMP-2. MMP-9 
protein was abundant in leukocytes, in granulocytes, and in giant cells in acute specimens, 
whereas only few granulocytes stained positive for the protease in the chronic state. 
MMP-1, -7, and -10 expression was virtually not detectable [130].  
Up-regulation of MMP activity in inflammation can induce a breakdown of the ECM, 
provided that levels between active MMP and their inhibitors are deregulated. This is 
believed to happen in patients suffering from IBD: an overproduction of MMPs in the 
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intestine and the failure to control their activity by TIMPs is probably the main cause of 
ulceration, tissue inflammation, and fistulae formation in CD and UC [137; 138; 139; 140]. 
Expression of MMPs and TIMPs is also deregulated in other diseases of the intestine, like 
enterocolitis (upregulation of MMP-3) [141], collagenase colitis (upregulation of TIMP-1, 
downregulation of MMP-1, -13) [142; 143] and colorectal cancer where MMPs are 
involved in metastasis (upregulation of MMP-1, -2, -3, -7, -9, -13, 14) [144]. In contrast to 
other MMPs, overexpression of MMP-12 is associated with increased survival in colon 
cancer [144]. 
 
2.3.4.4 MMPs and the intestinal immune system 
Many MMPs such as MMP-1 and MMP-7 play an important role in tissue homeostasis and 
the repair of different epithelial tissues [134]. However, there is increasing evidence that 
in addition to their direct effects on extracellular matrix, MMPs are also involved in 
immune responses, for example the recruitment of inflammatory cells to the intestine. 
Another possible mechanism of MMP action is the modulation of biologically active 
mediators (chemokines and cytokines) such as TNF-α and interleukins. The following 
section describes MMP functions in cell recruitment, chemokine and cytokine release, 
and antimicrobial peptide activation. 
The presence of MMPs is necessary for lymphocyte transmigration through the basement 
membrane [145; 146; 147; 148]. The role of MMP-9 in migration of neutrophils across the 
basement membrane is not well understood but TIMP-1, the preferential MMP-9 
inhibitor, was found to inhibit neutrophil migration. In several animal models of colitis, 
MMP inhibitors have been shown to reduce neutrophil accumulation in the intestinal wall 
[149; 150]. It was also reported that neutrophil infiltration is reduced in MMP-3- or  
MMP-12-deficient mice [151; 152]. MMP-3 was also shown to control the mobilization of 
T cells in the lamina propria [153]. 
MMPs can modulate biologically active mediators such as TGF-β, TNF-α, and interleukins 
(IL-1 and IL-6). They have the ability to shed the proinflammatory cytokines from the 
surface of macrophages, which are known to upregulate MMP production in 
macrophages and parenchymal cells. Cleavage of TGF-β by MMP-3, -9, and -14 was 
reported in cell and tissue culture models, the activation in vivo has to be shown [154; 
155]. The main activator for IL-1β is caspase-1 (ICE) but at least three MMPs can cleave 
and activate the precursor as well: MMP-2, -3, and -9. Here MMPs show a dual role as 
they either activate (MMP-3, -9) or degrade (MMP-3) the cytokine [156]. Similarly, 
ADAM17 (TACE) is the main sheddase of TNF-α [157; 158] but also several MMPs (MMP-1, 
-2, -3, -9, -17) can process proTNF-α to its active form. It seems that ADAM17 is mainly 
responsible for the inducible shedding where high levels of TNF-α are needed and MMPs 
like MMP-7 and MMP-12 constitutively shed proTNF-α from macrophages which is 
required for normal tissue repair [118; 158; 159; 160]. Macrophages play an important 
role in tissue damage and their numbers are strongly increased in the mucosa of IBD 
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patients; thus, macrophages are a potentially important source of MMPs at the 
inflammatory site.  
MMPs can also directly modulate chemokine activity and establish chemokine gradients. 
Several members of the monocyte-chemotactic protein (MCP) group of CC-chemokines 
can be activated or inactivated by cleavage through MMPs. For example MMP-2 cleaves 
CCL7 and the truncated chemokine than acts as an antagonist. Similarly, MMP-1, -3, -13, 
and -14 cleave CCL2, CCL8, and CCL13 to produce receptor antagonists [121]. Also several 
CXC-chemokines are processed by MMPs (CXCL11, CXCL5, CXCL6). In all cases, the 
cleavage leads to a loss of chemotactic activity [161]. In contrast the cleavage of CXCL8 
(IL-8, the mouse homolog is KC) by MMP-9 leads to a significant increase of its 
chemotactic activity [162; 163].  
Host recognition of bacteria is an important factor in IBD; it is thought that patients have 
a deregulated immune response to endogenous gut flora. MMP-7, as one of the few 
MMPs steadily expressed in healthy mucosal tissue, has been shown to activate 
antimicrobial peptides (AMPs) like α-defensins that are produced by Paneth cells and are 
bactericidal. Coexpression of MMP-7 and defensins was shown in these cells of the small 
intestine in mice. Also in this context MMP-3 plays an important role as it activates the 
proforms of MMP-7 and -9 [164; 165; 166]. 
 
2.3.4.5 MMPs and animal models of IBD 
Over the last several years mouse models of IBD have been developed to identify the role 
of MMPs in the disease. Higher mRNA levels of MMP-3, -7, -9, -12, and TIMP-1 in colonic 
tissues of mice treated with DSS to induce colitis were reported [149]. During the 
development of DSS-induced colitis, the expression of MMPs is up-regulated, 
accompanied by increased production of pro-inflammatory cytokines. 
Several MMP-deficient mice were used in different models of colitis to reveal the role of 
MMPs in IBD. It turned out that, for example, MMP-10 is protective in DSS-induced colitis. 
MMP-12-deficient mice were less susceptible to TNBS-induced colitis than WT animals 
[167] and the lack of MMP-7 protects mice against acute injury in a DSS colitis model 
[168], which shows the negative effect of these proteinases in colitis .  
MMP-9, according to the expression level, is the main MMP involved in TNBS-induced 
colitis, whereas levels of MMP-2 remain unchanged [169; 170]. Epithelial derived MMP-9 
plays a crucial role in DSS-induced colitis as it is important for tissue damage and in 
Salmonella typhimurium-induced enterocolitis [170; 171]. Interestingly it was found that 
neutrophil MMP-9 is neither needed for migration nor for induction of tissue damage. 
MMP-9 deletion leads to reduced inflammation and severity of colitis [171]. In contrast to 
MMP-9-deficiency, deletion of MMP-2 exacerbates colitis; these mice are highly 
susceptible to DSS- and Salmonella typhimurium-induced colitis [172]. Using a double-
deficient mouse for MMP-2 and -9, it turned out that MMP-9-mediated tissue injury 
overrides the protective effect of MMP-2 during colitis [173]. 
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In contrast to MMP-9, mucosa-derived MMP-2 may be a critical host factor that is 
involved in the regulation of the host response to luminal pathogens or toxins, an 
important aspect of healing and tissue resolution. A critical balance between the two 
gelatinases determines the outcome of inflammatory response during acute colitis. 
In general, it seems that the inducible MMPs such as MMP-9 and -12 mediate tissue 
damage and other negative effects in colitis whereas the constitutively expressed MMPs, 
like MMP-2 and -10 are more protective in the disease. 
Recently, several MMP inhibitors were tested in mouse models of IBD which all resulted 
in reduced tissue injury and inflammation in the treated mice (Table 2-1). 
 
Table 2-1: MMP inhibitors tested in animal models of colitis. 
Adapted from [149; 150; 169; 170; 174] 
Inhibitor Chemical class MMP inhibition Dose (mg/kg) Model Outcome 
1,10-Phenanthroline Phenanthroline Broad spectrum 20 DSS, 
TNBS 
effective 
Marimastat Hydroxamate Broad spectrum 40 TNBS effective 
Batimastat Hydroxamate Broad spectrum 5-20 TNBS effective 
CGS-27023 Hydroxamate Collagenase, 
gelatinase, 
stromelysin 
20 DSS, 
TNBS 
effective 
ONO4817 Hydroxamate Broad spectrum 
except for 
MMP-1 and -7 
30 DSS effective 
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2.3.5 Matrix metalloproteinases-19 and -28 
 
2.3.5.1 Matrix metalloproteinase-19 (MMP-19) 
The human matrix metalloproteinase 19 was first cloned from a cDNA library, generated 
from the synovium of a rheumatoid arthritis patient by Sedlacek et al. [175]. It was 
discovered as an autoantigen in rheumatoid arthritis. Thereafter it was also named RASI 
(rheumatoid arthritis sign of inflammation) which indicates the origin of the enzyme [176]. 
Independently and in parallel, MMP-19 was cloned by two other groups from cDNA of the 
liver and mammary gland [177; 178]. 
The human MMP-19 gene is located on chromosome 12 mapping to the 14q region [179], 
while several other MMP genes are found on chromosome 11. Whereas most other 
MMPs are encoded by 10 exons, human and murine MMP-19 are encoded by 9 exons. 
Therein, exons 1-3 determine the prodomain, exons 4 and 5 mainly encode for the 
catalytic domain, and the hemopexin-like domain is distributed over 4 exons [180; 181]. 
The human proenzyme consists of 508 amino acids and has a molecular weight of 57.4 
kDa. Detailed characterization of the sequence and comparison to all other known MMPs 
showed that MMP-19 had the least similarity to all other family members [182]. It does 
not belong to any of the described subgroups like collagenases, gelatinases, stromelysins, 
or membrane-type MMPs. Lately, another novel MMP, MMP-28 (epilysin) was discovered 
that is the closest homologue to MMP-19 [183; 184]. The identity of the catalytic domain 
is 46%. Further analysis revealed more similarities to MT1-MMP and the group of 
stromelysins (especially stromelysin-3) and thus it was also termed stromelysin-4 (Gordon 
Research Conference, 2001). 
MMP-19 is, like most other members of the MMP family, secreted as a zymogene and 
displays the typical structural features characterizing this enzyme family. The proteinase 
consists of a signal peptide, a propeptide domain, a catalytical domain, a hinge region, 
and a hemopexin-like domain. The active part of MMP-19 matches the ones of other 
matrix metalloproteinases but the hemopexin-like domain shows less than 25% identity 
to other MMPs. Despite of the typical domain structure of the family of matrix 
metalloproteinases MMP-19 also exhibits specific features. At first, there is a 
characteristic threonine-rich region at the C-terminal part consisting of 27 amino acids. 
This hydrophobic region has no known function so far and does not show any sequence 
homology to other members of the MMP family. Differences are also found in the auto-
inhibitory part of the sequence within the propeptide domain where the consensus 
sequence is PRCGLED in contrast to the generally found PRCXXPD. This unique feature 
enables the enzyme to be autocatalytic active [185]. Mutation studies where the carboxy-
terminal proline was replaced by glutamic acid on other MMPs showed the same effect of 
self-activation of the proenzyme [186; 187]. Within the hinge region, a unique 
oligoglutamic acid stretch followed by a proline-rich sequence (NH2-
EEEEETELPTVPPVPTEPSPM) is located; the function is unknown so far. The catalytic 
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domain of MMP-19 contains an additional cysteine that is also present in MMP-28 and 
MMPs from chicken (CMMP) and xenopus (XMMP) [184; 188]. hMMP-19 contains two 
putative N-glycosylation sites and mMMP-19 has four [176; 180; 181]. 
It was reported that the hemopexin-like domain is responsible for the association of 
MMP-19 to the cell surface [189]. The mechanism of the interaction with the cell surface 
is unclear. 
 
MMP-19: expression pattern, regulation, and proteolytic activity 
MMP-19 expression differs from the other MMPs as it is expressed in normal, healthy 
tissue, suggesting a role in tissue homeostasis. Its mRNA is highly expressed in various 
tissues except of brain [178; 179]. Protein expression is more restricted to several cell 
types like vascular smooth muscle cells, myoepithelial cells, basal keratinocytes, epithelial 
cells of different tissues (mammary gland [190], colon [131], intestine, lung, ovary, spleen 
[191]), and microglia that express the enzyme constitutively. Other cells (also epithelial 
cells and endothelial cells) show differential regulation of MMP-19. In healthy blood 
specimens, PBMC (peripheral blood mononuclear cells) that are positive for the surface 
marker CD14 produce MMP-19 as well i.e. macrophages [189]. This specific expression 
pattern suggests a specific role for MMP-19 in the epithelium and the basal membrane as 
well as macrophages. 
 
  Role in wound healing  
The role of MMP-19 in the wound healing process is still poorly understood and 
controversial. Despite its association with cell proliferation, Suomela et al have 
demonstrated that MMP-19 is not expressed in healing wounds of the skin [192]. By 
contrast, a study by Hieta et al suggests that the protease is expressed during later phases 
of wound repair by skin-resident and infiltrating cells including fibroblasts and endothelial 
cells.  The same authors have also shown that macrophages located in the wound bed 
produce MMP-19 protein [193], a finding that is in line with other reports demonstrating 
expression of the enzyme in blood mononuclear cells and myeloid cells [175; 189]. Thus, 
the role of MMP-19 in tissue repair might be associated with macrophage function. This 
cell population is believed to be essential in wound healing due to its capacity to remove 
cellular debris and to release a large number of growth factors. It seems plausible that 
MMP-19 could be involved in the release of membrane-associated cytokines and growth 
factors from the macrophages or could facilitate their migration in the wound bed [194]. 
However, further studies are needed to verify these hypotheses.  
 
  Expression in cancer 
During tumor growth, MMP-19 acts as a negative regulator of angiogenesis and invasion 
[195] and induction of fibrosarcomas is reduced in MMP-19-deficient mice [177]. MMP-
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19 shows differential expression in squamous cell carcinoma (SCC),it is up-regulated 
during melanoma progression [196] but down-regulated in colon cancer [131]. High 
expression was detected in human lung cancer and astroglial tumors where it promotes 
invasion of glioma cells [197]. The loss of MMP-19 is associated with malignant 
progression in chronic wounds [198] and it can act as a tumor suppressor and shows anti-
angiogenic activities in nasopharyngeal carcinoma [199]. 
 
  Regulation 
Analysis of the promoter region of MMP-19 revealed that several transcription factors like 
AP-1, AP-2, Ets, NF-κB, Myc, and E12/E47 can bind to the promoter sequence. Also 
regulatory elements as RARE (retinoic acid response element) and TIE (TGF-β inhibitory 
element) are present in this region [181]. Potent inhibitors of MMP-19 activity are TIMP-2, 
-3, and -4, whereas TIMP-1 is less capable of inhibiting this proteinase [185].  
 
  Proteolytic activity and substrates 
Known substrates of MMP-19 are mainly members of the extracellular matrix (ECM) like 
collagen type IV, laminin5 γ2 chain, tenascin-C, and nidogen. Also fibrinogen, fibrin, COMP 
(cartilage oligomeric protein), aggrecan, and brevican are processed by MMP-19 [185; 
197; 200; 201; 202]. The analysis of substrate specificity was done mainly in in vitro 
experiments by using the recombinant catalytical domain [185]. Also non-matrix proteins 
like IGFBP-3 (insulin-like growth factor binding protein-3) and a variant of VEGF (vascular 
endothelial growth factor) are cleaved by MMP-19 [203; 204]. MMP-19 is also able to 
cleave MMP-9 but this does not lead to enzyme activation [185]. 
Because of its unique features including expression pattern, autocatalytic activity, and the 
ability to cleave several important ECM proteins, MMP-19-deficient mice were generated. 
 
2.3.5.2 Generation of MMP-19-deficient mice 
The murine Mmp19 gene was first amplified from liver cDNA and from a mouse myoblast 
cell line [180]. The gene is located on chromosome 10 and shows 79% similarity to its 
human ortholog. The homology for the catalytic domain is 84%, while the hemopexin-like 
domain with only 65% is less identical to human MMP-19 (Figure 2-11). All characteristics 
of the human MMP-19 are also displayed in the murine one. mMMP-19 protein consists 
of 527 amino acids and has a molecular weight of 59.1 kDa. In comparison to the human 
protein the murine one lacks one glutamic acid residue in the oligoglutamic acid stretch 
[180; 205]. 
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Figure 2-11: Human and murine orthologues of MMP-19. 
The schematic picture of human and murine MMP-19 is showing the homology of the two 
enzymes (by courtesy of Dr. Radislav Sedlacek) 
 
MMP-19-deficient mice were generated by targeted disruption of the Mmp19 gene, as 
shown in figure 2-12 [206]. To design a targeting construct, a part of exon 3 and whole 
exon 4 encoding for the catalytic domain were replaced by a neomycin resistance 
cassette orientated in the opposite direction to the endogenous Mmp19 gene. For 
construction of the 5’-arm homology of the targeting construct, a 2.8 kb fragment 
spanning a region including exon 2 and most of exon 3 was amplified from genomic DNA 
using PCR. The 3’-arm homology was created the same way; it is spanning a region of 2.8 
kb including exon 5 and part of exon 8. The complete construct, called pPNT/mmp19del, 
was injected into mouse embryonic stem cells derived from 129 strain. The neomycin-
resistant colonies were screened for homologous recombination by Southern blotting 
[207]. Two selected clones (G5 and F6) were introduced into blastocysts via 
microinjection and chimeras were generated [208]. Mice were analysed by PCR and 
animals positive for the disrupted MMP-19 allele were backcrossed to C57BL/6NCrl mice. 
Resulting MMP-19-deficient mice develop without obvious alteration in morphology, 
weight, size, and fecundity compared to wild-type mice, which is consistent with the work 
of Pendas et al., who generated MMP-19-deficient mice by replacing the Mmp19 
promoter region and exons 1 and 2 [177]. Breeding of mice heterozygous for the targeted 
gene for MMP-19 produces the expected Mendelian ratio of knockout animals of 25%. 
Thus, MMP-19 does not seem to be essential for blastocyst implantation or embryonic 
development. No apparent changes in the histology of brain, bones, heart, kidney, liver, 
lung, reproductive organs, pancreas, skin, and spleen of MMP-19-deficient mice were 
seen at 1, 3, 6, and 12 months. 
Previous studies showed that MMP-19 is steadily expressed in the normal healthy 
epithelia, macrophages, and smooth muscle cells; it may play a role in wound healing, cell 
proliferation, migration, and vascularisation. The impact of this metalloproteinase in 
acute as well as chronic inflammatory diseases is not known so far. 
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Figure 2-12: Generation of MMP-19-deficient (MMP-19 -/-) mice. 
(A) Schematic representation of the murine Mmp19 gene and its exon/intron-organization as 
previously described by Mueller et al.; pPNT targeting vector construct, and the resulting deleted 
active site locus of the mouse mmp19 gene are depicted. The targeting construct was generated 
by replacement of 1088 bp region of Mmp19 gene spanning the end of exon 3 and the whole 
exon 4 encoding the catalytic domain by the neomycin resistance cassette. (B) For screening of 
MMP-19-deficient mice Southern blot analyses were performed. Probing led to identification of 
either a 7.3 kb band (wild-type allele, +/+) or a 5 kb band for the targeted allele (-/-). In 
heterozygous mice (+/-) both alleles are present. (C) Genotyping of targeted alleles using PCR. 
Wild-type alleles are detected by an 800 bp band, while PCR for the MMP-19-deficient allele 
results in a 600 bp product. (D) Primary keratinocytes isolated from wild-type, heterozygous, and 
homozygous MMP-19-deficient mice were analyzed for MMP-19 expression by western blotting 
using anti-MMP-19 antibodies purified against a peptide derived from the hinge region of murine 
MMP-19, that is detected in size of 59 kDa. [206] 
 
2.3.5.3 Matrix metalloproteinase 28 (MMP-28) 
Epilysin (MMP-28) is the latest member of the mammalian matrix metalloproteinase 
(MMP) family of extracellular proteases. It was cloned from human keratinocyte and 
testis cDNA libraries [183; 209]. The cDNA contains an open reading frame of 1560 
nucleotides coding for a 520 aa protein. The human Mmp28 gene is located on 
chromosome 17 (17q11.2) [209], which is a locus that differ from all other known Mmp 
genes. Mmp28 gene consists of only eight exons instead of ten, which is typical for Mmp 
genes [183]. This unique gene organisation can just be found in one other MMP, MMP-11 
(Stomelysin-3). It seems that these two MMPs are the most similar ones but concerning 
overall gene organization Mmp28 resembles most closely Mmp19 [181].  
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MMP-28 contains a prodomain, a zinc-binding catalytic domain, and a hemopexin-like 
domain. In contrast to most other MMPs (except of MMP-11 and the membrane-bound 
MT-MMPs) it also contains a furin activation sequence and can be activated during its 
secretion. The furin site is conserved and functional as well in the MMP-28 homologues in 
mouse and Xenopus leavis (XMMP-28) [210]. The catalytic domain is typical for soluble 
MMPs although the sequence of the Zn-binding site (HEIGHTLGLTH) is unique as no other 
MMP contains threonine within this sequence.  
The identity between human and mouse epilysin is 85% of the overall amino acid 
sequence and 97% in the catalytic domain [211], which suggests a well-conserved 
function of this proteinase. These findings are supported by the high identity to XMMP-28, 
as 56% of the overall amino acids and 65% in the catalytic domain are identical to the 
human sequence [212]. The epilysin homologue in Xenopus laevis (XMMP-28) is 
expressed in neural tissues, where it cleaves the neural cell adhesion molecule. 
Comparison of the amino acid sequence of MMP-28 with other MMPs showed that it is 
most closely related to MMP-19. This resembles the results from the gene analysis.  
 
MMP-28: expression pattern, regulation, and proteolytic activity 
Epilysin differs from most other MMPs as it is expressed in normal, healthy tissue, 
suggesting a role in tissue homeostasis. Its mRNA is highly expressed in testis, at lower 
levels in lung, heart, gastrointestinal tract (small intestine, colon), brain, and in wounded 
epidermis [211] in humans. The expression pattern in mice is slightly different; the 
highest expression is found in lung but mRNA could be also detected in placenta, heart, 
uterus, and the gastrointestinal tract. A peak of epilysin expression can be found during 
the embryonal development at day E14 in developing neural system. The expression 
pattern in rats resembles the one in mice. This pattern of expression is different from 
most other members of the MMP family, as most MMP are expressed only under special 
conditions, like injury, inflammation, or several diseases [213]. The MMP-28 expression 
pattern suggests that epilysin plays an important role in normal tissue homeostasis and 
turnover. 
Regarding tissue and cell culture, MMP-28 is expressed in epithelial cells (from skin, 
placenta, and lung) and bone marrow derived macrophages [183]. mRNA could be also 
detected in unstimulated and PMA and ionomycin stimulated T lymphocytes. Cytokines 
like TNF-α were proposed to induce the expression of MMP-28 in vitro [214].  
 
  Role of MMP-28 in wound healing 
As MMP-28 was found to be expressed in keratinocytes and in intact human skin, several 
wound healing experiments were done to analyze a putative role of epilysin. In ex vivo 
models, MMP-28 was detected in non-migrating keratinocytes at a distance from the 
wound edge as well as in migrating ones at the wound edge [183; 214] (Figure 2-13). 
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These observations may indicate a role of MMP-28 in epithelial cell proliferation or 
rebuilding of the newly formed basement membrane during wound repair. 
 
Figure 2-13: MMPs in wound healing. 
MMPs are expressed in different areas of the epithelium during dermal wound healing. Taken 
from [209].  
 
  Expression in cancer 
MMP-28 expression is up-regulated in various different types of cancer (e.g. invasive 
ductal cell carcinoma [215], squamous cell carcinoma (grade I) [214], but also several 
cases of down-regulation of this enzyme are reported (e.g. basal and squamous cell 
carcinoma (grades II and III) [214], colon carcinoma (epithelium) [131]. The role and 
expression of MMP-28 seems to be dependent on the type and stage of cancer. In cell 
culture, MMP-28 mRNA has been detected in colon adenocarcinoma cells, ovarian 
carcinoma cells, pancreatic adenocarcinoma cells and breast carcinoma cells. 
 
  Regulation 
Like all other MMPs, MMP-28 is tightly regulated on the transcriptional level because of 
overlapping biological functions and substrate specificity. Promoter analysis of epilysin 
revealed a sequence known as GT-box, a homologue to the consensus binding site for the 
Sp-family of transcription. It is highly conserved in human and mouse promoters 
indicating an important role in regulation of gene expression. The transcription factors 
Sp1 (inducer of transcription) and Sp3 (inducer or repressor of transcription) bind to the 
GT-box. A mutation in the GT-box resulted in significantly reduced transcriptional activity 
especially in keratinocytes [210]. 
Histone deacetylation inhibitors (HDAC) can induce MMP-28 transcription as well as few 
other Mmp genes. In general, most Mmp genes are repressed by these inhibitors [216]. 
The actual target of the HDAC inhibitors seems to be Sp1 as it is regulated by acetylation 
itself [217]. 
Another mechanism of MMP-28 regulation is the compartmentalization of the cell. 
Experiments showed that MMP-28 is attached to the cell membrane; the responsible 
structural part of the enzyme is the hemopexin domain. This mechanism of pericellular 
localization seems to be an epithelial-cell specific structure as it does not occur in other 
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cell types. Cells which went through EMT showed no longer cell surface expression of 
epilysin that suggests that during EMT there is a downregulation of the receptor binding 
epilysin to the cell surface. MT1-MMP induction during EMT may cause the 
destabilization or degradation of the surface receptor and with this a loss of bound MMP-
28 [218]. 
 
  Proteolytic activity 
Recombinant MMP-28 was used to determine substrates of this new proteinase; the first 
one verified was casein [183]. The proteolytic activity could be inhibited by EDTA and 
batimastat, a selective MMP inhibitor. In vitro XMMP-28 and recombinant human    
MMP-28 degraded the neural cell adhesion molecule (NCAM). 
The functions of epilysin still are largely unknown. As several MMPs function in immunity, 
it was hypothesized that also MMP-28 may have a regulatory role in the tissue response 
to environmental challenge. To test this, MMP-28 KO mice were generated in the 
laboratory of William C. Parks, Washington University (St. Louis, MO, USA).  
 
2.3.5.4 Generation of MMP-28-deficient mice 
The murine Mmp28 gene was cloned from the SV129 genome (gene ID 118453). For 
construction of the homologous extensions of the targeting construct, a 4.8 kb EcoRI-XbaI 
fragment containing the 3’ terminus of intron 1, exons 2 and 3, and ~ 4 kb of intron 3 and 
a 2.1 kb XhoI-EcoRI fragment containing the 3’ untranslated end of exon 8 and 
downstream sequence (Fig. xA). Two cassettes were inserted into the target gene; a pgk-
neomycin resistance cassette was inserted between the two arms and a diphtheria toxin 
(dta) cassette was fused to the 3’ end. Linearization of targeting construct was done with 
XhoI (the XhoI site at the 5’ end of the short arm was deleted by ligating to the SalI site in 
the neomycin cassette). Transfection of 129X1/SvJ (RW4) embryonic stem (ES) cells was 
done by the Murine Embryonic Stem Cell Core of the Siteman Cancer Center at 
Washington University (St. Louis, MO). For screening of ES cell clones, genomic DNA was 
isolated and digested with BamHI. Southern blotting of the digests was done using a 694-
bp probe to the 3’ terminal end of intron 1, upstream of the targeting construct (Fig. xA).  
Positive ES cells were injected into C57BL/6 blastocysts by the Mouse Models Core at 
Washington University. Genotyping of mouse tail DNA was done by PCR and positive 
results were confirmed by Southern hybridization (Fig. 1B). For PCR, we used two forward 
primers, one specific to the WT locus (5’GTGAAGATGTCCCATGCCCACAGT3’) and the other 
to the target construct (5’GAGGAAATTGCATCGCATTGTCTGAG3’), and a common reverse 
primer (5’CACATTCCCTCCTGCTCTGCATCC3’) to generate a 259 bp product from the WT 
Mmp28 gene and a 324 bp product from the mutated gene (Figure 2-14). Male chimeric 
mice were bred to female C57BL/6 mice to generate germline heterozygotes, which were 
then bred to yield homozygous nulls. MMP-28 KO mice were then backcrossed for more 
than 10 generations with C57BL/6 mice from Taconic. Wild-type and MMP-28 KO mice 
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(C57BL/6NTac background) were housed as described in ‘Material and Methods’, section 
3.1.1. Age-matched mice of both genotypes were used for all studies. Similar to many 
other MMP knock out mice, also MMP-28 KO mice revealed no overt phenotype. 
 
 
Figure 2-14: Generation of MMP-28-deficient (MMP-28 -/-) mice. 
(A) The targeting construct was designed to replace most of the exons, including exon 5, which 
codes for the catalytic domain. After recombination, exons 4 –7 and the full coding portion of the 
exon 8 are removed, and the epilysin transcript only contains exons 1–3. (B) ES cell clones were 
screened by Southern hybridization; WT epilysin gene gives a 9 kb band while targeted gene gives 
a 7.5 kb band. (C) F1 offspring of chimeric mice were screened by Southern and PCR analysis. For 
the PCR assay, the recombined locus produces a larger DNA fragment (324 bp) than that from the 
WT gene (259 bp). Three primers were used, the position and orientation of which are indicated 
by arrowheads: a WT forward primer, a neomycin cassette forward primer, and a common 
reverse primer [219]. 
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3 Material and methods 
 
 
3.1 Mice and in vivo models 
 
3.1.1 Animal housing 
 
Housing of mice and in vivo experiments were performed after approval by the Animal 
Care Committee of the Institute of Molecular Genetics, Prague, Czech Republic in 
compliance with national and institutional guidelines. Mice were housed in open cages 
with 12h/12h light/dark cycle under standard conditions and were provided with 
autoclaved food (Rod18-A10, LASvendi, Soest, Germany) and acidified drinking water ad 
libitum.  
Health monitoring was performed on a quarterly basis according to the recommendations 
of the Federation of European Laboratory Animal Science Associations (FELASA). 
Additionally, Helicobacter species were tested every three months. Test results showed 
an infection with Helicobacter during the time of the breeding and the experiments for 
this study. Mice with targeted disruption of the Mmp19 gene were generated as 
described above (introduction). For colony maintenance, MMP-19 -/- mice were 
backcrossed to C57BL/6NCrl background (Charles Rivers Laboratories, Sulzfeld, Germany). 
All assays were performed with MMP-19 -/- mice that have been backcrossed at least to 
the F20 generation. Studies focussing on the role of MMP-19 were performed using the 
MMP-19 F6 line as the second line, G5, did not show any different characteristic in 
previous experiments. 
MMP-28-deficient mice were kindly provided by William C. Parks (University of 
Washington, Seattle, USA). The generation of MMP-28 -/- mice was published previously 
by Manicone et al. [219]. Experiments to study the role of MMP-28 were carried out with 
MMP-28-deficient mice backcrossed more than 10 times to C57BL/6NCrl background. In 
order to obtain aged-matched MMP-deficient mice for the experiments, backcrossed 
mice heterozygous for MMP-19 or MMP-28 were crossed. After genotyping of the 
newborn mice, those with homozygous deletion of the MMP locus were crossed further.  
To generate mice lacking MMP-19 and -28 homozygous mice of both strains were crossed 
which resulted in double heterozygous animals in the F1 generation, which were then 
further breed to obtain double-deficient animals, named MMP-19/-28 dbKO. 
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3.1.2 Genotyping of mice 
 
3.1.2.1 Isolation of genomic DNA from mouse tail 
For MMP genotyping, genomic DNA was isolated according to a protocol described by 
Hogen et al [220]. A short part of the tail (0.3-0.4 cm) was cut from 3-weeks old animals; 
the tail biopsy was then cut into smaller pieces and incubated in 1 ml lysis buffer (200 mM 
NaCl, 100 mM Tris, 5 mM EDTA, 0.2% SDS, pH 8.0) with proteinase K (7.2 mU) and placed 
in a water bath at 55°C overnight. 1 ml phenol: chloroform (1:1) was added to the 
digested tissue and mixed for 15 s and centrifuged (900 x g, 2 min) to separate the phases. 
The upper phase was transferred to a new tube and mixed with 1 ml chloroform, and 
centrifuged again (900 x g, 2 min). The aqueous supernatant was transferred into new 
tube and mixed with 1 ml 100 % ethanol and 100 μl sodium acetate (3 M, pH 6.0). For 
precipitation of DNA the solution was mixed carefully. Following another centrifugation 
step the pellet was washed with 75% ethanol. After discarding ethanol, the pellet was 
dried at room temperature and dissolved in 100 μl dH2O overnight at 4 °C. Quality of the 
DNA was measured at 260 and 280 nm. The genomic DNA samples were stored at 4 °C 
until they were used for PCR. 
 
3.1.2.2 PCR of genomic DNA 
Mice were genotyped by PCR according to the original method [220; 221; 222]. After 
isolation of genomic DNA two separate PCR set-ups for detecting the targeted and the 
wildtype allele of MMP-19 were performed. Components for the reactions such as PCR 
buffers, dNTPs, MgCl2, and Taq-polymerase were purchased from Fermentas (St. Leon-
Rot, Germany). The forward primer for the wildtype allele was designed on exon 4      
(m1-U10, 5’-CCGCATCTTCAATGTGCCC-3’), the reverse one on exon 5 (mD1-21,                 
5’-GATCGCCAGGTTCACTCC-3’). These primers amplified a fragment of 800 bp. For the 
targeted allele a forward primer on exon 3 (m1-U3, 5’-AGATGGATGACGCCACAAG-3’) and 
a reverse one based on the sequence of the PGK-Neo cassette (neofwd,                             
5’-CTTCTATCGCCTTCTTGACG-3’) were used, the reaction resulted in a product of 600 bp. 
Control setups with DNA from MMP-19 -/-, MMP-19 +/-, and WT mice as well as without 
DNA template were run additionally. One reaction consisted of 1.5 mM MgCl2, 2 mM 
dNTPs, 0.5 μM of each primer, 1.25U Taq-polymerase, and 50 - 100 ng genomic DNA in 
PCR buffer (10 mM Tris, 50 mM KCl, 0.8% Nonidet P40, pH 8.8). The PCR program is 
described in table 3-1. Steps 2 to 4 were repeated 30 times. 
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Table 3-1: PCR conditions for genotyping of MMP-19 knockout mice. 
 
Step Temperature Time 
1 - initial denaturation 95°C 2 min 
2 - denaturation 95°C 30 sec 
3 - annealing 60°C 30 sec 
4 - extension 72°C 2 min 
5 - final extension 72°C 5 min 
 
Detection of the MMP-28 wild-type or mutated allele was performed in one reaction. The 
following primers were used: The wild-type allele was amplified with a forward (Epi WT, 
5’-GTGAAGATGTCCCATGCCCACAGT-3’) and a reverse primer (MMP28 rev common,        
5’-AGGGCCCTCTTTCATCTTCCTGATG-3’). The mutated MMP-28 allele was detected by a 
forward primer (MMP28 KO For, 5’-GCTGACCGCTTCCTCGTGCTTTAC-3’) and the same 
reverse primer (MMP28 rev common). The set up is the same as for genotyping of    
MMP-19 allele. The PCR program is described in table 3-2. Steps 2 to 4 were repeated 30 
times. The size of the PCR fragment for the WT allele was 535 bp, and the one for the 
disrupted allele of MMP-28 834 bp.  
 
Table 3-2: PCR conditions for genotyping of MMP-28 knockout mice. 
 
Step Temperature Time 
1 - initial denaturation 95°C 2 min 
2 - denaturation 95°C 30 sec 
3 - annealing 66°C 30 sec 
4 - extension 72°C 1 min 
5 - final extension 72°C 5 min 
 
3.1.2.3 Agarose gel electrophoresis  
PCR products were analyzed by agarose gel electrophoresis. PCR products were mixed 
with 10 x loading buffer (40% glycerol, 0.1% (w/v) bromephenole blue, 0.1% (w/v) xylene 
cyanole, 40 mM Tris, pH 8.0) and loaded into slots of agarose gels (1% in TAE buffer) that 
were run with 9 V/cm2 in TAE buffer (10 mM Tris, 20 mM Acetic acid, 1 mM EDTA;          
pH = 8.0). A DNA standard (Fermentas) was used to compare the size of amplified DNA. 
PCR fragments were visualized by ethidium bromide (Roth, Karlsruhe, Germany) staining 
(final concentration in the gel: 0.5 μg/ml) and UV trans-illumination at λ=312 nm (BioRad, 
München, Germany). 
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3.1.3 Animal model of DSS-induced colitis 
 
3.1.3.1 Induction of DSS-colitis and determination of the disease activity index score 
Acute colitis was induced by administration of 2% dextran sulfate sodium (DSS) (TdB 
Consultancy, Uppsala, Sweden) in the drinking water for 6 days. To study the recovery 
phase of colitis the disease was induced by 2% DSS in the drinking water for 5 days 
followed by 10 days of regular, non-acidified, UV irradiated and filtrated drinking water. 
For maintaining chronic colitis this procedure was repeated twice. Groups of four to eight 
mice were used to monitor the disease activity index (DAI) [223], which consists of three 
parameters: loss of body weight, intensity of bleeding and stool consistency. Faecal blood 
loss was determined using the hemoccult test (Beckman Coulter, Krefeld, Germany). All 
parameters were recorded daily. DAI and histology were performed as previously 
described by Siegmund et al. [224] and Grivennikov et al. [225]. 
The murine colitis phenotypes were measured by the disease activity index score, which 
is the sum of body weight, diarrhea, and bleeding scores determined daily during the 
treatment, as previously described [224; 226] 
All scores were relative to the scores on day 0, which were set as 0. For body weight, no 
weight loss was scored as 0. The scoring system was following: loss of 1% – 5% weight, 1; 
loss of 5% – 10% weight,2; loss of 10% – 20%,3; 20% and higher body weight loss, 4. For 
stool consistency, 0 was scored for well-formed stool pellets, 1 was scored for loose stool 
pellets, 2 was scored for pasty and semi-formed stools that did not adhere to the anus 
(mild diarrhea), 3 was scored for slimy stool (moderate diarrhea) and 4 was scored for 
severe watery diarrhea that adhered to the anus and contained blood. For bleeding, 
which was analyzed by the Hemoccult faecal occult blood test (Beckman Coulter), 0 was 
assigned for no blood, 2 was assigned for positive Hemoccult test, and 4 was assigned for 
gross bleeding. The determination of the DAI is summarized in table 3-3. 
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Table 3-3: DAI assessment. 
 
Body weight loss  
0 No loss 
1 1–5% loss of body weight 
2 5–10% loss of body weight 
3 10–20% loss of body weight 
4 >20% loss of body weight 
 
Stool consistency  
0 Normal feces 
1 Loose stool 
2 Watery diarrhea 
3 Slimy diarrhea 
4 
Severe watery diarrhea with 
blood 
 
Bleeding  
0 No blood 
2 Positive  Hemoccult test 
4 Visible bleeding 
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3.2 Tissue analysis 
 
3.2.1 RNA analysis 
 
3.2.1.1 RNA extraction from colon tissue samples 
Total RNA was extracted from 10 mg colon tissue samples using the TissueLyserII (Qiagen, 
USA) in combination with the RNeasy Mini kit (Qiagen, USA). In brief, tissue samples 
stored in RNALater (Ambion, USA) at -20°C were placed in 2 ml RNAse-free plastic tubes 
containing 600 µl RLT lysis buffer and stainless steel beads (Qiagen), followed by 
disruption through high-speed shaking (2 x 1.5 min at 20 Hz) at room temperature. Total 
RNA was then isolated using the RNAeasy Mini kit according to the manufacturer’s 
instructions.  
 
3.2.1.2 cDNA synthesis  
First Strand cDNA Synthesis kit (Fermentas, Canada) was used to prepare cDNA from 
isolated RNA. Per one sample, 500 ng of RNA was mixed with 1 μl of oligo (dT)18  primer 
and diluted by DEPC- treated water to a final volume of 10 μl. The mixture was incubated 
at 70 °C for 10 min, centrifuged and cooled on ice for 2 min. The mixture of 4 μl of 5x 
Reaction buffer, 2 μl of 10 mM dNTP mix, 1 μl of RiboLock RNase Inhibitor (20 U/μl) was 
added to each sample. Afterwards, 2 μl of M-MuLV Reverse Transcriptase (20 U/μl) was 
added and the mixture incubated at 37 °C for 60 min. The reaction was terminated by 
incubation at 70 °C for 5 minutes, and the cDNA was stored at -20 °C. 
 
3.2.1.3 Semi-quantitative real-time PCR 
To determine MMP-19 and MMP-28 transcript levels in colon of wild-type or mutant mice, 
semi-quantitative real-time PCR was performed. Expression of murine GAPDH 
(mGAPDH_RT_F: 5’-AACTTTGGCATTGTGGAAGG-3’ and mGAPDH_RT_R:                              
5’-GTCTTCTGGGTGGCAGTGAT-3’, PCR fragment size 65 bp) served as endogenous 
control. The exon-spanning primers used for MMPs were able to distinguish between 
transcripts of WT and deficient mice as they were designed in the modified exons of the 
genes and could not bind to cDNA from MMP-deficient animals. The forward primer for 
murine MMP-19 binds in exon 4 (mMMP19_RT_F3: 5’-ATCTTCAATGTGCCCTCCAC-3’) 
whereas the reverse primer binds in exon 5 (mMMP19_RT_R3:                                             
5’-CCACGCTGCTCCAGTACTTA-3’). The resulting product had a size of 82 bp. The primers 
for detecting murine MMP-28 bind DNA in exon 4 and 5, generating a product of 101 bp 
(mMMP28_RT_F3: 5’-CCTGTACGGAAAGCCTCTGG-3’ and mMMP28_RT_R3:                       
5’-GTCTGCTCTGGGAGTTGTGG-3’). The PCR set-up was the same as for the genotyping 
MATERIAL AND METHODS 40  
(3.2.1) but instead of genomic DNA 2 μl of cDNA were used in the reaction. The PCR 
program is described in Table 3-4. Steps 2 to 4 were repeated 35 times. The products 
were analyzed by gel electrophoresis using a 1.5% agarose gel. 
 
Table 3-4: PCR conditions of the RT-PCR. 
 
Step Temperature Time 
1 - initial denaturation 95°C 2 min 
2 - denaturation 95°C 15 sec 
3 - annealing 60°C 20 sec 
4 - extension 72°C 30 min 
5 - final extension 72°C 3 min 
 
 
3.2.2 Colon organ culture 
 
Colons were excised, flushed with PBS containing 2% Penicillin/Streptavidin, and opened 
along the longitudinal axis. Thereafter, from the distal colon 3 x 8 mm (24 mm2) biopsies 
were excised and incubated for 24 h in a 12-well plate containing 1 ml fresh RPMI 1640 
lacking FCS but supplemented with 2% penicillin and streptomycin at 37°C and 5% CO2. 
Culture supernatants were harvested and kept at -20°C until assessed for 
cytokines/chemokines by ELISA or Bio-Plex suspension array system (Bio-Rad Laboratories 
Inc., CA, US). 
Supernatants were analyzed for KC and MCP-1 levels by ELISA (R&D Systems, Germany) 
according to the manufacturer’s protocols. Optical densities were measured at 450 nm 
using ELISA plate reader (Tecan Reader Infinite M200) and were evaluated using a 
standard curve. Other cytokines and chemokines were determined by Bio-Plex bead array 
(see 3.2.3.2). 
 
3.2.3 Cytokine analysis 
 
The concentrations of 23 cytokines (IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 
(p40), IL-12 (p70), IL-13, IL-17A, eotaxin, G-CSF, GM-CSF, IFN-γ, KC, MCP-1, MIP-1α, MIP-
1β, RANTES, TNF-α) were analyzed in plasma and CEC supernatants using Bio-Plex Pro 
Mouse Cytokine 23-Plex Assay with a Bio-Plex instrument based on Luminex xMAP 
technology (Bio-Rad). The procedure was carried out according to manufacturer’s 
instructions with high sensitivity range standard settings. The conditions of the assay 
were standardized and optimized, prior to the analysis, to ensure optimal reproducibility. 
The plasma samples were centrifuged for 10 min at 13300 x g before the assay and 
diluted 1:3 in an appropriate sample matrix. Pooled plasma sample was used to control 
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for inter-assay variation. The results were automatically calculated with Bio-PlexManager 
Software version 4.3 with five-parameter logistic equations. 
Cytokine levels of KC, MCP-1 additionally were measured in colon explant culture (CEC) 
supernatants using the ELISA Duo-Set kit according to the manufacturer’s instructions 
(R&D Systems). 
 
3.2.4 Myeloperoxidase activity measurement 
 
Myeloperoxidase (MPO) activity, which is widely used to quantify neutrophil 
accumulation in tissues, was assessed using the O-dianisidine method [227]. Tissue 
samples were harvested and immediately frozen in liquid nitrogen. MPO activity was 
measured in colon tissue taken from the distal colon. After freezing in liquid nitrogen, 
equal aliquots of tissue samples (30 μl buffer/mg colon tissue) were homogenized in MPO 
buffer (50 mM potassium phosphate buffer (KPO4), pH 6.0, containing 0.5% 
hexadecyltrimethylammonium bromide buffer (C19H42BrN) (0.1 g/20 ml KPO4)), incubated 
at 60°C for 2 h and centrifuged at 10,000 rpm for 5 min. 10 μl of the supernatant were 
mixed with 50 μl peroxidase substrate. After 20 min 50 μl of H2SO4 were added to stop 
the reaction and the absorbance was measured at 450 nm on an ELISA plate reader 
(Tecan Reader Infinite M200) and evaluated using a standard curve.  
 
3.2.5 Histochemistry techniques  
 
3.2.5.1 Tissue processing 
The isolated colon was divided into three parts, proximal (containing the ceacum), middle, 
and distal part, and fixed in 4% neutral buffered formaldehyde (10% formalin) in 1 x PBS 
for 24 h. Fixed tissue was rinsed under running tap water for at least 30 min. Tissues were 
dehydrated in an ascending ethanol and xylol series in a 16h protocol using a Tissu-Tek® 
Vacuum Infiltration Processor (Sakura, USA). Samples were embedded in paraffin (Tissue-
Tek® TEC™ 5 Embedding Console System, Sakura, USA) and sectioned to 4 μm using a 
microtome (Leica RM2165). Mouse spleens were treated the same way. 
 
3.2.5.2 Hematoxylin-eosin staining  
Sections were deparaffinized by washing three times with xylene for 5 min. Descending 
alcohol set (2 x 100%, 1 x 95% , 1 x 70% ethanol, 10 min each) was used for rehydration. 
The sections were rinsed in distilled water twice for 5 min, stained by hematoxylin (50 ml 
of 5% KAl(SO4)2 x 12 H2O), 1 ml of 10% hematoxylin (Sigma-Aldrich, Czech Republic) in 
96% ethanol, 1 ml of 2% H5IO6, and 10 drops of 35% HCl) for 1 min and differentiated by 
running tap water for 3 min. Sections were washed once in distilled water and 
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counterstained by Eosin-Y for 20s and rinsed in tap water for 1 min. Dehydration was 
performed by ascending alcohol set (1 min in 70%, 80%, and 100% ethanol) and the 
sections were incubated with xylene for 3 min. Slides were allowed to dry and PERTEX 
Mounting Media (CellPath) was used as a mounting reagent. For histological evaluation of 
the tissue damage, areas of inflammatory lesions were microscopically evaluated and 
quantified, essentially by the method of Cooper et al. [92]. 
 
3.2.5.3 Trichrome staining 
After deparaffinization and dehydration, slides were stained with Mallory Trichrome kit 
(DIAPATH, Italy) according to the manufacture’s protocol. In brief, slides were washed 
with distilled water three times and incubated for 3 min with reagent A (fuchsine acid), 
washed again and incubated with reagent B (phosphomolybdate) for another 3 min. 
Reagent B was allowed to run of the slide and immediately after reagent C (Mallory 
solution: methylen blue, Orange G, oxalic acid) was added and slides were incubated for  
5 min. Slides were washed with distilled water and differentiated in 96% ethanol for 1 
min followed by dehydration and mounting.  
 
3.2.5.4 Immunohistochemistry (IHC) 
Slides were stained for proliferation marker Ki-67 (DAKO, Denmark), macrophage marker 
F4/80, as well as for collagen I and IV (all AbD Serotec, UK). Antibodies were summarized 
in table 3-5. For the Ki-67 and the collagen I antibody the pre-treatment for epitope 
retrieval was done by boiling the slides in 10 mM Citrate buffer, pH 6.0 at 96 °C for          
20 min. For the F4/80 and the collagen IV antibodies the epitope retrieval was done by 
incubation with 0.01% Proteinase K (20 mg/ml) (Biolabs, Germany) in 20 mM Tris-HCl 
buffer (pH 7.4) for 5 min at RT. Afterwards, slides were washed in 1 x PBS three times for 
5 min and blocked for endogenous peroxidase with 3% H2O2 in 1 x PBS for 10 min.             
A second blocking step with 3% low-fat milk powder, 2% BSA, and 0.1% NaN3 in 1 x PBS  
was carried out for 1h at RT to reduce unspecific binding. Subsequent incubation with the 
primary antibody, which was diluted in 1 x PBS containing 10% FCS and 0.1% NaN3 , was 
done for 1h at RT (F4/80) or overnight at 4°C (Ki-67, collagen I and IV). The secondary 
antibody was diluted 200 times in 1 x PBS + 10% FCS without NaN3 and slides were 
incubated for 1.5h at RT. As these antibodies were biotinylated, streptavidin-HRP          
(BD Pharmingen, USA) was added to the slides and incubated for 30 min at RT. The 
visualization of positive cells by the chromogen DAB (3,3- diaminobenzidin) (DAKO, 
Denmark) was performed according to the manufacturer’s protocol for 5 to 10 min. The 
staining procedure was completed by a counterstaining with hematoxylin (30 sec) to 
visualize the nuclei of the cells.  
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Table 3-5: Primary antibodies used for immunohistochemistry. 
 
primary antibodies distributor dilution 
monoclonal rat anti-mouse F4/80 
(clone Cl:A3-1, # MCA497GA) 
AbD Serotec, UK 1 : 2000 
polyclonal rabbit anti-mouse Collagen I 
(# 2150-1410) 
AbD Serotec, UK 1 : 1000 
polyclonal rabbit anti-mouse Collagen IV 
(# 2150-1470) 
AbD Serotec, UK 1 : 1000 
monoclonal rat anti-mouse Ki-67 
(clone TEC-3, # M7249) 
DAKO, Denmark 1 : 50 
 
 
Table 3-6: Secondary antibodies used for immunohistochemistry. 
 
secondary antibodies distributor dilution 
biotinylated polyclonal rabbit anti-rat IgG 
(# E0468) 
DAKO, Denmark 1 : 200 
biotinylated polyclonal goat anti-rabbit IgG Vector Laboratories, 
UK 
1 : 300 
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3.3 Cell analysis 
 
3.3.1 Migration assay 
 
RAW 264.7 cells were cultured under standard cell culture conditions in RPMI-1640 media 
(Media facility, Institute of Molecular Genetics, Prague, Czech Republic) supplemented 
with 10% FCS (PAA, Austria) and 1% penicillin/streptomycin (PAA, Austria) at 37°C with 
5% CO2. CIM-plate16 with the xCELLigence RTCA DP Instrument (Roche) were used to 
monitor migration of macrophages in real-time using label free conditions. The CIM-
plate16 is a 16-well modified Boyden chamber composed of an upper chamber and a 
lower chamber. The upper chamber is sealed at its bottom by a microporous 
polyethylene terephthalate membrane. These micropores permit the physical 
translocation of cells from the upper part to the bottom side of the membrane. The lower 
side of the membrane (side facing the lower chamber) contains interdigitated gold 
microelectrode sensors which will come in contact with migrated cells and generate an 
impedance signal. The lower chambers contain 16 wells, which each of them serves as 
reservoir for a chemoattractant solution on the bottom side of the wells. For optimal 
RAW 264.7 cell migration, it was determined that extracellular matrix proteins are 
necessary. The membrane therefore was coated with 10 μg/cm2 of collagen type IV. After 
CIM-plate16 assembly, 100 μl of cell suspension (30 000 cells per well) were added to 
each well of upper chamber. The CIM-plate16 was placed in the RTCA DP Instrument 
equilibrated in a CO2 incubator and migration of RAW 264.7 cells was continuously 
monitored. The combination of chemoattractants (colon explant culture supernatants, 
RPMI media including various cytokines/chemokines) provides a signal, which induces the 
directional migration of RAW 264.7 cells through the micropores of the CIM-plate16. 
Migrating cells were detected by the electronic sensing and data are expressed as slopes 
of cell index values. 
 
3.3.2 Isolation and analysis of murine cells 
 
To further analyze the impact of MMP-deficiency, different cell types were isolated from 
wild-type, MMP-19-, MMP-28-deficient, and MMP-19/28-double-deficient mice. 
Experiments were carried out with peripheral blood mononuclear cells (PBMCs) and 
splenocytes. Blood collection was performed by retro-orbital bleeding of anaesthetized 
mice. Blood was collected in heparin coated tubes (Microvette® CB 300, Sarstedt, 
Nümbrecht, Germany) to avoid clotting.  
Cells were washed in PBS and centrifuged for 5 min at 300 x g. To remove erythrocytes, 
cells were treated with sterile filtrated 1 x ammonium chloride lysis buffer (150 mM 
NH4Cl, 10 mM Na2CO3, 1 mM EDTA, pH 7.4) for 5 min on ice. After centrifugation (5 min at 
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300 x g) and washing with PBS, cells were resuspended in PBS containing 1% BSA and 
0.1% NaN3, counted using the Neubauer counting chamber, and used for FACS analysis. 
Spleens were isolated from C57BL/6NCrl mice and passed through a nylon mash into a   
50 ml tube containing 5 ml 1 x PBS supplemented with 1% penicillin/streptomycin. The 
cell suspension was centrifuged at 300 x g for 5min at room temperature. The cell pellet 
was resupended in red cell lysis buffer, incubated for 5 min on ice and centrifuged again 
at 300 x g for 5 min. The supernatant was discarded, cells were washed with 1 ml PBS and 
resuspended in FACS solution (PBS, 1% BSA, 0.1% NaN3), and counted using Neubauer 
counting chamber. 
 
3.3.3 Flow cytometry 
 
Analysis by flow cytometry was performed using cells isolated from blood and spleen. 
Once the cells were resuspended in FACS solution (PBS, 1% BSA, 0.1% NaN3) following 
steps were performed on ice. For each analysis 300 000 cells were taken and 
centrifugation steps were run with 300 x g for 5 min at 4°C. For detection of surface 
molecules only antibodies directly conjugated with fluorochromes were used. Staining 
with antibodies was performed in 100 μl FACS solution for 30 min on ice in the dark. 
Antibodies used for flow cytometry are listed in following table (Tab. 3-7). Before 
incubation with fluorochrome-conjugated antibodies cells were pre-treated with rat anti-
mouse CD16/CD32 antibodies to block Fc-receptors to reduce unspecific binding. 
Additionally, in each experiment unstained cells were prepared to generate the settings 
of the FACS (LSRII, BD, CA, USA) before starting the measurement. Also, all antibodies 
were used in single stainings for compensation. 
Single-cell suspensions were washed with FACS buffer (PBS, 1% BSA, 0.1% NaN3) and 
incubated with combinations of the following antibodies:  
 
Antibody cocktail  
Mix 1 (T cells) CD3 ε, CD4, CD8, CD69 
Mix 2 (T and B cells) CD4, CD25, B220 
Mix 3 (NKT cells) CD45, CD3 ε, NK1.1 
Mix 4 (macrophages) CD45, CD11b, F4/80 
Mix 5 (granulocytes) CD45, CD69, Ly6G/C 
 
Cells were analyzed on an FACS LSRII (BD Immunocytometry Systems, CA, USA), and 
analysis was performed using FlowJo software (Tree Star, OR, USA). 
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Table 3-7: Antibodies used for flow cytometry. 
 
Molecule Host and Species Specificity Fluorochrome Distributor 
CD3ε monoclonal hamster anti-mouse FITC EXBIO 
CD4 monoclonal rat anti-mouse APC EXBIO 
CD8 monoclonal rat anti-mouse Alexa700 EXBIO 
CD11b monoclonal rat anti-mouse FITC BD Biosciences 
CD25 monoclonal rat anti-mouse FITC BD Biosciences 
CD45 (pan) monoclonal rat anti-mouse Alexa647 gift of Dr. Waldman 
CD69 monoclonal rat anti-mouse PE BioLegend 
Ly6 G/C monoclonal rat anti-mouse FITC BD Biosciences 
F4/80 monoclonal rat anti-mouse PE BioLegend 
NK1.1 monoclonal mouse anti-mouse PE BD Biosciences 
B220/CD45R monoclonal rat anti-mouse PE BD Biosciences 
    
CD16/CD32 monoclonal rat anti-mouse -- BioLegend 
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3.4 Protein analysis  
 
 
3.4.1 Expression and purification of human MMP-19 GST-fusion protein  
(GST-MMP19) 
 
MMP-19 was produced as a fusion protein with glutathione-S-transferase [228] in the BLR 
(DE3) strain of E. coli (Novagen, Germany) using the expression vector pGEX-2T. The 
recombinant protein starts N-terminally with the GST fused in frame to Phe, the first 
amino acid of the propeptide domain, and ends with Arg, the first amino acid of the 36 
amino acid-long C-terminal tail. The expression of MMP-19 was induced by 0.6 mM IPTG. 
MMP-19 was produced as a fusion protein of glutathion-S-transferase [228] and MMP-19 
as described [203; 229]. Purification was done according to Rohman and Harrison-Lavoie 
[230] with slight modifications. In brief, the pelleted bacteria were resuspended in 20 ml 
buffer A (sonication buffer, 100 mM triethanolamine-HCl (TEA-HCl), 150 mM NaCl,         
1% Triton X-100, pH 7.4) and disrupted in the presence of Complete
TM 
proteinase inhibitor 
(Roche, Mannheim, Germany) by sonification. The sonicate was pelleted and the 
supernatant transfered into 4 ml of buffer B (100 mM TEA-HCl, 200 mM MgCl2, 500 mM 
KCl, 100 mM ATP, pH 7.4) and incubated for 30 min at room temperature. This step was 
followed by an incubation for 45 min with 0.5 ml 50% slurry of Glutathione Sepharose 4B 
(GE Healthcare, UK). The sepharose mixture was washed three times with 10 ml buffer C 
(100 mM TEA-HCl, 150 mM NaCl, 20 mM MgCl2, 50 mM KCl, 1% Triton, 10 mM ATP, 
protease inhibitors, pH 7.4). In the last washing step buffer D was used (100 mM TEA-HCl, 
150 mM NaCl, 20 mM MgCl2, 50 mM KCl, 5 mM ATP, pH 7.4). For elution of the bound 
fusion protein we used 50 mM Tris-HCl with 10 mM reduced glutathione, pH 8.0 which 
was prepared freshly prior use. 5 elutions were performed and analyzed by SDS-PAGE. 
The fractions were pooled and dialysed over night at 4°C against 2 l TNC buffer (50 mM 
Tris-HCl, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2, pH 7.4) using a Slide-a-lyser cassette 
(PIERCE, USA) to get rid of the reduced glutathione. The concentration was determined 
using BCA kit (PIERCE, USA). 
 
3.4.2 Determination of GST-MMP-19 activity 
 
To test whether the purified MMP-19 protein was active, a cleavage assay using a 
quenched fluorescence substrate (MMP-2 Substrate, fluorogenic, Calbiochem) was 
performed for 1h at 37°C. Cleavage of the fluorogenic substrate resulted in increasing 
fluorescence. Different concentrations of GST-MMP-19 WT (1.5 - 6 μg/well) were used in 
order to evaluate the protein dependency of the activity. A sample without GST-MMP-19 
served as control to exclude self degradation of the fluorogenic substrate during the assay. 
To verify the specific effect of recombinant GST-MMP-19 the inhibitor MMP-9/MMP-13 
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Inhibitor II (10 μM, N-Hydroxy-1-(4-methoxyphenyl)sulfonyl-4-benzyloxycarbonyl- 
piperazine-2-carboxamide, Calbiochem) was used to block its activity. All assays were 
carried out in TNC buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2,        
pH 7.4) containing 10 μM ZnCl2. 
 
3.4.3 Fractalkine cleavage assay  
 
The processing of 1 μg human fractalkine (R&D Systems, USA) was done in TNC buffer   
(50 mM Tris-HCl, 150 mM NaCl, 5 mM MgCl2, 5 mM CaCl2, pH 7.4) containing 10 μM ZnCl2 
with 4 μg GST-MMP-19 at 37°C for 35h. To determine the specificity of the cleavage, the 
inactive MMP-19 mutant (E213A) was used instead of the active protein as well as a     
set-up without any enzyme to observe self-processing of fractalkine.  
 
3.4.4 Protein isolation from tissue biopsies  
 
Colon biopsies were snap-frozen in liquid nitrogen and stored at -80°C. Colon from DSS-
treated WT and MMP-19-deficient mice were excised, crushed in liquid nitrogen and 
lysed for 45 min on ice in modified RIPA buffer (50 mM Tris HCl, 150 mM NaCl, 0,1% SDS, 
0.5% DOC (sodium deoxycholate), 1% Triton X-100, pH 7.5) containing 1 mM EDTA, and 
proteinase inhibitors (Complete EDTA-free, Roche, Germany).  
 
3.4.5 BCA protein assay  
 
BCA Protein Assay kit (PIERCE, IL, USA) was used to determine the protein concentration 
in tissue lysates. The protein samples were 10 times diluted in dH2O, standards and 
working reagent were prepared according to the manufacturer´s protocol. To the 25 μl of 
the sample or standard, 100 μl of working reagent was added. The mixture was incubated 
at 37 °C for 30 minutes and absorbance of standards or samples was measured at 562 nm 
by a Tecan Reader Infinite M200 (Tecan group, Switzerland). The concentration of 
samples was calculated from the standard curve. 
 
3.4.6 TCA protein precipitation  
 
Supernatants (RIPA media without FCS) of colon explant cultures had to be concentrated 
before analysis by immunoblotting. Concentration was done by TCA (Trichloroacetic acid) 
protein precipitation. In brief, to one volume protein 1/100 volume of 2% DOC (sodium 
deoxycholate) were added and the mixture were kept on ice for 15 min. Afterwards 1/10 
volume of 100% TCA were added and kept on ice for 1 h. The precipitated proteins were 
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collected by centrifugation at 10000 x g for 10 min at 4°C. The resulting pellet was 
washed in ice-cold acetone to get rid of residual TCA. The protein pellet was resuspended 
directly in reducing Laemmli sample buffer. In case the protein mixture changed to 
yellow, indicating remains of TCA a few microlitres of 1 M Tris, pH 8.8 were added until 
the colour changed back to blue. 
 
3.4.7 Preparation of protein samples for SDS-PAGE  
 
Lysates or mixture of recombinant proteins were mixed with reducing loading dye       
(250 mM Tris, 40% glycerol, 20% β-mercaptoethanol, 8% SDS, 0.05% bromophenol blue). 
Samples were mixed by vortexing and incubated at 95 °C for 5 minutes. In case of the 
colon lysates, 30 μg of protein and 10 μl of concentrated CEC supernatants were loaded 
on a polyacrylamide gel. For the analysis of the fractalkine cleavage assay 15 μl of the 
digest were loaded.  
 
3.4.8 Immunoblotting (Western blotting) 
 
Proteins were separated on 12.5% SDS gels, followed by electrophoretic transfer (transfer 
buffer: 3.03 g Tris, 14.27 g Glycine, 20% methanol) onto a PVDF membrane, pore size 
(0.45 μm) (Macherey-Nagel, Germany). Membranes were blocked with 5% non-fat milk in 
TBST buffer containing 20 mM Tris-HCl, 500 mM NaCl, and 0.1% Tween-20, pH 7.5        
(5% TBSTM buffer) for an hour at room temperature. For detection, polyclonal goat anti-
fractalkine antibody (Santa Cruz, CA, USA) or anti-fractalkine serum (gift of Dr. Andreas 
Ludwig, Aachen, Germany) were diluted in 2% TBSTM buffer and incubated on the 
membrane overnight. After three washing steps, the bound antibody was detected using 
peroxidase-conjugated rabbit anti-goat antibody (Jackson Immuno Research, West Grove, 
PA) and the ECL plus Western Blotting Detection System (GE Healthcare, UK). Signals 
were recorded with a Luminescent Image Analyzer (LAS-3000, Fujifilm Life Science, USA). 
 
Table 3-8: Primary antibodies used for immunoblotting. 
 
primary antibodies distributer dilution 
polyclonal goat anti-fractalkine antibody (C-20) 
(sc-7225) 
Santa Cruz, USA 1 : 500 
fractalkine anti-serum (polyclonal rabbit) 
Dr. Andreas Ludwig, 
Germany 
1 : 2000 
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Table 3-9: Secondary antibodies used for immunoblotting. 
 
secondary antibodies distributer dilution 
peroxidase-conjugated rabbit anti-goat 
antibody 
Jackson Immuno 
Research, USA 
1 : 20 000 
peroxidase-conjugated goat anti-rabbit 
antibody 
PIERCE, Germany 1 : 10 000 
3.4.9 Zymography 
 
For the detection of gelatinase activity (e.g. MMP-2 (gelatinase A) and MMP-9 (gelatinase 
B)) an 8% SDS-PAGE containing 1 mg/ml gelatine was prepared. Colon homogenates of 
healthy and DSS-treated WT and MMP-19-deficient mice were used in this analysis. The 
gel was prepared as follows: 
After finishing the protein separation, gels were washed two times for 20 min in 2.5% 
Triton X-100 to remove the SDS. Afterwards they were incubated for 24h in TNC buffer 
(50 mM Tris-HCl, pH 7.5, 5 mM CaCl2, 10 µM ZnCl2, 0.05% Triton X-100) at 37°C. The parts 
of gelatinase activity were displayed by staining with 0.5% Coomassie Blue R-250 (Sigma, 
Germany) and appeared in white on a blue background. 
 
 
3.5 Barrier function 
 
3.5.1 FITC dextran administration 
 
Intestinal permeability was assessed by administration of non-metabolizable 
macromolecule FITC-dextran 4 (MW: 4000 Dalton) (TdB Consultency, Uppsala, Sweden). 
FITC-dextran was administered by gavage (0.6 g/kg body weight) 4 h before sacrifice.  
Food and water were removed 4 h before administration. Whole blood and plasma were 
obtained by retro-orbital bleeding of anaesthetized mice. Blood was collected in heparin 
coated tubes (Microvette® CB 300, Sarstedt, Nümbrecht, Germany) to avoid clotting. 
Dilutions of FITC-dextran 4 in PBS were used as a standard curve and absorption of 100 μl 
serum or standard was measured in a fluorometer at 488 nm. 
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3.6 Statistical analysis 
 
All parametric data are presented as means ± standard deviation [155]. Statistical 
analyses were performed with GraphPad Prism. Data from two groups were analyzed for 
significance using a student’s unpaired t-test. More groups were compared using one-way 
ANOVA (Kruskal-Wallis and Dunns Post test). Differences were considered significant at   
p < 0.05 and marked with *. ** designates p < 0.005 and *** p < 0.001. 
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4 Results 
 
4.1 Constitutive expression of MMP-19 and MMP-28 in mouse 
colon 
 
Unlike human MMP-19 and MMP-28, which have been shown to be expressed in normal 
intestine [131], expression of the murine orthologs in the colon is less well characterized. 
To address this point, colonic tissue samples of wildtype (n = 3), MMP-19-, and                
MMP-28-deficient mice (both n = 3) were analysed for basal expression of MMP-19 and 
MMP-28 by semi-quantitative PCR. GAPDH mRNA expression served as endogenous 
control (Figure 4-1A and C). The expected PCR fragment had a size of 65 bp. As shown in 
Figure 4-1, MMP-19 and MMP-28 were constitutively expressed at similar levels in colonic 
tissue of wildtype mice. The absence of MMP-19 or MMP-28 transcript in the tissue of the 
respective knockout mice was in agreement with the genotyping data confirming the 
disruption of the MMP genes. MMP-19 expression levels in the colon of MMP-28 -/- mice 
as well as MMP-28 expression levels in the colon of MMP-19 -/- mice were comparable to 
those observed in the wildtype animals (Figure 4-1B and D). The size of the PCR products 
was 82 bp for MMP-19 and 101 bp for MMP-28. 
 
 
 
Figure 4-1: mRNA expression of MMP-19 and MMP-28 in mouse colon.  
mRNA for both MMPs was detected in murine colonic tissue by semi-quantitative RT-PCR. 
Transcripts could not be detected in tissues from MMP-deficient mice. +/+: wildtype; 19-/-:  
MMP-19 -/-; 28 -/-: MMP-28 -/-. 
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4.2 Acute colitis 
 
To investigate the impact of MMP-19 and MMP-28 deficiency on colitis development, 
acute colitis was induced in WT (n = 10), MMP-19 -/- (n = 11), MMP-28 -/- (n = 7) as well 
as MMP-19/-28 double-deficient (n = 12) mice by administration of 2% DSS in the drinking 
water for six days. Only males was used for all experiments as a significant gender bias in 
susceptibility to DSS-induced colitis were reported. Female mice seemed to be more 
susceptible to the treatment [168]. The use of females was also avoided from the 
beginning of the study because of the probable influence of hormonal changes during 
long-term experiments (e.g. chronic colitis). Untreated mice, wildtype, and single MMP-
deficient mice (n = 5) were used as control. The mice were sacrificed after they had 
received normal drinking water for another two days (Figure 4-2). Body weight, disease 
activity index (DAI) [223], and survival rates were monitored daily. Besides, changes in 
colon length, spleen size and weight were recorded, and histological analysis of colon and 
spleen tissue was performed.  
 
 
 
Figure 4-2: Induction of acute colitis, course of experiment.  
Mice were treated with 2% DSS for 6 days and then received 2 days normal drinking water. 
 
 
4.2.1 MMP-19- but not MMP-28-deficient mice show increased susceptibility 
to colitis 
 
In contrast to the DSS-treated MMP-28 -/- mice, which only started to lose weight from 
day 5 and had not lost more body weight than the treated wildtype animals after day 8, 
the MMP-19-deficient mice lost weight starting at day 3 and, at the end of the 
experiment, showed a significantly higher weight loss than the wildtype mice (25 ± 5% 
versus 12 ± 3%, p < 0.005) (Figure 4-3A). The untreated control animals did not lose any 
weight. The prominent weight loss of the MMP-19 -/- mice was reflected in a higher 
disease activity index [223] score compared to the MMP-28 -/- mice (DAI on day 7:  4.0    
± 0.58 (MMP-19 -/-) versus 2.3 ± 0.56 (MMP-28 -/-) versus 2.0 ± 0.3 (WT), p < 0.05) (Figure 
4-3B). The more severe colitis in the MMP-19 -/- mice also resulted in the death of about 
15% of the animals. In contrast, all MMP-28-deficient mice survived (Figure 4-3C). 
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Figure 4-3: MMP-19 -/- but not MMP-28 -/- mice are more susceptible to colitis than WT mice. 
(A) Body weight development of DSS-treated WT (n = 10), MMP-28 -/- (n = 7, left panel) and 
MMP-19 -/- (n = 9, right panel) mice over the course of acute colitis (8 days).  The body weight of 
untreated animals was recorded as control (right panel). (B) Development of disease activity index 
[223] of DSS-treated MMP-28 -/- (left panel) and MMP-19 -/- (right panel) mice. Data points for 
body weight and DAI are expressed as the mean value of all surviving animals within one group    
± SD. (C) Survival curves (Kaplan-Meier) for MMP-28 -/- (left panel) and MMP-19 -/- (right panel).  
 
 
Analyzing the colon of the mice on day 8, all DSS-treated animals displayed a shortened 
colon compared to the untreated control group (average: 6.8 ± 0.53 cm, set as 100%). 
However, whereas the colon length of the treated MMP-28 -/- mice (4.82 ± 0.43 cm, i.e. 
70.9% of untreated colon length) was not significantly different from the one of the 
treated wildtype animals (4.65 ± 0.37 cm, i.e. 68.4%), the colon length of the MMP-19 -/- 
mice was reduced to 3.8 ± 0.27 cm, i.e. 55.9% , p < 0.01) (Figure 4-4A and C).  
Size and weight of the spleen were increased in the DSS-treated WT mice compared to 
the untreated control (Figure 4-4B). This was not observed for the spleens of the       
MMP-28- or MMP-19-deficient mice. Accordingly, the spleen weight of the MMP-19 -/- 
mice was similar to the one measured for the control animals and significantly reduced 
compared to the spleen weight of the WT mice (Figure 4-4B and C). MMP-28 -/- mice had 
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a similar body weight than MMP-19 -/- and untreated mice but also in this experiment 
there was a tendency for an increased spleen in WT animals. 
Taken together, most of these data demonstrate an increased susceptibility of MMP-19-
deficient mice to DSS-induced colitis.  
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Figure 4-4: Colon length and spleen weight of MMP-19- and MMP-28-deficient mice with acute 
colitis. 
(A) Colon length of DSS-treated MMP-28 -/- (left panel) and DSS-treated MMP-19 -/- (right panel) 
compared with the treated wildtype and the untreated controls. Whereas no significant 
differences were observed in the colon length between treated WT and MMP-28 knockout mice, 
the colon length of the MMP-19 -/- mice was significantly reduced compared to the wildtype        
(-12.5%, p < 0.01). (B) Spleen weight of DSS-treated MMP-28 -/- (left panel) and DSS-treated   
MMP-19 -/- (right panel) compared with the treated wildtype and the untreated controls. The 
spleen weight of the MMP-19 -/- (right panel) but not the MMP-28 -/- (left panel) mice was 
significantly reduced compared to the wildtype. Data for (A) and (B) are expressed as means ± SD. 
(C,D) Representative pictures showing colon length (C) and spleen size (D) of treated WT,      
MMP-19 -/-, and MMP-28 -/- mice. 
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4.2.2 Acute colitis is most severe in MMP-19/-28 double-deficient mice 
 
Functional redundancy and compensation mechanisms due to overlapping substrate 
specificity are common among the MMP family members. To assess if MMP-19 and  
MMP-28 could compensate for each other in the single-deficient mouse models, the 
acute colitis experiment was repeated with MMP-19/-28 double knockout mice. Wildtype 
and MMP-19 -/- mice served as controls.  
The most striking result was a dramatic reduction in survival of the MMP-19/-28     
double-deficient mice compared to the control animals (survival rate on day 8: WT, 100%;    
MMP-19-/-, 85%; MMP-19/-28 -/-, 25%) (Figure 4-5C). Those MMP-19/-28 dbKO mice that 
survived lost also more weight and showed a higher DAI score than the MMP-19      
single-deficient or wildtype mice (Figure 4-5A and 4-5B).  
 
 
 
 
 
Figure 4-5: Acute colitis is considerably exacerbated in MMP-19/-28 double-deficient mice.  
Body weight changes (A), disease activity index [223] (B) and survival (C) of DSS-treated WT          
(n = 10), MMP-19 -/- (n = 9) and MMP-19/-28 dbKO (n = 3) were recorded daily and monitored 
over 8 days.  Data points for body weight and DAI are expressed as mean values of all animals 
within one group ± SD. 
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In addition, the colon length was significantly reduced compared to wildtype animals 
(4.11 ± 0.29 cm, i.e. 60.4%) but similar to the length of MMP-19 -/- colons. The spleen, 
however, did not display any major changes in size and weight (Figure 4-6).  
Together, these findings demonstrate that the phenotype of the MMP-19/-28 double 
knockout mice is more severe than the one observed for the MMP-19 -/- single-deficient 
mice. Considering that the MMP-28 -/- animals did not show a phenotype, this indicates 
the capacity of MMP-19 to at least partially compensate MMP-28 function but not vice 
versa. 
                  
 
                                    C 
 
Figure 4-6: Colon length and spleen weight of MMP-19/-28 double-deficient mice with colitis. 
(A) Colon length of DSS-treated MMP-19/-28 double-deficient, MMP-19 -/- , wildtype (WT) and 
untreated control mice. The MMP-19/-28 dbKO (-7.9%) and the MMP-19 single-deficient mice      
(-12.5%) showed a significantly reduced colon length compared to the wildtype animals.              
(B) Spleen weight. No significant differences were detected between the groups.                           
(C) Representative pictures showing the shortened colon and the unchanged size of spleen of the 
MMP-19/-28 dbKO mice.  
 
 
To evaluate if the onset or progression of colitis was different between the strains, a time 
course experiment was performed (Figure 4-7). Acute colitis was induced as described, 
and every second day three mice per strain were sacrificed in order to analyze the 
development of the shortening of the colon, the size of the spleen as well as histological 
parameters.  Up to day 2, no shortening of the colon was detected in any of the strains, 
and differences to the healthy control mice were not significant. The first signs of disease 
were observed at day 4, with a reduced colon length of the MMP-19 -/- mice compared to 
the WT and MMP-28 animals. However, the differences were not significant at this point. 
By contrast, in case of the double-deficient mice, the colon was shortened to an average 
** 
* 
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of 5 cm, which was highly significant (p < 0.005). Analyzing the colon length two days later 
(day 6), a statistically significant difference was seen in MMP-19 single- as well as      
MMP-19/-28 double-deficient mice compared to the wildtype group (p < 0.05). This 
difference was still observed at day 8 (p < 0.05).  
The weight of the spleen did not change significantly throughout the experiment but at 
day 8, spleens of wildtype mice were markedly bigger than those of MMP-19 -/- animals 
(see also 4.2.1). However, no significant difference was detected among the mutant 
strains, MMP-19 -/-, MMP-28 -/-, and MMP-19/-28 double-deficient mice. 
 
 
Figure 4-7: Monitoring colon length and spleen weight during the course of colitis.  
Acute colitis was induced in WT (n = 12), MMP-19 -/- (n = 12), MMP-28 -/- (n = 12), and          
MMP-19/-28 dbKO mice (n = 12). Every other day until the end of the experiment (day 8), 3 mice 
per group were sacrificed, and colons and spleens were analyzed for changes in size and weight. 
(A) A continuous reduction in colon length was observed in all groups, with no significant 
differences between MMP-28-deficient and wildtype mice. In contrast, the colon length of the 
MMP-19-deficient and the MMP-19/-28 double-deficient mice were markedly reduced compared 
to the wildtype animals throughout the experiment. (B) The spleen weight of wildtype mice 
increased steadily during the course of the experiment, whereas the one of the other groups 
increased only until day 4 and afterwards remained largely unchanged or even decreased.             
*, p < 0.05; **, p < 0.005. 
 
 
4.2.3 MMP-19 single- and MMP-19/-28 double-deficient mice developed 
anemic spleens 
 
The spleen consists of two major parts, the red pulp and the white pulp. Whereas the 
white pulp is responsible for the immune response, the red pulp filters the blood for 
pathogens and dying cells and serves as a reservoir for monocytes [231]. Under normal 
conditions the red pulp is always filled with blood in order to clean it. Analysis of mouse 
spleens after acute DSS-treatment revealed signs of severe anemia (loss of red blood 
cells) in case of the MMP-19-deficient and MMP-19/-28 double-deficient animals. This 
phenotype is due to the excessive blood loss caused by the acute colitis and damaged 
epithelia, which leads to internal bleeding into the colon and is detectable during the 
course of colitis. At day 8 all strains had anemic spleens; however, the double-deficient 
mice were most affected as all surviving mice depicted this phenotype. 
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Figure 4-8: Development of anemic spleens during the course of acute colitis.   
Spleens were found to be anemic already at day 4 in more than half of the experimental cohort of 
MMP-19 -/- and MMP-19/-28 double-deficient mice. At day 8 also the other strains showed a 
decreased number of red blood cells in the spleens. All double-deficient mice were showing this 
phenotype. Two independent experiments were performed. 
 
 
4.2.4 Extensive colon inflammation and damage in MMP-deficient mice with 
acute colitis 
 
For histological analysis, the mouse colon was divided into three parts – proximal, middle, 
and distal. All parts were analyzed throughout the study. Only results of the distal part of 
the colon are shown as this area was reported to be the most affected one in DSS-
induced colitis [98; 232], which is in line with the obtained results. Three mice per group 
and experiment were randomly picked and the tissue sections evaluated in a blind 
analysis by a pathologist.  Colon sections stained with hematoxylin/eosin were analyzed 
for parameters related to tissue destruction and inflammation (Figure 4-11).  
All untreated mice did not show any signs of disease, even if analyzed in detail         
(Figure 4-9). 
 
 
Figure 4-9: Representative pictures of colons of untreated (healthy) mice.  
Hematoxylin/eosin staining of WT, MMP-28 -/-, MMP-19 -/-, and MMP-19/-28 dbKO mice, 
magnification x 100. 
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All DSS-treated mice showed clear signs of colon inflammation and damage. Thus, about 
50% of the colon mucosa of WT mice displayed inflamed lesions and oedema (Figure 4-10 
and 4-11A and 4-11B), and about 40% of the tissue was affected by crypt damage (Figure 
4-11G). An oedema is an abnormal accumulation of fluid in the tissue due to increased 
blood vessel wall permeability e.g. during inflammation. It is one of the first signs of 
inflammation caused by a strong acute inflammatory response. The spatial extent of crypt 
damage needs to be seen in conjunction with the depth of damage. A damage score of 1 
means the whole crypt is destroyed and not recognizable anymore. 
A considerable neutrophil influx was another symptom of increased inflammation (Figure 
4-11B). However, the most severe colon damage was observed for the MMP-19-deficient 
mice. The area showing inflamed lesions covered about 80% of the tissue, which was 
significantly more than seen in all other groups (Figure 4-11A). Ulceration intensity and 
depth as well as crypt damage and depth were also significantly increased compared to 
the WT and the MMP-28 -/- mice (Figure 4-11C, D, G and H). Ulceration describes the loss 
of the epithelium in the colon during DSS-treatment. In case of 100% ulceration intensity 
the whole epithelium is absent. The depth score also describes how deep the ulceration 
affects the mucosa. Remarkably, the MMP-28-deficient mice displayed generally less 
severe colon inflammation and destruction than the WT animals. For instance, the extent 
of inflamed lesions and the intensity of ulceration were markedly reduced, although no 
significance was achieved. The MMP-19/-28 double-deficient mice showed a trend 
towards more severe colon damage than observed in the MMP single- deficient animals. 
However, the differences were not significant, which probably resulted from the fact that 
only surviving mice were analyzed. Furthermore, especially the MMP-19-deficient mice 
showed a high percentage of hyperregenerative tissue (Figure 4-11F). Regeneration 
means normal restoration/repair of the epithelium, which is a positive effect. In contrast, 
the term hyperregeneration means that large numbers of immature epithelial cells are 
present at the site of restoration, the repair mechanisms are not controlled properly, 
which can lead to tumor development.  
  
Taken together these findings further support the increased susceptibility of the       
MMP-19-deficient mice to DSS-induced colitis and suggest that they are also more prone 
to develop colon cancer. 
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Figure 4-10: Representative pictures of proximal colon after acute colitis of WT, MMP-28 -/-, 
MMP-19 -/-, and MMP-19/-28 double-deficient mice.  
Extensive oedema formation could be observed in MMP-19 -/- and MMP double-deficient mice 
(arrows), compared to milder influx of liquids in WT and MMP-28 -/- animals. Arrowheads are 
pointing to the epithelium of the mucosa, which is still present in WT and MMP-28 -/- mice but 
nearly completely absent in MMP-19 -/- and MMP double-deficient mice. Hematoxylin/eosin 
staining, magnification x 40. 
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Figure 4-11: Histological analysis of colon tissue of MMP-deficient mice with colitis.  
Colon tissue sections of DSS-treated WT, MMP-19 -/-, MMP-28 -/-, and MMP-19/-28 double-
deficient mice were stained with hematoxylin/eosin and analyzed for parameters related to 
inflammation and tissue destruction. Untreated mice of each group served as controls. All DSS-
treated animals showed clear signs of colon inflammation and tissue damage. The most severe 
symptoms, however, were observed for the MMP-19-deficient mice, which displayed a 
significantly higher percentage of inflamed lesions (A), ulceration (C) and crypt damage (G) as well 
as hyperregenerative  tissue (F) than WT and MMP-28 -/- mice. The MMP-19/-28 double-deficient 
mice showed a trend towards more severe colon inflammation and damage compared with the 
WT animals but no significant differences were seen (data are shown as dot plot with means.        
*, p < 0.05). 
 
 
4.2.5 Decreased and delayed neutrophil influx and higher inflammation 
scores in MMP-19-deficient mice 
 
Analysis of hematoxylin/eosin stained distal parts of the colon over the course of acute 
colitis revealed that the percentage of inflamed colonic tissue in MMP-19 -/- mice is 
higher during the whole treatment (Figure 4-11A), whereas oedema formation is similar 
in both lines at the beginning and only significantly increased at day 8 in the MMP-19-
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deficient mice (Figure 4-11B). The amount of neutrophils in the inflamed tissue rose to 
90% of all cells in WT mice on day 2 of the treatment, during the progression of the 
disease the numbers of neutrophils decreased to 20% of all cells at day 8. At this time 
point of the colitis, WT and MMP-19-deficient mice showed the same numbers of 
neutrophils in the inflamed colon tissue, whereas at the beginning neutrophils were not 
accumulating at the sites of inflammation in MMP-19 -/- mice (Figure 4-12C).  An ulcer is a 
sore in the lining of the colon epithelium, accompanied by disintegration of tissue. Ulcers 
could result in a complete loss of the epithelium and often affect the underlying layers of 
the colon wall as well. The disrupted bleeding tissue causes inflammation in the colon, 
causing diarrhea. It was a few days before ulceration developed in the DSS-treated mice 
but it was earlier seen in the MMP-19 -/- mice and around 90% of the tissue was affected 
in these animals compared to only 20% in WT mice (Figure 4-11D). 
 
Figure 4-12: Higher inflammatory lesion extent and low numbers of neutrophils in lesions over 
the course of acute colitis in MMP-19-deficient mice.  
The percentage of inflamed colonic tissue (A) in MMP-19 -/- mice is higher during the whole 
treatment, whereas oedema formation (B) is similar in both lines at the beginning and only 
significantly increased at day 8 in the MMP-19-deficient mice. Neutrophils are not accumulating in 
the tissue of MMP-19 -/- mice, numbers stayed at low levels during the course of colitis (C). In 
contrast, the amount of tissue affected by ulceration of the mucosa rose to 90% until the end of 
the experiment (D). 
 
 
In addition to the evaluation of the amount of neutrophils in the tissue, MPO 
(Myleoperoxidase) activity was measured in WT and MMP-19 -/- mice at day 8 of the 
experiment. MPO is an enzyme produced mainly in neutrophils [233; 234] but also other 
inflammatory cells like macrophages. MPO is secreted by activated neutrophils and 
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macrophages during inflammation and after phagocytosis of bacteria. The higher the 
amount of this enzyme the more neutrophil granulocytes are present in the analyzed 
tissue, which indicates higher inflammation. An increase of MPO levels was detected in 
MMP-19-deficient mice, whereas WT mice showed only low activity (Figure 4-13). Thus, 
these results supported the histological findings where a slight tendency of higher 
numbers of neutrophils was observed (Figure 4-12C) and indicated more severe 
inflammation in MMP-19-deficient animals than in wildtype mice at day 8. The elevated 
numbers of neutrophils in the knockout tissue fit with the increased activity of gelatinases 
in the tissue as neutrophils are one source of these enzymes (see section 2.4.). 
 
Figure 4-13: Increased MPO levels in MMP-19-deficeient mice. 
MPO levels in the colon of MMP-19-deficient mice (n = 3) were increased compared to WT 
animals (n = 3). Data are shown as means ± SD. * p < 0.05. 
 
 
4.2.6 Higher amount of active gelatinases in colon tissue of MMP-19-
deficient mice after administration of 2% DSS 
 
To analyze the regulation of other MMPs in WT and MMP-19 -/- mice under normal and 
disease conditions a method called zymography was applied. Zymography is an 
electrophoretic technique to detect gelatinolytic activity. It is based on SDS-PAGE that 
includes a substrate, in this case gelatine, copolymerized with the polyacrylamide gel. 
Areas of gelatinolytic activity appear as clear bands against a darkly stained background. 
Gelatine is the most commonly used substrate, and is useful for demonstrating the 
activity of gelatine-degrading proteases, such as MMP-2 and MMP-9 (gelatinases A and 
B). Pro-forms of MMP-2 and MMP-9 could be detected in colon lysates of untreated mice. 
Also a faint signal for the active enzymes was visible (Figure 4-14A). Analysis of the band 
intensities revealed that around 20% of MMP-2 and less than 10% of MMP-9 were 
present in their active form (Figure 4-14C). Analyzing DSS-treated mice suffering from 
acute colitis, no changes were observed for levels of active MMP-2 in WT animals, 
whereas the MMP-19 -/- mice showed a fourfold higher amount of active gelatinase A. 
Concerning MMP-9, there was a slight increase in the active form of the enzyme, which 
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was not significant. In MMP-19-deficient mice in contrast, the amount of active MMP-9 
was elevated five times (Figure 4-14B and C). 
 
Figure 4-14: Zymography of colon lysates of healthy and diseased WT and MMP-19 -/- mice.  
(A) Zymogram of colon lysates of healthy WT and MMP-19 -/- mice (n = 2). (B) Zymogram of colon 
lysates of WT and MMP-19 -/- mice treated with DSS (n = 3). (C) Evaluation of percentage of active 
MMP-2 and MMP-9 in the colon lysates of WT and MMP-19 -/- mice by Aida Image Analyzer 
software. Data are shown as means ± SD, *** p < 0.001. 
 
 
4.2.7 MMP-19-deficient mice had increased permeability of the mucosa 
 
A coordinated regenerative response is required to maintain the intestinal barrier 
function. Impaired barrier integrity leads to fast and severe progression of intestinal 
diseases. Membrane integrity was measured in the experiment by permeability of FITC-
dextran [235]. FITC-dextran was administered by oral gavage four hours before sacrifice 
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and plasma was analyzed for the presence of FITC. In untreated animals, only low levels 
of FITC were detected and no difference could be found between WT and KO mice.  Upon 
DSS administration, the intestinal barrier became permeable for FITC-dextran in both 
lines although to higher extent in MMP-19-deficient mice (Figure 4-15). This 
demonstrated the highly destroyed barrier in the MMP-19-deficient animals. 
 
 
Figure 4-15: Permeability in colon of WT and MMP-19 -/- mice.  
Acute colitis was induced as described. Plasma FITC-dextran concentrations in WT (n = 2) and 
MMP-19-deficient (n = 2) mice 4h after administration. No significance was detected as only two 
mice per group were used but there is a strong trend towards an increased permeability in the 
MMP-19-deficient mice. 
 
 
4.2.8 Reduced proliferation and no significant change in amount of 
macrophages in MMP-deficient mice with acute colitis 
 
Proliferation in the colon tissue was analyzed by immunohistochemistry using an 
antibody against murine Ki-67, which is a nuclear antigen expressed by all proliferating 
cells. Only dark brown stained nuclei were counted as positive. 
Renewal of the colonic epithelial cells starts from the basal part of the crypts, from where 
dividing cells migrate towards the apical side. In the intestine, a constant cell turnover is 
needed to replace cells damaged through contact with luminal contents. Under normal 
conditions, cells migrate at a constant speed to the non-dividing segments of the crypts. 
In untreated mice a normal proliferative pattern was observed (Figure 4-16A).  
In contrast, the proliferation was diminished in the DSS-treated animals (Figure 4-16B and 
C). A significant difference was detected among WT, MMP-19-deficient, and MMP-19/-28 
double-deficient mice; in WT animals 25% of Ki-67 positive cells were present, whereas in 
the MMP-deficient mice only 10% of the epithelial cells were proliferating. This strong 
reduction of proliferating cell in acute colitis is due to the destructive effect of DSS to the 
epithelial cells, especially the basal ones. 
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Figure 4-16: Decreased proliferation of epithelial cells in colon of WT, MMP-19 -/-, MMP-28 -/- 
and MMP-19/-28 dbKO mice.  
The proliferation pattern in healthy colon mucosa was the same for all strains, a representative 
picture is shown (A and C). Strongly diminished numbers of proliferating epithelial cells were 
observed in all DSS-treated mice (C) although MMP-19 -/- and MMP-19/-28 double-deficient mice 
showed significantly less cells positive for the proliferation marker Ki-67 in the mucosa (B and C). 
Data are shown as individual data points with means, n = 2 for untreated mice; n = 5 for DSS-
treated mice. *, p < 0.05. 
 
 
Macrophages function in both innate as well as adaptive immunity of vertebrate animals 
and are the most important mediators in wound healing. They phagocytose (engulf and 
then digest) cellular debris and pathogens, either as stationary or as mobile cells, and in 
addition stimulate lymphocytes and other immune cells to respond to pathogens by 
releasing various cytokines. Another important function of macrophages is phagocytosis 
of ageing and apoptotic neutrophils, which are the predominant cells at the early stages 
of inflammation. Under normal conditions, only few macrophages are present in the 
colon mucosa (10%) (Figure 4-17B). Acute inflammation leads to activation and migration 
of macrophages to the site of tissue damage to initiate the healing process. At day 8 of 
acute DSS-induced colitis, inflammation was already well established in the colon. 
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Macrophages were detected with an antibody against F4/80, a transmembrane 
glycoprotein specific for these cell type. High numbers of macrophages were found in the 
mucosa of all analyzed mouse strains, although with no significant differences. Still, F4/80 
positive cells were reduced by trend in the MMP-19/-28 double-deficient mice         
(Figure 4-17A and B), an observation that fits well with the severe phenotype as the 
healing process in those mice appears to be impaired. 
 
 
 
Figure 4-17: Similar numbers of macrophages present in colon of WT, MMP-19 -/-, MMP-28 -/- 
and MMP-19/-28 dbKO mice in acute colitis.  
The amount of macrophages in the inflamed colon tissue was not significantly different in the 
analyzed mice (B), representative pictures are shown (A). Brown cells were positive for the 
macrophage marker F4/80. Data are shown as individual data points with means, n = 2 for 
untreated mice; DSS-treated mice: n = 5, WT; n = 6, MMP-19 -/-; n = 5, MMP-28 -/-; n = 3,      
MMP-19/-28 dbKO. *, p < 0.05. 
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4.2.9 Levels of cytokines and chemokines remained unchanged in plasma of 
MMP-19-deficient mice 
 
Only a few samples could be analyzed by BioPlex assay, as the number of tests available 
was limited. Plasma and supernatant of colon explant cultures were randomly picked (but 
both from the same mouse). In case of the untreated control animals, two samples were 
analyzed, for the treated ones three to six. Selected cytokines/chemokines out of a panel 
of 23 are shown in this study. 
To reveal the severity of acute colitis and the systemic impact of the inflammation in mice, 
levels of various inflammatory cytokines and chemokines in mouse plasma were assessed. 
Overall, there was no significant difference in the cytokine/chemokine levels. Acute phase 
cytokines like IL-1α and IL-6 were elevated in comparison to control although not changed 
between the DSS-treated mice of different genotype. Levels of TNF-α and IFN-γ did not 
change significantly (Figure 4-18A) and the same was true for the chemokine 
concentrations, no significant differences were detected between the treated groups 
(Figure 4-18B). Interestingly, very high levels of G-CSF (granulocyte colony-stimulating 
factor) were observed in plasma samples from all mouse strains. This chemokine 
stimulates the bone marrow to produce granulocytes that are released into the blood 
stream in order to migrate to sites of inflammation. All together, as no pro-inflammatory 
cytokine exhibited an increase in the plasma, the mice suffering from acute colitis did not 
exhibit any systemic inflammatory response. 
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Figure 4-18: No significant differences in levels of cytokines and chemokines in plasma of mice 
with acute colitis.   
In general, concentrations of pro-inflammatory cytokines (A) and chemokines (B) in murine 
plasma were elevated compared to untreated samples but no differences were detected between 
the treated groups. Data are shown as individual data points with means, n = 2 for untreated 
groups; DSS-treated mice: n = 7, WT; n = 7, MMP-19 -/-; n = 3, MMP-28 -/-; n = 4, MMP-19/-28 
dbKO. No significant differences were detected. 
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4.2.10 Pro-inflammatory cytokines are highly elevated in mice with acute 
colitis 
 
All chemokines assessed in the supernatants of colon explant cultures (CEC) were 
enhanced in DSS-treated mice compared to control animals (Figure 4-19). In general, Th1 
cytokines like TNF-α and IFN-γ were increased in MMP-19 single- and MMP-19/-28  
double-deficient mice and showed higher values than wildtype mice. MMP-19 -/- mice 
exhibited also remarkably high values of the pro-inflammatory cytokine IL-6 secreted 
from colon tissue, which points to a high local acute phase response in the mice. IL-6 can 
be secreted by macrophages in response to specific microbial molecules, referred to as 
pathogen associated molecular patterns (PAMPs). The high IL-6 concentrations correlated 
with the destroyed epithelium and likely invasion of bacteria into the tissue. IL-1 was 
significantly increased in supernatants of MMP-19/-28 double-deficient mice, only a 
tendency to higher concentrations was observed in case of MMP-19 -/- mice. Anti-
inflammatory Th2 cytokines analyzed were IL-4 and IL-10, which were found to be 
significantly increased in colonic tissue of MMP-19 single- and MMP-19/-28               
double-deficient animals pointing to an attempt of the immune system to suppress the 
inflammation. Th2 cytokines stimulate the humoral immune system; they induce B cell 
proliferation, and increase neutralizing antibody production. 
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Figure 4-19: Highly elevated cytokine levels in colon tissue of MMP-19 single- and MMP-19/-28 
double-deficient mice.  
Pro- and anti-inflammatory cytokines were analyzed by BioPlex assay in supernatants of CEC. 
Increased levels of all depicted cytokines were found especially in the double-deficient animals. 
Data are expressed as dot plot with means, n = 2 for control mice, n = 3 for MMP-28 single- and 
MMP-19/-28 double-deficient animals, and n = 7 for MMP-19-deficient and WT mice (* p < 0.05, 
** p < 0.005, *** p < 0.001). 
 
 
4.2.11 Extremely high increase in chemokines release from colon tissue of 
MMP-19/-28 double-deficient mice 
 
To be able to complete the picture obtained from the histological analysis, amounts of 
chemoattractants released from mouse colon tissue in ex vivo colon explant culture 
model were analyzed. Levels of chemokines in all lines were elevated in comparison to 
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unchallenged control mice. Comparing the DSS-treated mice, it was obvious that WT and 
MMP-28 -/- mice produced the same amounts of chemokines, which were significantly 
lower than those of MMP-19 -/- and the double-deficient animals (Figure 4-20). 
Interestingly, extremely high values were found for G-CSF, KC, and MCP-1. These three 
proteins play an important role in the attraction of neutrophils and macrophages to sites 
of inflammation. KC (keratinocyte chemoattractant protein that replaces the activity of 
human IL-8) and MCP-1 (monocyte chemoattractant protein) act on activated neutrophils 
as well as macrophages. RANTES, which was elevated as well, plays an active role in 
recruiting leukocytes into inflammatory sites and induces proliferation and activation of 
Natural Killer (NK) cell subsets. 
 
 
 
 
Figure 4-20: Increased chemokine levels released from colon tissue of MMP-19 single- and 
MMP-19/-28 double-deficient mice.  
Chemokines responsible for the attraction of inflammatory cells, especially neutrophils and 
macrophages, depicted enhanced levels in CEC supernatants of MMP-19 -/- and double-deficient 
mice. Data are expressed as dot plot with means, n = 2 for control mice, n = 3 for MMP-28 single- 
and MMP-19/-28 double-deficient animals, and n = 6 for MMP-19-deficient and WT mice              
(* p < 0.05, ** p < 0.005, *** p < 0.001). Concentrations of KC and MCP-1 were analyzed by ELISA, 
whereas all other values were obtained from the multiplex analysis (BioPlex).  
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4.2.12 Enhanced production of chemokines released from MMP-19 -/- colon 
tissue promotes higher migratory level of RAW cells 
 
Migration of cells is essential for inflammatory processes, since granulocytes, 
macrophages, and other blood cells have to cross the basement membrane of the 
vascular endothelium to act at the site of affected tissues. Collagen type IV is the main 
component of the basement membrane that has to be disrupted upon transmigration. 
Migration through connective tissues containing high amounts of collagen type I requires 
activity of collagen type I-cleaving enzymes. Cells often migrate in response to, and 
towards, specific external signals, a process called chemotaxis. Chemoattractants are 
inorganic or organic substances possessing chemotaxis-inducer effect in motile cells. The 
chemoattractant moiety of a ligand is often target cell specific and concentration 
dependent. Most frequently investigated chemoattractants are chemokines. As 
remarkable high levels of several chemoattractants were observed in explants of colonic 
tissue of MMP-19-deficient and MMP-19/-28 double-deficient mice, the functionality of 
these chemokines was addressed. RAW 264.7 cells, a mouse leukaemic monocyte 
macrophage cell line, were used in a migration assay towards supernatants of colon 
explant cultures derived from WT and MMP-19 -/- tissues to study if some chemokines 
were not active due to absence of MMP-19 processing. Cells migrated three times faster 
towards the supernatant of MMP-19 -/- colon tissue (Figure 4-21), which resembled the 
higher concentrations of various chemokines in these samples. Probably non-active 
chemokines in this mixture did not impair the migratory efficiency of a monocytic cell line. 
 
 
Figure 4-21: Mouse macrophages migrate faster towards colon explant culture supernatants of 
DSS-treated MMP-19 -/- mice. 
Migration of RAW264.7 cells exhibited three fold higher level through a layer of collagen type IV 
towards supernatants of colon explants cultures from DSS-treated MMP-19-deficient mice, which 
contained significantly higher levels of cytokines and chemokines than the samples obtained from 
WT mice. (n = 4; **, p < 0.005) 
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4.2.13 Increase in granulocytes but reduced T cell numbers in peripheral 
blood of  MMP-19-deficient mice with acute colitis  
 
To investigate if MMP-19-deficiency had an impact on cell populations present in blood or 
spleen, leukocytes from peripheral blood and spleen of wildtype and MMP-19 -/- mice 
were isolated and analyzed by flow cytometry. CD3, CD4, and CD8 were used as            
cell-surface markers for T cells, representing the adaptive arm of the immune system, 
whereas Ly6G/C (for granulocytes) and F4/80 (for monocytes/macrophages) were the 
markers chosen to identify innate immune cells. The NK marker NK1.1 was used in 
combination with CD3 to detect unconventional NKT cells, which have the capacity to 
elicit both adaptive and innate immune responses. 
Analyzing the peripheral blood, a highly significant decrease in CD4+ and CD8+ T cell 
numbers was observed for the MMP-19-deficient mice compared to the WT and 
untreated animals (CD4+ T cells:  MMP-19 -/-, 14.3 ± 2.3% versus WT, 24.1 ± 2.2 versus 
untreated control group, 22.5 ± 2.9% of CD3+ cells; p < 0.001). In contrast, NK1.1+ NKT 
cells were significantly increased in both groups of DSS-treated mice, although not as 
pronounced in the MMP-19 knockout mice as in the WT animals (Figure 4-22A). The 
decrease in conventional CD3+ T cell numbers was accompanied by a marked increase in 
CD45+/CD11b+/Ly6G/C+ granulocytes in the peripheral blood of the MMP-19-deficient 
mice. This increase was about 2-fold compared to the DSS-treated wildtype group and 
highly significant (MMP-19 -/-, 31.4 ± 4.4 versus WT, 16.4 ± 6.2, p < 0.001). Compared to 
the untreated control animals, the blood of the WT also contained a significantly higher 
proportion of this cell population (Figure 4-22C). The increase of granulocytes in mouse 
blood nicely goes together with the elevated levels of G-CSF in plasma. Remarkably, the 
F4/80+ monocyte population in the blood of the MMP-19-deficient mice remained largely 
unchanged compared to the healthy controls and was significantly diminished compared 
to the DSS-treated WT mice (WT, 8.8 ± 2.4 versus MMP-19 -/-, 3.8 ± 0.7, p < 0.005) (Figure 
4-22C).  
In the spleen, CD4+ T cell numbers of the MMP-19 -/- mice were similar to those 
observed in the control group, although significantly higher than those of the DSS-treated 
WT mice. In contrast, the CD8+ T cell population was increased about 50% compared to 
the WT and the control animals (untreated control, 11 ± 0.2% versus WT, 10.4 ± 1.7% 
versus MMP-19 -/-, 16 ± 0.9%; p < 0.005) (Figure 4-22B).  
Despite a trend towards increased numbers of granulocytes (Ly6G/C+ cells) in spleen of 
MMP-19-deficient mice, no significant differences were seen between the three groups 
(Figure 4-22D). The macrophage population (F4/80+ cells) was only increased in spleens 
of treated WT but normal in MMP-19 -/- mice (Figure 4-22D).  
 
Taken together, these data indicate an abnormally strong innate immune response of the 
MMP-19-deficient mice to DSS-induced colitis, which negatively affects components of 
the adaptive immune system. 
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Figure 4-22: Adaptive and innate immune cell populations in blood and spleen of wildtype and 
MMP-19-deficient mice with acute colitis.  
Leukocytes were isolated from peripheral blood and spleen from wildtype and MMP-19 -/- mice 
and analyzed by flow cytometry. A significant decrease in T cell numbers in the blood of         
MMP-19 -/- mice was matched by a significant increase in granulocytes compared to the WT. In 
contrast, the monocyte population was reduced (A and D). CD8+ T cells were increased in the 
spleen of MMP-19 -/- mice, whereas granulocyte numbers remained unchanged and 
macrophages were reduced compared to the WT (B and D). * p < 0.05; ** p < 0.005, *** p < 0.001. 
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4.3 Recovery phase 
 
In this experiment, the acute colitis was induced by administration of 2% DSS for 5 days 
and this period was followed by an extended recovery phase of 10 days (Figure 4-23). The 
objective of this experiment was to analyze the significance of the MMPs studied in the 
wound healing process in colitis.    
 
 
 
Figure 4-23: Induction of acute colitis followed by a recovery phase.  
Five days of DSS administration led to acute colitis, during a ten day water period the mice could 
recover from the acute disease. 
 
 
4.3.1 Reduced survival and incomplete recovery of MMP-19-deficient mice 
 
In contrast to the wildtype and MMP-28 -/- mice, which behaved similarly during the 
experiment, the MMP-19-deficient mice showed a more severe colitis from which they 
never fully recovered. Survival of the MMP-19 -/- mice was significantly reduced 
compared to the WT animals, with mice starting to die from day 9. Opposed to the WT 
mice, which all survived the experiment, 40% of the MMP-19-deficient animals did not 
survive (Figure 4-24C). For the remaining mice, maximum body weight loss was observed 
at day 8 for WT (94.4 ± 3.2%), at day 9 for MMP-28 -/- (86 ± 5%), and at day 8 for MMP-19 
-/- mice (83.0 ± 3.1%). Whereas the wildtype and MMP-28 -/- mice regained their body 
weight relatively fast and still showed an increasing trend at day 14 (Figure 4-24A, left 
panel), the recovery of the MMP-19 -/- mice was less pronounced and their body weight 
ceased to increase towards the end of the experiment (92.7 ± 5% versus 103.5 ± 3% in the 
WT mice) (Figure 4-24A, right panel). They also showed a higher DAI score than the WT 
mice with a peak value of 3.6 at day 7 (Figure 4-24B). In contrast, WT and MMP-28 -/- 
mice did not differ significantly in DAI and survival rate (Figure 4-24B and C). The survival 
rates of WT and MMP-28 -/- mice, however, was relatively poor compared to the survival 
rates observed for both groups in other experiments. Here, a possible explanation could 
be the slightly lower mean body weight of the mice at the beginning of the experiment.   
Consistent with disease development, WT and MMP-28 -/- mice did not display any 
significant differences in colon length or spleen weight (Figure 4-25A and B, left panel). In 
contrast, MMP-19 -/- mice showed a shortened colon and an increase in spleen weight, 
which was reflected in a markedly enlarged spleen (Figure 4-25A and B, right panel).  
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Figure 4-24: MMP-19-deficient mice show impaired recovery from colitis.  
(A) Weight development during recovery from acute colitis. Whereas the body weight of        
MMP-28 -/-  and WT mice developed in a similar way (left panel), the MMP-19 -/- mice lost more 
weight than the WT animals and never regained their original weight. (B) DAI score. In contrast to 
the MMP-28 -/- mice (left panel), the DAI score of the MMP-19-deficient mice was consistently 
higher than the one of the WT mice. (C) Survival curves (Kaplan-Meier).  MMP-19 -/- but not 
MMP-28 -/- mice showed a significantly reduced survival compared to the WT mice. Data are 
expressed as mean ± SD (left panel: n = 6, DSS-treated WT group; n = 6, DSS-treated MMP-28 -/- 
group; right panel: n = 14, DSS-treated WT group; n = 14, DSS-treated MMP-19 -/- group). 
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Figure 4-25: Colon length and spleen weight of MMP-19- and MMP-28-deficient mice after 
recovery from acute colitis.  
(A) Colon length. Whereas no significant differences were observed in the colon length between 
treated WT and MMP-28 -/- mice (left panel), the colon length of the MMP-19 -/- mice was 
significantly reduced compared to the wildtype (-19.1%, p < 0.005)(right panel). (B) Spleen weight. 
The spleen weight in the MMP-19 -/- mice (right panel) but not in the MMP-28 -/- mice (left 
panel) was significantly enhanced compared to the wildtype (+76.7%, p < 0.005).                             
(C, D) Representative pictures of colon (C) and spleen (D). Data are expressed as mean ± SD (left 
panel: n = 6, DSS-treated WT mice; n = 6, DSS-treated MMP-28 -/- mice; right panel: n = 14, DSS-
treated WT mice; n = 14, DSS-treated MMP-19 -/- mice). **, p < 0.005. 
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4.3.2 MMP-19 -/- mice showed impaired recovery from colon tissue 
destruction depicted in increased inflammatory lesion extent and 
depth of tissue damage 
 
After the recovery phase, histological analysis of the distal part of the colon tissue was 
performed to assess potential differences in the wound-healing capacity of the MMP-19- 
and MMP-28-deficient mice. Colon sections stained with hematoxylin/eosin were 
analysed for various parameters related to tissue destruction and inflammation as 
described before (4.2 Acute colitis) (Figures 4-26 and 4-27).  
The most significant differences were seen between the colons of the wildtype and the 
MMP-19-deficient mice: Whereas the wildtype had recovered and did not show any signs 
of inflammation, about 40% of the MMP-19 -/- colonic tissue were still inflamed      
(Figure 4-27A). In contrast, the extent of remaining lesions in the colon of                   
MMP-28-deficient mice was clearly reduced.  The persistent inflammation in the       
MMP-19 -/- mice was also reflected in a considerable influx of neutrophils into the 
lesional colon tissue, which was significantly higher than the one observed for the    
MMP-28 -/- mice (MMP-19 -/-, 15% versus MMP-28 -/-, 3%, p < 0.05) (Figure 4-27E). 
Further major differences between the MMP-19- and the MMP-28-deficient group were 
related to the extent of tissue destruction: The depth of ulceration (Figure 4-27D) as well 
as the percentage of crypt damage (Figure 4-24G) and crypt damage depth (Figure 4-27H) 
were significantly greater in the MMP-19-deficient mice. However, the percentage of 
oedema and hyperregenerative tissue was similar in both groups (Figure 4-27B and C). 
Taken together, these data clearly show that MMP-19-deficient mice exhibit lower 
capability to recover from the colon damage and inflammation inflicted by DSS-induced 
colitis than the wildtype and MMP-28-deficient mice.  
 
 
 
Figure 4-26: Representative pictures of colon sections of WT and MMP-19-deficient mice after 
ten days of recovery. Arrows are pointig to oedema, which in case of the MMP-19 -/- was filled 
with inflammatory cells. Arrowheads show the rebuilt mucosal architecture (crypts and 
epithelium were present) in the WT mice, whereas in the MMP-19 -/- the tissue was still 
destroyed. Hematoxylin/eosin staining, magnification x 40. 
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Figure 4-27: Histological analysis of colon tissue after recovery from colitis.  
Sections of colon tissue of DSS-treated WT, MMP-19- and MMP-28-deficient mice were stained 
with hematoxylin/eosin and analyzed for parameters related to inflammation and tissue 
destruction. Compared to the MMP-28 -/- mice, the extent of inflamed lesions (A), the neutrophil 
influx (B), ulceration depth (D), percentage of crypt damage (G), and crypt damage depth (H) were 
significantly increased in the colon of the MMP-19 -/- mice (p < 0.01). Although the colon of the 
MMP-28-deficient mice showed some remaining signs of destruction, it had mostly recovered 
from the colitis, similarly to the colon of the DSS-treated wildtype mice which was 
indistinguishable from the untreated control animals. Data are expressed as means ± SD (n = 3 for 
all groups).   
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4.3.3 Decreased proliferation of colon epithelial cells in MMP-19- and   
MMP-28-deficient mice 
 
The strongly reduced proliferation of epithelial cells in the acute phase of colitis was 
totally restored in the WT mice. In contrast, numbers of epithelial cells positive for the 
proliferation marker Ki-67 in the mucosa of MMP-19-deficient were decreased 
dramatically – only some hyperproliferative areas were found (Figure 4-28A and B). 
Interestingly, also the MMP-28-deficient mice showed impaired proliferation activity 
when compared to WT animals (Figure 4-28B). 
 
 
 
Figure 4-28: Proliferation of colon epithelial cells is decreased in MMP-deficient mice. 
The amount of proliferating cells was decreased more than 40% in MMP-deficient mice compared 
to WT animals (B). Representative pictures are shown for WT and MMP-19 -/- mice (A). n = 2, 
MMP-19 -/-, and MMP-28 -/- mice in control group; n = 6, WT and MMP-19 -/- mice and n = 5, 
MMP-28 -/- mice in DSS-treated group. *, p < 0.05. 
 
 
The number of macrophages (F4/80 positive cells) seen in the colon increased by more 
than 20% in all analyzed mouse strains in comparison to the acute phase of the colitis. 
There was no significant difference between the WT, MMP-19-, and MMP-28-deficient 
mice (Figure 4-29). High amounts of macrophages in the tissue indicate the healing 
process.  
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Figure 4-29: Similar numbers of macrophages incolon tissue of mice recovering from colitis.  
The numbers of F4/80 positive cells increased compared to the acute phase of colitis, however, 
the amount of macrophages did not differ among WT, MMP-19 -/-, and MMP-28 -/- mice. n = 2 
for untreated mice; n = 6 DSS-treated mice. 
 
 
4.3.4 Increased cytokine and chemokine concentrations in plasma of     
MMP-19-deficient mice point to a systemic inflammatory response 
 
To compare the development of the recovery and healing process in the inflammatory 
response among DSS-treated wildtype, MMP-28 -/-, and MMP-19 -/- mice, plasma 
cytokine and chemokine concentrations were analyzed at day 14, i.e. at the end of the 
defined recovery phase. In contrast to the non-significant results in plasma of acute 
inflamed mice, now the immune response became a more systemic one as elevated levels 
of pro-inflammatory cytokines were detected in plasma of recovered mice. Whereas the 
cytokine levels in plasma of the treated WT and MMP-28-deficient mice were not 
significantly different from those measured in the untreated control group, the IL-1α and 
IL-6 concentrations in the plasma of the treated MMP-19 -/- animals were markedly 
increased. Levels of IL-6 were shown to be at least ten times higher than in plasma of WT 
mice. Such high levels of IL-6 could denote an acute phase response in recovering     
MMP-19-deficient animals. Analysis of the liver enzymes ALT (alanine aminotransferase) 
and AST (aspartate aminotransferase) revealed no enhanced systemic response similar to 
acute colitis (see section 4.3.6, Figure 4-33). However, TNF-α and IFN-γ levels remained 
largely unchanged (Figure 4-30A). Furthermore, the levels of the chemokines MCP-1,      
G-CSF, and KC were also significantly higher in plasma of MMP-19 -/- mice than in WT 
animals (Figure 4-30B). High levels of these chemokines in the blood marked as well a 
starting systemic response to the injury in the gut. Strikingly increased levels of G-CSF 
(Granulocyte colony-stimulating factor) pointed to the beginning of a systemic response 
as this chemokine stimulates the bone marrow to produce granulocytes. Corresponding 
to the high values in MMP-19-deficient mice inflammation was more pronounced in these 
animals. No difference was found in levels of GM-CSF. 
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Figure 4-30: Cytokines and chemokines in plasma of healthy mice and MMP single-deficient 
mice during recovery phase following acute colitis.  
Cytokine (A) and chemokine (B) levels in plasma prepared on day 14 were determined by BioPlex 
bead assay. Data are represented as individual data points and mean of duplicate measurements 
(n = 2, WT and MMP-19 -/- mice in control group; n = 4, WT and MMP-19 -/- mice and n = 2, 
MMP-28 -/- mice in DSS-treated group).  *, p < 0.05; **, p < 0.005; ***, p < 0.001. 
 
 
4.3.5 Enhanced release of cytokines and chemokines from colon tissue of 
MMP-19-deficient mice 
 
Whereas the levels of cytokines were going back to normal values in case of wildtype 
mice, MMP-19-deficient mice still depict increased concentrations in the supernatant of 
colon explant cultures (Figure 4-31). IL-1 levels are even higher after recovery then they 
were in acute colitis. Concentrations of IL-10 in MMP-19 -/- mice were found to be 
increased twice compared to acute colitis (see section 4.2.10, Figure 4-19), which pointed 
to a strong anti-inflammatory reaction in these animals. In WT mice IL-10 concentrations 
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are normal. Levels of TNF-α and IFN-γ did not change much in comparison to the acute 
inflammation; they are just slightly decreased but still significantly enhanced in the  
MMP-19-deficient mice. 
 
 
Figure 4-31: Cytokines in supernatants of colon explant cultures were significantly increased in 
MMP-19 -/- mice. 
CEC supernatants analyzed by BioPlex bead assay showed high levels of pro-inflammatory 
cytokines IL-1 β and IL-6 in MMP-19-deficient animals whereas the WT mice showed much lower 
levels of these cytokines. TNF-α and IFN-γ are still released in high amounts that were similar to 
the acute colitis although in general the cytokine levels are lower than in the acute experiment. 
Also anti-inflammatory cytokines like IL-4 and IL-10 were highly elevated in MMP-19-deficient 
mice. (n = 2, WT and MMP-19-/- mice in control group; n = 3, WT and MMP-19-/- mice in DSS-
treated group; *, p < 0.05; **, p < 0.005; ***, p < 0.001). 
 
 
Concentrations of various chemokines released from the healing tissue were lower when 
compared to the acute phase of colitis (Figure 4-32). The extremely high levels of G-CSF 
and MCP-1 were reduced to moderate ones but still the MMP-19-deficient mice showed 
increased values when compared to WT mice. Levels for KC and RANTES did not change 
much during the recovery phase and were increased in knockout animals all the time. 
RESULTS 87  
Interestingly, the amount of produced MIP-1α (macrophage inflammatory protein 1) was 
doubled in the MMP-19 -/- mice, whereas it was only slightly increased in WT mice. MIP-1 
is crucial for immune responses towards infection and inflammation, it is a major factor 
produced by macrophages after they are stimulated with bacterial endotoxins and 
activate human granulocytes which can lead to acute neutrophilic inflammation. MIP-1 
also induces the synthesis and release of other pro-inflammatory cytokines such as IL-1, 
IL-6, and TNF-α from fibroblasts and macrophages. 
The recovery resulted in a decreased inflammatory response and a starting healing 
process in the WT mice, whereas MMP-19-deficient mice still suffered from pronounced 
inflammation. As they showed high levels of both pro- and anti-inflammatory cytokines, 
there are both stages present – acute inflammation and healing. 
 
 
Figure 4-32: Chemokines in supernatants of CECs of healthy and MMP-19-deficient mice during 
recovery phase following acute colitis. 
The levels of several chemokines (KC, MCP-1, MIP-1, and RANTES) were significantly higher in the 
supernatants of MMP-19 -/- mice than in those of the WT animals. Concentrations of G-CSF and 
GM-CSF are lower than in the acute colitis but not significantly different between the analysed 
groups. A twofold increase in MIP-1 was observed in the knockout animals, which did not occur in 
WT mice (n = 2, WT and MMP-19 -/- mice in control group; n = 3, WT and MMP-19 -/- mice in DSS-
treated group; levels for KC were analyzed by ELISA, n = 4, WT and MMP-19 -/- mice in control 
group; n = 10, WT and MMP-19 -/- mice in DSS-treated group * p < 0.05, ** p < 0.005). 
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4.3.6 No significant changes in ALT and AST plasma concentrations of 
wildtype and MMP-19-deficient mice: the systemic response does not 
involve liver  
 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are crucial enzymes 
in the amino acid metabolism. They are found in various organs but are most abundant in 
the hepatocytes found in the liver. Leakage of the enzymes, particularly ALT, into the 
blood stream is an important marker for liver damage or abnormal liver function [236; 
237]. However, both enzymes can also be dysregulated in a variety of disorders and 
diseases that are not directly associated with liver dysfunction. Since imbalanced ALT and 
AST levels often indicate systemic inflammation [236; 237]  levels of both enzymes were 
measured in the plasma of wildtype and MMP-19-deficient mice during acute colitis and 
after the recovery phase. 
The normal range of ALT and AST plasma levels, as described for healthy C57Bl/6 mice are 
24 ± 10 U/ml for ALT and 47 ± 13 U/ml for AST (Charles River Laboratories). As shown in 
Figure 4-33, both ALT and AST plasma levels of WT and MMP-19 -/- mice remained within 
the normal range during acute colitis and after the recovery phase, despite a clear 
increase of the transferases in MMP-19 -/- mice in acute colitis . 
These results suggest that DSS-induced acute colitis did not lead to systemic inflammation, 
neither in the WT nor in the MMP-19-deficient mice but there was a tendency to develop 
a more systemic immune response in MMP-19-deficient animals. 
 
 
Figure 4-33: ALT and AST levels in mouse plasma remain within the normal range. 
ALT (alanine aminotransferase) (A) and AST (aspartate aminotransferase) (B) levels in plasma of 
WT and MMP-19 -/- mice during acute colitis and after the recovery phase. 
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4.3.7 MMP-19/-28 double-deficient mice do not recover from acute colitis 
 
In order to be able to analyze the recovery of the MMP-19/-28 double-deficient mice 
from acute colitis, the experimental conditions had to be modified, as initial studies 
showed that the mice did not survive the treatment applied for the single-deficient 
animals (Figure 4-34). 
 
 
Figure 4-34: 100% mortality of MMP-19/-28 double-deficient mice during recovery from acute 
colitis. 
The Kaplan-Meier survival curve clearly depicts the fast progress in mortality of the double-
deficient mice. After 9 days 50% of mice and after 12 days all mice were dead (n = 12; WT and 
MMP-19 -/-: n = 14, MMP-19/-28 dbKO: n = 12). 
 
 
Thus, a much milder treatment was chosen to analyze double-deficient mice in the 
recovery phase from acute colitis. The five days lasting supply of DSS in the drinking water 
that was established for the previous experiment was shortened to just three days of 
treatment (Figure 4-35), which basically showed no effect in WT animals. 
 
 
Figure 4-35: Modified recovery experiment for the treatment of MMP-19/-28 double-deficient 
mice.  
The shorter treatment with 2% DSS was used to decrease the mortality of double-deficient mice 
during the recovery. 
  
 
Despite the relatively mild treatment, the MMP-19/-28 double-deficient mice developed 
colitis rapidly and showed a steep increase in the DAI score that peaked at day 6      
(Figure 4-36B). In contrast to the wildtype mice, which all survived the experiment, the 
MMP-19/-28 dbKO started to die from day 6 and displayed a very poor overall survival 
rate of just 50 % (Figure 4-36C). The remaining mice lost about 12% of their body weight 
until day 8, and afterwards, recovered only moderately and never regained their original 
weight (Figure 4-36A). These results were highly significant and in strong contrast to the 
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data obtained for the WT animals, which showed only very mild symptoms of disease 
throughout the experiment.  
 
 
 
 
Figure 4-36: Body weight changes, disease activity index [223], and survival curves of MMP-19/-
28 double-deficient and WT mice after recovering from colitis. 
(A) Weight development after recovery from acute colitis. MMP-19/-28 double-deficient mice lost 
significantly more weight than the WT animals, which did not lose any weight (maximum weight 
loss at day 8: 10 ± 3%, p ≤ 0.005). The double-deficient animals never regained their original 
weight (day 10: 10 ± 7%, p ≤ 0.005). (B) MMP-19/-28 double-deficient mice showed a higher DAI 
than WT even at the end of the experiment. (C) Survival curves (Kaplan-Meier) showed that only 
50% of the double-deficient animals survived the milder treatment and managed to recover. Data 
are expressed as mean ± SD (n = 6, DSS-treated WT mice; n = 10, DSS-treated MMP-19/-28 dbKO 
mice). 
 
 
Whereas the colon of treated WT mice (7.0 ± 0.5 cm) did not display any significant 
changes to untreated mice, the colon of MMP-19/-28 double-deficient animals (4.7 ± 0.4 
cm) was one third shorter than in WT mice (Figure 4-37A and C). Comparing the size and 
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weight of the spleen, no enlargement was observed in WT animals but double-deficient 
mice showed an increase in weight about 45% (Figure 4-37B and C). Splenomegaly is 
usually associated with increased workload (such as in anemias), which suggests that it is 
a response to hyperfunction. 
 
 
                                            
                                               C 
 
 
Figure 4-37: Colon length and spleen weight of WT and MMP-19/-28 double-deficient mice. 
The parameters were measured in untreated, healthy mice as well as in mice which are 
recovering from colitis (day 10) (A and B) and representative pictures are shown (C). Data are 
expressed as mean ± SD (n = 4, control mice; n = 6, DSS-treated WT mice; n = 5, DSS-treated 
MMP-19/-28 dbKO mice). *** p < 0.001  
 
 
4.3.8 Hyaline arteries are present in the spleen of all MMP-19/-28 double-
deficient mice  
 
As the spleen from MMP-19/-28 dbKO mice exhibited a significantly higher weight, spleen 
tissue after the recovery was isolated, sectioned and stained with hematoxylin/eosin to 
reveal the reason of the spleen enlargement. Strikingly, arteries from the double-deficient 
mice showed deposition of hyaline material in 100 % of tissue sections. In wildtype mice 
only about 30 % of mice showed hyaline material in the inner wall of the blood vessels 
(Figure 4-38). Thickening of the walls of arterioles by the deposition of homogeneous pink 
hyaline material is called hyaline arteriolosclerosis and leads to hardening of the vessel 
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wall [238]. This process is due to the accumulation of extracellular matrix components. 
This phenotype might be responsible for the enlargement of the spleen as cells do not 
have proper access to the blood stream. Two experiments were performed showing 
similar results. 
 
 
Figure 4-38: Hyaline arteries in the spleen of MMP-19/-28 double-deficient mice recovering 
from colitis. 
Percentage of mice in an experiment (two in total) showing hyaline arteries in the spleen. 100% of 
spleen sections stained with hematoxylin/eosin showed deposition of hyaline material in the 
blood vessel; only 36% of WT mice depict this phenotype. 
 
 
4.3.9 MMP-19/-28 double-deficient mice showed severe signs of colitis at 
cellular level in the colon wall 
 
At the end of the recovery experiment, histological analysis of the distal part of the colon 
tissue was performed. Colon sections stained with hematoxylin/eosin of WT (n = 3) and 
MMP-19/-28 double-deficient mice (n = 3) were analyzed for the same parameters as 
described before (see 4.2 Acute colitis) (Figure 4-39 and 4-40). Colon tissue of untreated 
mice was analyzed as well and served as control. In addition, the colon tissue was also 
assessed for symptoms of acute and chronic inflammation as well as for inflammation 
depth. 
 
Figure 4-39: Representative pictures of WT and MMP-19/-28 double-deficient mice recovering 
from acute colitis. 
Colon tissue sections of DSS-treated WT and MMP-19/-28 dbKO mice were stained with 
hematoxylin/eosin, arrows mark oedema in the tissue (only present in the MMP-19/-28 double-
deficient mice), and arrowheads are pointing to the epithelium. Hematoxylin/eosin staining, 
magnification x 40. 
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Whereas the DSS-treated WT mice showed hardly any signs of colon inflammation or 
tissue destruction, the colons of the MMP-19/-28 double-deficient mice were highly 
inflamed and damaged (Figure 4-39 and 4-40). All parameters measured were 
significantly increased compared to the WT group (Figure 4-40, p < 0.05).  
Colon tissue of this experiment was accessed for differences in acute versus chronic 
inflammation (Figure 4-41). Simplified, acute inflammation is described by a majority of 
neutrophils present in the tissue, oedema formation, and severe tissue alterations may be 
present as well as necrosis. During chronic inflammation predominantly lymphocytes and 
plasma cells are accumulated in the tissue and usually fibrosis is present. The colon tissue 
of treated wildtype mice appeared essentially healthy, whereas about 50% of the colon in 
MMP-19/-28 dbKO tissue was chronically inflamed and about 20% showed signs of acute 
inflammation. Inflammation depth was also very pronounced in these animals, and 
differences to the other groups were significant (Figure 4-41). 
These results illustrate that the healing process of the colonic tissue in MMP-19/-28 
double-deficient mice suffering from acute colitis is severely impaired and the 
inflammatory response dramatically exacerbated. 
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Figure 4-40: Histological analysis of colon tissue of MMP-19/-28 double-deficient mice 
recovering from acute colitis. 
Colon tissue sections of DSS-treated WT (n = 3) and MMP-19/-28 dbKO mice (n = 3) were stained 
with hematoxylin/eosin and analyzed for parameters related to inflammation and tissue 
destruction. Compared to the WT mice, the values of all parameters measured were significantly 
higher in the MMP-19/-28 dbKO group. DSS-treated wildtype mice did not show major differences 
to the untreated control animals. Data are shown as dot plot with means. The difference between 
the treated WT and MMP-19/-28 dbKO mice was significant in all panels (*, p < 0.05). 
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Figure 4-41: Extent of acute and chronic inflammation in colonic tissue of DSS-treated MMP-
19/-28 mice. 
MMP-19/-28 dbKO mice showed a higher percentage of acute and chronic inflamed tissue. WT 
animals appeared healthy. The depth of inflammation was significantly increased in deficient 
versus wildtype mice. Data are shown as mean. Differences between DSS-treated WT and dbKO 
mice are highly significant, p < 0.005. 
 
 
4.3.10 Reduced epithelial cell proliferation and macrophage accumulation in 
colon tissue of MMP-19/-28 double-deficient mice 
 
The number of proliferating cells was dramatically decreased in the colonic tissue of 
animals with acute colitis (see section 4.2.8, Figure 4-16). Proliferation was normal in the 
WT mice that recovered from colitis but still decreased in MMP-19-deficient mice. In the 
modified recovery experiment for the double-deficient mice, significantly lower numbers 
of Ki-67 positive epithelial cells were seen compared to the WT, so proliferation was 
reduced (Figure 4-42A and B).  
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Figure 4-42: Epithelial cell proliferation was decreased in MMP-19/-28 dbKO mice.  
Whereas WT mice showed nearly normal amount of proliferating cells in the intestine, the 
number of Ki-67 positive cells in double-deficient mice was decreased 75% compared to wildtype 
colons (B). Representative pictures of DSS-treated animals are shown (A). n = 2, WT and         
MMP-19/-28 double-deficient mice in control group; n = 3, WT and MMP-19/-28 double-deficient 
mice in DSS-treated group, * p < 0.05. 
 
 
Macrophages are required for initiation of the healing process by phagocytosis of bacteria 
and cell debris. They also release numerous cytokines (e.g. growth factors like EGF, TGF, 
and FGF as well as interleukins) to attract fibroblast to the site of repair. After a short 
DSS-treatment and seven days to recover, WT mice hardly showed any signs of colitis. 
Macrophages were still present in the colon tissue to support the healing process. In the 
tissue of treated MMP-19/-28 double-deficient mice no significant increase in the amount 
of macrophages was seen (Figure 4-43A and B). 
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Figure 4-43: Reduced macrophage accumulation in colon tissue of MMP-19/-28 dbKO mice.  
Macrophages were present in slightly higher amounts in WT mice, numbers in double-deficient 
mice did not differ significantly from untreated mice (B). Representative pictures of DSS-treated 
animals are shown (A). n = 2, WT and MMP-19/-28 double-deficient mice in control group; n = 3, 
WT and MMP-19/-28 double-deficient mice in DSS-treated group. 
 
 
4.3.11 MMP-19/-28 double-deficient mice recovering from colitis had highly 
elevated levels of cytokines and chemokines in plasma  
 
Plasma levels of a variety of cytokines and chemokines were determined by BioPlex bead 
analysis. The MMP-19/-28 double-deficient mice showed enhanced levels of several pro-
inflammatory cytokines in plasma. For instance, the IL-1α and IL-6 concentrations 
increased more than twofold compared to those measured for the wildtype animals 
(Figure 4-44A). These differences were highly significant (p < 0.005), and not observed for 
other cytokines. Strikingly, TNF-α levels were slightly decreased compared to the WT, and 
IFN-γ levels remained unchanged. In line with the results of the colon histology, the DSS-
treated WT mice had recovered from colitis and showed similar cytokine levels than the 
untreated control groups.  
The concentrations of several additional chemokines were also significantly elevated in 
the plasma of the MMP-19/-28 dbKO mice, most notably KC and G-CSF, which in the DSS-
treated wildtype and the untreated control animals remained at very low levels. In 
contrast, no significant differences were detected in the amounts of MCP-1 and GM-CSF 
(Figure 4-44B), which means only chemoattractants for neutrophils are upregulated in the 
double-deficient mice.  
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Figure 4-44: Cytokines and chemokine levels in plasma of healthy and MMP-19/-28 double-
deficient mice recovering from acute colitis. 
Cytokines analyzed by BioPlex bead assay showed high levels of pro-inflammatory cytokines such 
as IL-1β and IL-6 in MMP-19/-28 double-deficient animals whereas cytokines of the WT mice 
remained at normal levels. There were no significant differences in TNF-α and IFN-γ levels, 
including the control mice (A). Levels of the chemokines KC and G-CSF were significantly higher in 
the plasma of MMP-19/-28 dbKO mice compared to the WT animals. For MCP-1, a non-significant 
increase was observed, whereas GM-CSF levels did not change (B). (n = 2, WT and MMP-19/-28 
double-deficient mice in control group; n = 4, WT and MMP-19/-28 double-deficient mice in DSS-
treated group) * p < 0.05, ** p < 0.005. 
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4.3.12 Highly enhanced release of cytokines and chemokines from colon 
tissue correlates with DAI in MMP-19/-28 double-deficient mice 
 
Colon explant cultures (CEC) from DSS-treated wildtype, MMP-19/-28 dbKO and 
untreated control mice were prepared after the recovery phase. The supernatants were 
analyzed after 24h culture for cytokine and chemokine concentrations by BioPlex bead 
assay.  
Whereas no significant differences were detected in DSS-treated WT and the untreated 
control groups, the levels of pro- and anti-inflammatory cytokines as well as several 
chemokines were highly elevated in the supernatants of the MMP-19/-28 double-
deficient mice. The upregulated pro-inflammatory cytokines included IL-1, IL-6, TNF-α, 
IFN-γ and the Th17 cytokine IL-17. IL-4 and IL-10 were among the upregulated anti-
inflammatory cytokines (Figure 4-45). 
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Figure 4-45: Cytokines in supernatants of colon explant cultures from healthy and recovering 
tissues. 
Cytokines analyzed by BioPlex bead assay showed high levels of pro-inflammatory cytokines IL-1 
(α and β), IL-6, and IL-17 in MMP double-deficient animals whereas the WT mice showed no 
elevation of these cytokines. Anti-inflammatory cytokines such as IL-4 and IL-10 were highly 
elevated in MMP-19/-28 dbKO mice (A), n = 2, WT and MMP-19/-28 double-deficient mice in 
control group; n = 3, WT and MMP-19/-28 double-deficient mice in DSS-treated group. All 
differences were highly significant (*** p < 0.001 for all cytokines). 
 
 
All chemokines measured showed also highly elevated levels in the MMP-19/-28 dbKO 
mice. They included G-CSF, GM-CSF, KC, RANTES, MCP-1, and MIP-1a. In contrast, 
concentrations in the CECs of the DSS-treated WT mice were only moderately 
upregulated or remained unchanged compared to the WT group (Figure 4-46). 
These data are in agreement with the observed severity of disease in the MMP-19/-28 
dbKO mice and the histological analysis of the colon. The increased levels of pro-
inflammatory cytokines and chemokines indicate ongoing inflammation and illustrate the 
impaired healing process seen in the MMP double-deficient mice. On the other hand, the 
presence of anti-inflammatory cytokines suggests the initiation of disease resolving 
mechanisms, too. 
RESULTS 101  
 
 
 
Figure 4-46: Chemokines in supernatants of colon explant cultures from healthy and recovering 
tissues. 
The levels of several chemokines (KC, MCP-1, MIP-1, G-CSF, and GM-CSF) were significantly higher 
in the supernatants of MMP-19/-28 double-deficient mice than in those of the WT (B), n = 2, WT 
and MMP-19/-28 double-deficient mice in control group; n = 3, WT and MMP-19/-28 double-
deficient mice in DSS-treated group. All differences were highly significant (***, p < 0.001 for all 
cytokines). 
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4.4 Chronic colitis 
 
4.4.1 Reduced body weight, increased DAI and reduced survival of         
MMP-19-deficient mice  
 
Chronic colitis was induced by two cycles of 2% DSS (Figure 4-47). In this experiment, only 
MMP-19-deficient and wildtype mice were analyzed. 
 
Figure 4-47: Induction of chronic colitis, course of experiment. 
To induce acute colitis mice were treated by two cycles of DSS-induced colitis followed by a 
recovery phase. 
 
 
A group of 12 MMP-19 -/- mice and 14 wildtype animals was used in this experiment. The 
control group of untreated mice consisted of five mice of each strain. Disease severity 
was monitored daily by weight progression, hemoccult test, and stool consistency. During 
the course of the experiment the MMP-19-deficient mice lost significantly more weight 
than the WT animals, a trend, which was already obvious at the beginning of the first 
cycle (Figure 4-48). The maximum weight loss was observed at day 8 (22 ± 3% in        
MMP-19 -/- mice versus 5 ± 1.5% in WT mice, p ≤ 0.005). After establishing chronic colitis, 
the MMP-19-deficient mice never regained their original weight and showed a profound 
weight loss after day 28, the endpoint of the experiment (-10 ± 5%). In contrast, the WT 
animals returned to their original weight at day 18 and then further increased the weight 
until the end of the experiment (day 28; +9 ± 2%). The weight difference between the 
MMP-19 -/- and the WT mice at the endpoint of the experiment was highly significant (p ≤ 
0.005) (Figure 4-48A). The DAI considers body weight loss, stool consistency, and amount 
of blood in stool. MMP-19 -/- mice showed a much higher DAI during all phases of colitis 
(Figure 4-48B). The Kaplan-Meier-survival curves demonstrate that nearly all WT mice 
survived the chronic treatment whereas the survival rate of MMP19 -/- mice was only 
50% (Figure 4-48C). 
 
 
 
 
  H2O 
day 
0      2      4       6      8     10    12    14    16   18    20    22    24    26    28   
 H2O 2% DSS  2% DSS 
RESULTS 103  
 
Figure 4-48: Body weight changes, disease activity index and survival curves of MMP-19 -/- and 
WT mice suffering from chronic colitis. 
(A) Weight development after applying two cycles of 2% DSS followed by normal drinking water. 
MMP-19-deficient mice lost significantly more weight than the WT animals. Whereas the      
MMP-19-deficient mice never regained their original weight, the WT animals recovered and from 
day 18 even increased their weight (day 28: MMP-19 -/-; -10% ± 5% versus WT; +9% ± 2%, p ≤ 
0.005). (B) MMP-19 -/- mice showed a higher DAI during all phases of colitis. (C) Survival curves 
(Kaplan-Meier) showed nearly all WT mice survived the chronic treatment but the survival rate of       
MMP-19 -/- mice was only 50%. Data are expressed as mean ± SD (n = 5, control mice; n = 14, 
DSS-treated WT group; n = 6, DSS-treated MMP-19 -/- group). 
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4.4.2 Reduced colon length and splenomegaly in MMP-19-deficient mice 
 
At the endpoint of the chronic colitis experiment (day 28), colons and spleens of DSS-
treated wildtype (n = 14) and MMP-19-deficient (n = 6) mice were removed and analyzed 
for their size and weight (spleen only), and compared to the control group of untreated 
animals (n = 5 for WT and KO). Whereas the mean colon length of the DSS-treated 
wildtype mice was largely unchanged compared to the one measured in the control group,  
the treated MMP-19 -/- mice showed a significantly reduced colon length (WT, 6.64 ± 
0.35 cm versus MMP-19 -/-, 5.4 ± 0.2 cm, p < 0.001)  (Figure 4-49A and C). Even greater 
differences were observed in the spleen: The mean spleen weight of the DSS-treated 
MMP-19 -/- mice increased by more than 150% compared to the one of the treated 
wildtype mice (p < 0.001). This increase in weight was reflected in splenomegaly, i.e. a 
profound enlargement of the spleen (Figure 4-49C). The spleen weight of the treated 
wildtype mice was only marginally larger than that of the control mice (non-significant,    
p > 0.5). 
 
 
 
Figure 4-49: Colon length and spleen weight of WT and MMP-19 -/- mice. 
Colon length (A) and spleen weight (B) of untreated as well as DSS-treated WT and MMP-19 -/- 
mice was determined on day 28. The colon of MMP-19 -/- mice was significantly shorter than the 
WT one (-18.24%) and the spleen weight was more than doubled. Data are expressed as mean ± 
SD (n = 5, control mice; n = 14, DSS-treated WT group; n = 6, DSS-treated MMP-19 -/- group).           
*** p < 0.001. (C) Representative pictures of colon (left panel) and spleen (right panel) from DSS-
treated WT and MMP-19 -/- mice are shown.  
 
 
C 
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4.4.3 Increase in hyaline arteries and proliferation in spleen of                
MMP-19-deficient mice  
 
To investigate if the splenomegaly seen in MMP-19-deficient mice was accompanied by 
structural alterations of the spleen, spleen tissue sections of DSS-treated wildtype and 
MMP-19 -/- mice were stained with hematoxylin/eosin and evaluated. Strikingly, arteries 
in MMP-19-deficient mice showed remarkable depositions of hyaline material. Whereas 
100 % of tissue sections from the MMP-19 -/- mice stained positive for hyaline material at 
the inner wall of the blood vessels, only 25% of wildtype mice exhibited such pathology 
(Figure 4-50A). Two experiments were performed giving similar results. 
 
 
Figure 4-50: Hyaline arteries are more frequent in MMP-19-deficient mice. 
Percentage of mice per experiment (two in total) that were showing hyaline arteries in the spleen 
(A). Hematoxylin/eosin staining of spleen section showed deposition of hyaline material in the 
blood vessel (hematoxylin/eosin staining, magnification x 200) (B). 
 
 
To investigate further the pathology of the spleen in chronic colitis, 
immunohistochemistry was used. The amount of proliferating cells in the spleen, 
especially in the red pulp, was analyzed by staining with Ki-67 antibody, which is a cellular 
marker for proliferation. It is strictly associated with cell proliferation. During interphase, 
the Ki-67 antigen can be exclusively detected within the cell nucleus, whereas in mitosis 
most of the protein is relocated to the surface of the chromosomes. Ki-67 protein is 
present during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent from 
resting cells (G0) [239; 240]. Only mitotic cells with a dark brown nucleus were counted as 
positive for proliferation. In the spleens of WT and MMP-19-deficient mice increased 
proliferative activity was observed compared to healthy mice (Figure 4-51A and B). In 
agreement with the splenomegaly, 20% more proliferating cells were found in the    
MMP-19 -/- animals. 
A B 
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Figure 4-51: Increased proliferative activity in MMP-19-deficient mice. 
Representative pictures of WT and MMP-19 -/- spleens stained for the proliferation marker Ki-67 
(original magnification x 40) (A). Percentage of Ki-67 positive cells in the red pulp of the spleen. 
MMP-19 -/- mice showed elevated numbers of proliferating cells (B). Untreated mice, n = 2; DSS-
treated mice, n = 4, * p < 0.05. 
 
 
4.4.4 MMP-19-deficient mice with chronic colitis show severe colon damage 
and inflammation 
 
At the end of the chronic colitis experiment, histological analysis of the distal part of the 
colon tissue was performed. Colon sections of WT (n = 4) and MMP-19-deficient mice     
(n = 4) stained with hematoxylin/eosin were analyzed for the same parameters as 
described before (see 4.2 Acute colitis) (Figure 4-52). Arrows are pointing to oedema in 
the mucosa, which is stronger in MMP-19 -/- mice. Differences in crypt damage are 
marked with arrowheads. 
Whereas the DSS-treated WT mice showed only minor signs of colon inflammation or 
tissue destruction, e.g. inflamed lesions covered about 10% of the colon (Figure 4-53A) or 
certain extent of crypt damage (Figure 4-53G), the colons of the MMP-19-deficient mice 
were highly inflamed and damaged. All parameters measured were significantly increased 
compared to the WT group. The most significant differences (p < 0.01) were observed for 
neutrophil influx (Figure 4-53E) and percentage of hyperregenerative tissue (Figure 4-53F). 
These findings depicted a persistent inflammation in the MMP-19 -/- mice and an attempt 
of re-epithelialization to remodel the normal mucosal architecture. 
 
 
A 
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Figure 4-52: Representative pictures of WT and MMP-19-deficient mice with chronic colitis. 
Hematoxylin/eosin staining, arrowheads are pointing to oedema in the tissue; arrows are marking 
crypt damage (hematoxylin/eosin staining, magnification x 40). 
 
 
 
Figure 4-53: Histological analysis of colon tissue of MMP-19-/- mice with chronic colitis.  
Colon tissue sections of DSS-treated WT and MMP-19-deficient mice were stained with 
hematoxylin/eosin and analyzed for parameters related to inflammation and tissue destruction. 
Compared to the WT mice, the extent of inflamed lesions (A), the percentage of oedema (B), 
ulceration intensity (C), ulceration depth (D), percentage of crypt damage (G), and crypt damage 
depth (H) were all significantly increased in the colon of the MMP-19 -/- mice (p < 0.05). An even 
higher significance was observed for neutrophil influx and percentage of hyperregeneration         
** 
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(p < 0.005). In contrast to the MMP-19 -/- group, the WT group had recovered from the colitis and 
did not show any major colon inflammation or damage. Data are shown as dot plot with means, 
all panels showed a significance of *, p < 0.05 except of those two which are marked                     
** for p < 0.005. 
 
 
The colonic tissue was further analyzed for areas showing acute (neutrophils, oedema, 
severe tissue damage) or chronic (plasma cells, fibrosis) inflammation and for depth of 
inflammation. In the MMP-19 -/- mice, over 40% of the colon was chronically inflamed 
and about 20% of the area showed signs of acute inflammation (Figure 4-54, left and 
middle panel). This was highly significant as compared to the DSS-treated WT group, 
which appeared similar to the untreated control groups. The inflammation depth was also 
very pronounced and significantly greater than the one observed for the controls (Figure 
4-54, right panel). 
  
 
Figure 4-54: Amount of acute and chronic inflammation in colonic tissue of DSS-treated mice 
and controls. 
MMP-19 -/- mice depicted higher percentage of acute and chronic inflamed tissue. WT animals 
appear healthy. Also the depth of the inflammation was significantly increased in deficient 
towards wildtype mice. Data are shown as dot plot with means, all panels showed a significance 
of *, p < 0.05. Untreated mice, n = 3; DSS-treated mice, n = 4. 
 
 
4.4.5 MMP-19-deficient mice show signs of fibrosis  
 
To investigate if MMP-19 deficiency and the exacerbated progress in chronic colitis 
promoted the development of fibrosis, collagen deposition in the colon wall of treated 
wildtype and MMP-19 -/- mice was analysed using trichrome staining.   In contrast to the 
colon wall of the WT animals, which had recovered and showed a similar architecture to 
the one observed in untreated mice, the colon wall of the MMP-19 -/- animals exhibited 
clear signs of damage and, moreover, the mucosa of the colon displayed an extensive 
increase in collagen disposition (Figure 4-55). 
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Figure 4-55: Trichrome staining of mouse colon. 
Trichrome staining of the middle part of the colon (day 28) was performed to visualize collagen 
deposition (blue staining, also the mucus in the goblet cells was stained in blue) in the colon wall. 
Upper panel: section of untreated mouse, lower panels: sections of DSS-treated WT and        
MMP-19 -/- animals. Collagen deposition is indicated by arrows. Representative pictures of two 
independent experiments are shown, magnification x 40. 
 
 
In addition staining for the expression of collagen type I, which is the most abundant 
collagen present in healing tissue and fibrosis, was performed. Fibrosis is developing due 
to injury or long-term inflammation. The tissues harden and the permeability decreases, 
which in case of the colonic mucosa is a disadvantage as it impedes the function of the 
colon. Consistent with the results of the trichrome staining, collagen type I was more 
abundant in the colon of the MMP-19-deficient mice (Figure 4-56). 
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Figure 4-56: Enhanced collagen type I expression in colon tissue of MMP-19-deficient animals. 
Collage type I (brown colour) colocalized with the trichrome staining. Collagen type I is the most 
abundant component in fibrotic tissue. Representative pictures of collagen type I immunostaining 
(magnification x 100) from WT and MMP-19 -/- mice are shown. 
 
 
4.4.6 Elevated levels of IL-1α and IL-6 but not TNF-α or IFN-γ in plasma of 
MMP-19-deficient mice during the chronic phase 
 
To compare the inflammatory response between DSS-treated wildtype and MMP-19 -/- 
mice, plasma cytokine and chemokine concentrations at day 28 were determined by 
BioPlex bead assay. Whereas the cytokine levels in plasma of the treated WT mice were 
not significantly different from those measured in the untreated control group, the IL-1α 
and IL-6 concentrations in plasma of the treated MMP-19-deficient animals were highly 
elevated (about 3-fold and 5-fold, respectively). However, TNF-α and IFN-γ levels 
remained largely unchanged (Figure 4-57A). Furthermore, the levels of several 
chemokines (MCP-1, G-CSF, and GM-CSF) were significantly higher in plasma of          
MMP-19 -/- mice than in WT ones (Figure 4-57B). No difference was found in levels of the 
chemokine KC. Concentrations of G-CSF in plasma of MMP-19 -/- mice were still as high as 
during the recovery phase, whereas the other chemokine levels decreased slightly  
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Figure 4-57: Cytokines and chemokines in plasma of healthy mice and mice suffering from 
chronic colitis. 
Cytokine (A) and chemokine (B) levels in plasma prepared on day 28 were determined by BioPlex 
bead assay. Data are represented as individual data points and mean of duplicate measurements 
(n = 2, WT and MMP-19 -/- mice in control group; n = 3, WT and MMP-19 -/- mice in DSS-treated 
group) * p < 0.05, ** p < 0.005. 
 
 
4.4.7 Elevated levels of pro- as well as anti-inflammatory cytokines in CEC 
supernatants of MMP-19-deficient mice 
 
In addition to elevated levels of cytokines in plasma, MMP-19-deficient mice depicted 
even higher values of pro- and anti-inflammatory cytokines in the supernatants of colon 
explant cultures (Figure 4-58). The levels of pro-inflammatory cytokines in WT animals 
were around normal values, they were just slightly elevated. Cytokines analyzed showed 
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clearly high levels of pro-inflammatory cytokines like IL-1 (α and β), IL-6, and IL-17 in 
MMP-19-deficent animals, the values for the MMP-19 -/- mice were in all cases more 
than two times higher than the WT ones. Especially levels of IL-17 that acts as a potent 
mediator in delayed-type reactions by increasing chemokine production to recruit 
monocytes and neutrophils to the site of inflammation were six times higher when 
compared to WT mice. All together, pro-inflammatory as well as anti-inflammatory 
cytokines are increased in the colonic tissue of MMP-19-deficient animals. Levels of IL-4 
and IL-10 are at least two times higher in the knockout mice. These cytokines are 
important in chronic inflammations and the healing process as they are major 
deactivators of activated, cytokine‐producing monocytes and macrophages.  
 
 
Figure 4-58: Cytokines in supernatants of colon explant cultures from healthy and colitic tissues. 
Cytokines analyzed by BioPlex bead assay showed elevated levels of pro-inflammatory cytokines 
such as IL-1 (α and β), IL-6, and IL-17 in MMP-19-deficent animals whereas the WT mice just 
showed slightly increased levels. Also anti-inflammatory cytokines like IL-4 and IL-10 were more 
elevated in MMP-19 -/- mice (A). n = 4, WT and MMP-19 -/- mice in control group; n = 4, WT and 
MMP-19 -/- mice in DSS-treated group), * p < 0.05, ** p < 0.005. 
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4.4.8 Increased levels of chemokines in CEC supernatants of                      
MMP-19-deficient mice 
 
The levels of chemokines in the CEC supernatants from wildtype mice returned in general 
to normal values or were slightly elevated. In contrast, the supernatants from MMP-19 -/- 
colons contained still extremely high levels of chemoattractants (Figure 4-59). 
Nevertheless, the levels of chemokines were lower than those in acute colitis. Peculiarly 
high amounts of MCP-1, and G-CSF were produced by MMP-19 -/- mice. G-CSF is 
produced by macrophages and then stimulates the bone marrow to release new 
granulocytes into the blood to fight inflammation; MCP-1 attracts macrophages. In case 
of MCP-1 there was only a tendency seen of more elevated levels in MMP-19-deficient 
than in WT mice. Levels of RANTES were three times higher in knockout animals than in 
WT. The synthesis of RANTES is induced by TNF-α and IL-1α, it is produced by circulating 
T-cells and plays an active role in recruiting leukocytes into inflammatory sites. In general, 
all addressed chemokines depicted similar levels as in the recovery experiment for   
MMP-19 -/- mice. Concentrations of chemoattractants in WT animals decreased in 
comparison to the recovery experiment, leading to less acute inflammation in the colon 
tissue. 
 
Figure 4-59: Chemokines in supernatants of colon explant cultures from healthy and diseased 
tissues. 
The levels of several chemokines (KC, MCP-1, MIP-1, G-CSF, and GM-CSF) were significantly higher 
in the supernatants of MMP-19 -/- mice than in WT ones. The values in the deficient animals were 
still extremely high. (n = 4, WT and MMP-19 -/- mice in control group; n = 4, WT and MMP-19 -/- 
mice in DSS-treated group) n.s. non significant, * p < 0.05, ** p < 0.005. 
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4.5 Fractalkine – a novel substrate of MMP-19 
 
Fractalkine (FKN, CX3CL1) is a unique chemokine combining adhesive and chemotactic 
properties. Its membrane-bound form promotes leukocyte adhesion, whereas its soluble 
form, generated by proteolytic ectodomain shedding, functions as a chemoattractant for 
cells expressing the receptor CX3CR1. The FKN-CX3CR1 system has been shown to play a 
major role in many inflammatory diseases such as atherosclerosis and rheumatoid 
arthritis [241; 242], and more recently, has also been implicated in IBD pathogenesis. At 
least two studies have reported an increase in circulating CX3CR1+ T cells in patients with 
IBD [243; 244], and it has also been demonstrated that CX3CR1+ cells are more abundant 
in IBD mucosa [244] and that FKN mRNA is upregulated in inflamed colonic tissues [243]. 
Moreover, a study by Kostadinova et. al has suggested a role for the CX3CL1-CX3CR1 axis 
in a DSS mouse model of colitis through regulation of iNOS [245].   
Since MMPs have emerged as major regulators of chemokine release, it seemed 
interesting to ask whether MMP-19 might have a role in leukocyte recruitment in IBD 
through processing of FKN. 
 
 
4.5.1 Purification of human recombinant MMP-19 
 
The MMP-19 fusion protein was generated and purified by using an N-terminal GST-tag. 
The expected size of the purified fusion protein was 85 kDa as detected by Coomassie 
staining and immunoblotting using an anti-MMP-19 antibody against the hinge domain of 
the protein (Figure 4-60A and B, arrowhead). The strong protein band of approximately 
40 kDa appearing in the Coomassie stained SDS-PAGE is a peptide composed of the         
N-terminal GST-tag and the propeptide domain of MMP-19, which is generated during 
purification due to autocatalytic activity of MMP-19 (Figure 4-60A).  
 
 
Figure 4-60: Purified recombinant MMP-19. 
(A) SDS-PAGE of purified GST-MMP-19 WT and Inactive mutant (EA). The full-length protein has a 
size of 85 kDa. (B) Immunoblot of recombinant MMP-19 proteins resulted as well in a signal at 85 
kDa. Taken from [246].  
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To test whether the purified wildtype protein was active a cleavage assay using a 
quenched fluorescence substrate (fluorogenic MMP-2 substrate, Calbiochem) was 
performed. In case of the active protein the quencher was released and an increase in 
fluorescence (RFU = relative fluorescent units) was detected. The activity was protein 
dependent and could be inhibited with an MMP inhibitor (MMP-9/MMP-13 inhibitor II, 
Calbiochem) (Figure 4-61). 
 
 
Figure 4-61: Determination of activity of recombinant MMP-19 WT protein. 
The buffer controls showed no increase in fluorescence (boxes), whereas the sample containing 
the recombinant MMP-19 depicted increasing RFUs. The activity was dependant on protein 
amount (triangles) and could be inhibited by a MMP inhibitor (x). 
 
 
4.5.2 MMP-19 degrades recombinant fractalkine 
 
To address the question if FKN can be processed by MMP-19, recombinant human FKN 
was incubated together with proteolytic active MMP-19 (GST-MMP-19 WT), or with an 
inactive mutant variant (GST-MMP-19 EA) at 37°C for 35h. The digests were then analyzed 
by immunoblotting. As shown in Figure 4-62A, FKN incubation with GST-MMP-19 WT 
resulted in the almost complete processing of the 90 kDa full-length form of the protein 
and the generation of at least three cleavage products of around 70, 20 and 15 kDa. In 
contrast, the inactive MMP-19 EA mutant was not able to process the chemokine. These 
findings suggest that FKN is a substrate of MMP-19 that can be cleaved by the protease at 
multiple sites. 
 
 
4.5.3 Reduced release of soluble fractalkine from colon of MMP-19-deficient 
mice 
 
To get further insight into the in vivo relevance of FKN-processing by MMP-19, colon 
tissue lysates as well as colon explant cultures were prepared and analyzed by 
immunoblotting, using antibodies against the N- or C-terminus of FKN. N-terminal 
detection revealed a fragment of about 40 kDa in colon tissue lysates of MMP-19 -/- mice 
which was virtually absent in lysates from WT animals (Figure 4-62B, upper panel). In 
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contrast, using antibodies against the C-terminus, a smaller fragment of about 25 kDa was 
detected in the WT lysates; this fragment was also present, although in lower amounts, in 
the MMP-19 -/- samples (Figure 4-62B, lower panel). Analyzing the concentrated 
supernatant of colon explant cultures (CECs), a soluble FKN variant of about 23 kDa was 
detected in all samples. However, considerably less protein was detected in the 
supernatants of the MMP-19 -/- mice (Figure 4-62C). 
Together, these results not only demonstrate that mouse colon constitutively expresses 
FKN at protein level, but moreover suggest that FKN expressed in colon is cleaved by 
MMP-19 to generate a soluble variant that likely has chemotactic activities. 
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Figure 4-62: In-vitro and ex-vivo processing of fractalkine (FKN) by MMP-19. 
(A) Western blot showing degradation of recombinant human FKN (carrier-free, CF) by an active 
form of MMP-19 (GST-MMP-19 WT). FKN protein was detected using an anti-FKN rabbit antibody 
serum raised against the N-terminal chemokine domain. Lane 1, 2.5 ng FKN; lane 2, 100 ng FKN in 
TCN buffer; lane 3, 100 ng FKN in TCN buffer plus GST-MMP-19 WT; lane 4, 100 ng FKN in TCN 
buffer plus an inactive mutant of MMP-19 (MMP-19 EA). The digest containing the active         
GST-MMP-19 WT protease (lane 3) but not the controls showed degradation of full-length FKN 
giving rise to at least 3 fragments of about 70, 20 and 15 kDa. (B) Immunoblotblot showing 
fractalkine expression in colon of healthy WT and MMP-19 -/- (19KO) mice. 30 μg of 
lysate/sample was loaded onto the gel. FKN protein was detected using antibodies against the 
extracellular N-terminus (upper panel) or the intracellular C-terminus (lower panel) of the 
molecule. Using N-terminal detection, a fragment of about 40 kDa was detected in the lysates of 
the MMP-19-deficient mice but not in those of the WT mice. In contrast, using the antibody 
against the C-terminus, a fragment of about 25 kDa was detected in all lysates, although the signal 
was stronger for those of the WT mice. (C) Immunoblot showing N-terminal detection of FKN in 
concentrated supernatants of colon explant cultures (CEC).  A clear signal for a soluble FKN variant 
of about 23 kDa is detected in the CEC supernatant of WT mice. Although present, the signal is 
much less prominent in case of the MMP-19 -/- mice.  
 
kDa 
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5 Discussion  
 
 
The etiology and the cascade of events leading to intestinal inflammation like IBD still 
remain unclear. Deregulation of MMP expression and activity has been associated with 
IBD and is thought to be a major factor in the development of colon inflammation and 
cancer, as administration of broad-spectrum metalloproteinase inhibitors reduced 
inflammation and disease severity in mouse models of colon injury [149; 150]. MMPs are 
thought to play a certain causative role in disease pathogenesis of IBD (Figure 5-1) [169; 
247]. Several MMPs such as MMP-2 and -9 are associated with tissue destruction and 
remodelling in the disease. The destructive effect of MMPs in the gut has been shown in 
several in vivo studies [168; 172; 248]. An exception is MMP-2, for which a protective 
influence was shown. Additionally, a function for many MMPs in immunity was reported 
[249].  
MMP-19 and MMP-28 are two metalloproteinases that are abundantly expressed in 
epithelial cells (Figure 5-1) and have been shown to be involved in cell proliferation, 
migration, and wound healing. In detail, MMP-19 and -28 are expressed in human colon 
in epithelium of the mucosa [131]. MMP-19 was detected in hyperproliferating 
keratinocytes [250] and it is thought that its presence particular in the cryptal epithelium 
of stromas [131; 251] may be associated with enterocyte proliferation and regeneration. 
Despite beeing constitutively expressed in normal tissues, MMP-19 -/-,  MMP-28 -/-, and 
even double-deficient  mice have no overt phenotype. This is in line with many other 
MMP-null mice. However, if mice are challenged in various mouse models (colitis, 
pneumonia, arthritis, dermatitis), a phenotype becomes obvious. MMPs exhibit 
redundancy in substrate specificity and cooperate in networks which are often activating 
but may also have destructive functions in order to limit the detrimental effects of their 
proteolytic activity. Therefore, this project aimed not only to investigate the single 
knockouts separately but also double-deficient mice to analyze their in vivo redundancy 
and substitutability. A lack of phenotype in unchallenged MMP-19- and MMP-28-deficient 
mice might implicate compensation by other MMPs. For example, in the MMP-19-
deficient mice we found an increase in the activity of gelatinases in acute colitis, which 
probably tries to rescue the loss of MMP-19. In case MMP-19 and -28 have a function in 
innate immunity, no phenotype will be displayed until the immune system is challenged. 
Nevertheless, little is known about the expression and function of MMP-19 and MMP-28 
in the intestine or the innate immune system. Therefore, it was the objective of this study 
to elucidate the role of MMP-19 and MMP-28 in intestinal homeostasis and inflammation 
using a mouse model of colitis.  
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Figure 5-1: Summary of different cell types producing MMPs and TIMPs in IBD.  
Luminal viruses, bacteria, or toxins can trigger immunological responses by activation of different 
cells such as macrophages, leucocytes and fibroblasts. These cells release several cytokines like 
TNF-α or IL-1. In addition activated cells can also release both MMPs and TIMPs. Inflammatory 
reactions can lead to an imbalance between MMPs and TIMPs followed by disturbing the ECM 
remodeling [130; 169; 252]. MMP-19 and -28 were included among the known proteinases and 
inhibitors. 
 
 
5.1 MMP-19 has a more pronounced protective effect in DSS-induced colitis than   
MMP-28 
Deficiency in the specific proteolytic activities in MMP-19 -/-, MMP-28 -/-, MMP-19/-28 
double-deficient mice do not per se affect the integrity of the gut mucosa, and there were 
no signs of spontaneous colitis. However, challenge with moderate concentrations of DSS 
resulted in development of acute colitis, thus pointing to a pivotal role of MMP-19 in the 
pathogenesis of induced colitis. To assess the healing process, mice were allowed to 
recover from the acute colitis. Chronic colitis was induced by two cycles of DSS 
administration. Untreated mice of all groups were used as controls. Also this model of 
colitis disclosed the critical role of MMP-19 alone, reflected in exacerbated inflammatory 
and destructive processes in the colon.  Moreover, in combination with MMP-28, the 
impact of MMP-19 on the acute as well as chronic course of the disease was even more 
pronounced and the double-deficient mice all died under conditions, in which the single 
knockout or control animals survived. The results clearly illustrated that in contrast to 
MMP-28-deficient mice, MMP-19-deficient animals show an increased susceptibility to 
acute and chronic DSS-induced colitis compared to the wildtype animals. However,  
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MMP-28-deficiency augments the effects of MMP-19 deficiency. Survival rates of       
MMP-19-deficient mice during acute and chronic colitis were significantly reduced. This 
correlates well with the strong colonic inflammation and tissue destruction, supported by 
high concentrations of chemokines (e.g. KC) and pro-inflammatory cytokines (e.g. IL-6,   
IL-1) in plasma and colon explant cultures. These findings point to a protective role for 
MMP-19 in colitis. 
Interestingly, mice deficient for both metalloproteinases, the MMP-19/-28 dbKO mice, 
developed even more severe symptoms leading to a dramatically reduced survival and 
abrogated recovering capacity from acute colitis. Regarding the phenotype of MMP-28-
deficient mice, a scenario may apply where an increase of MMP-19 activity overtakes 
most of the functions of MMP-28. This would be in line with results for gelatinase A and B, 
where MMP-9 is compensating for MMP-2 in the deficient mice [253].  
MMP-19 and MMP-28 have probably not completely overlapping functions or substrates. 
Although both proteinases are expressed by epithelial cells, they exhibit distinct impacts 
on the development of induced colitis. Whereas the loss of MMP-19 leads to a severe 
disease progression, the absence of MMP-28 does not cause a phenotype in spite of the 
concurrent deficiency of both proteinases where the mice exhibit dramatic susceptibility 
to DSS-induced colitis. Functions of MMP-19 cannot be replaced by MMP-28 in the 
deficient mice. In contrast it seems that MMP-19, and maybe also other MMPs, can 
substitute for MMP-28 as mice deficient in MMP-28 exhibit no changes in comparison to 
wildtype mice. Moreover, MMP-28 was described as an intrinsic negative regulator of 
macrophage recruitment by retarding the chemotaxis of these cells. This would lead to an 
early increase in macrophage recruitment into the lungs in a mouse model for pneumonia 
in MMP-28-deficient mice [219]. The same mechanism can apply in the DSS-induced 
colitis model, so that there is a fast protective response of macrophages to the injury and 
the invading bacteria and no differences could be detected in the outcome of the disease 
compared to witdtype mice. 
Another MMP that has a protective effect on colitis development is MMP-2 [172]. Similar 
to MMP-19, MMP-2 is constitutively expressed in intestinal and colon epithelia. In 
contrast to MMP-2, MMP-9 has a destructive effect on the course of colitis, and the 
extent and severity of intestinal epithelial injury was significantly attenuated in the 
deficient mice [248]. These opposite effects of MMPs expressed in both the epithelia and 
inflammatory cells suggest a complicated network, probably with a certain hierarchy, 
which balances the destructive and healing process in the colon. In this respect, it would 
be very useful to generate more such double and triple mutants to investigate the 
cooperative and overlapping functions of MMPs in the process of colitis development.  
As MMP-19-deficient mice show exacerbated destruction of colon in epithelium, deep 
ulceration and progressive fibrotic changes in chronic type of colitis, we suppose it is 
protective for certain homeostatic barrier functions. This is in line with increased FITC-
dextran translocation in these mice compared with WT counterparts. It was described in 
human and animal studies that epithelial dysfunction plays a central role in the 
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pathogenesis of intestinal inflammation [254; 255]. A similar barrier-maintenance 
function was described also in MMP-2 [172], MMP-7 [168], MMP-10 [256], or in ADAM-
17 (TACE) whose missing proteolytic activity in ADAM-17-deficient mice results in barrier 
leakiness [257]. This impact on barrier function and maintenance is probably not due to 
processing of basement membrane components as it might be in case of MMP-19, which 
is known to process laminin 5 2chain, nidogen-1, tenascin C, collagen type IV and some 
other ECM-proteins [185; 201; 202; 229].  
Evidence from human and animal studies as well as cell culture models suggest three 
major requirements essential for initiation and progression of IBD: First, disruption of the 
epithelial barrier by either a direct effect on the barrier or an impaired healing in 
response to injury. Second, the access of luminal contents to the lamina propria, resulting 
in interaction with immune cells. And third, an abnormal immune response of the 
organism [12; 254; 255]. Epithelial dysfunction is seen in patients much earlier than 
histological or clinical manifestations of IBD. It is thought that dysregulated barrier 
function allows contents of the intestinal lumen to enter the lamina propria, causing an 
immune response characterizing inflammatory diseases of the intestine. As the barrier of 
MMP-19-deficient mice was more severely damaged than the one of WT animals, it is 
likely that an enhanced contact between bacteria/luminal toxins and the host cells was 
the consequence. Our data show that barrier function is compromised in MMP-19 -/- 
mice, which possibly leads to their increased susceptibility to luminal toxins like DSS. 
There are several possible mechanisms by which MMP-19 might affect barrier function. 
One example is that MMP-19 modules tight junctions directly by associating with tight 
junction proteins. A similar mechanism as described for MMP-2, which binds to claudin 
[258; 259; 260], can also be applied to MMP-19. Claudins are proteins extensivly involved 
in barrier function [261; 262]. Overexpression of MMP-2 increases the barrier function 
(unpublished data, S.V. Sitaraman).  
MMP-19 is known to process collagen type IV, which is the major component of the 
basement membrane. The basement membrane is a thin sheet of fibres that underlies 
the epithelium and acts as a mechanical barrier. Cleavage of collagen type IV allows cells 
as well as chemokines to pass through the basement membrane to reach sites of tissue 
injury or inflammation in the up lying epithelium. 
Analyzing the findings from this study, i.e. experimental colitis in MMP-19- and          
MMP-28-deficient mice, and results from previously published work, it appears that 
MMP-19 may act via several molecular and cellular mechanisms: 1/ proliferation and 
survival of cells as it could regulate the IGF-signaling pathway and the necessary contact 
to ECM, which in turn is responsible for activation or quiescence of cell state [203; 263], 
2/ migration of keratinocytes and also other types of cells [200; 202; 203; 229], 3/ influx 
of inflammatory cells, especially macrophages that abundantly express this MMP, into 
inflammatory site (this study and [264]), 4/ vasculogenesis and angiogenesis [246], and 5/ 
bias of distribution and probably also development of immune cells [206].  
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5.2 MMP-19’s impact on epithelial healing process due to controlling proliferation and 
migration 
Cell proliferation is an important mechanism in maintaining tissue homeostasis and is 
especially needed in the healing phase following injury or inflammation. Dysregulated 
proliferation leads to impaired healing (reduced proliferation) and cancer development 
(increased proliferation). Under normal conditions no differences in proliferation of the 
epithelial cells was observed among the analyzed mouse strains. Upon DSS-challenge 
proliferation of epithelial cells in the colon mucosa was reduced in all mice, although 
MMP-19 -/- mice showed lower proliferation rates than counterpart wildtype mice. Even 
during the recovery phase, when an increase of dividing cells is expected and seen in 
wildtype mice, the MMP-19-deficient animals still showed decreased proliferation. This is 
likely one of the reasons for the impaired ability to recover from acute colitis and repair 
the damaged tissue in MMP-19 -/- mice. Re-epithelialization is the most crucial process 
[265]. Re-epithelialization during wound healing in the skin is impaired in MMP-19 -/- 
mice as they showed a slower kinetic at the beginning of this process (unpublished data, 
Dr. Radislav Sedlacek). Shedding of junctional proteins, which are required for re-
epithlialization is reported for MMP-7 and can be a way how MMP-19 develops its 
protective effect in injured tissue [123]. MMP-19 mediates beneficial functions in 
response to injury as its activity seems to be required for efficient repair of damaged 
epithelium and is likely to also control the transepithelial influx of neutrophils and 
macrophages across the colonic mucosa. 
 
Cell migration is a central process in the development and maintenance of tissues and 
cells often migrate in response to, and towards, specific external signals, a process called 
chemotaxis.  
At early stages of acute DSS-induced colitis, MMP-19-deficient mice showed significantly 
reduced numbers of neutrophils in the colon tissue when compared to wildtype mice. 
Neutrophils are an essential arm of innate immunity. However, an overload or chronic 
influx of these cells can cause severe damage. Whereas neutrophils were dispersed 
throughout the mucosa/submucosa in wildtype mice during the first days of colitis, they 
were not accumulating in the destroyed tissue in the MMP-19-deficient mice. Following 
the course of the disease, numbers of neutrophils did not change in the tissue of   
MMP19 -/- mice, whereas in the wildtype mice a strong increase at the beginning of the 
colitis was seen and at later time points the numbers decreased as expected. As 
neutrophils do not express MMP-19, the defect in transmigration into the inflamed tissue 
was probably a consequence of a lack of expression of an appropriate chemoattractant in 
the epithelial cells or, mechanically, their removal due to excessive damage. As colon 
damage was progressing, the WT mice appeared to actively recruit neutrophils to the site 
of injury, which was not observed in the MMP-19 knockout mice in the first part of acute 
colitis; the response of neutrophils and their recruitment into the colon wall was strikingly 
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delayed. Thus, MMP-19 seems to function as a mediator for neutrophil migration to 
wounded mucosa. 
Neutrophils migrate from the blood vessel into the interstitial tissue, following chemical 
signals such as IL-8 in human or KC and LIX in mouse and survive in the site of 
inflammation for 1–2 days. Once recruited, neutrophils kill bacteria through phagocytosis, 
release of soluble anti-microbial substances, and generation of neutrophil extracellular 
traps (NETs) [266; 267]. A massive, uncontrolled influx of neutrophils can cause 
indiscriminate, severe, and potentially mortal damage in experimental animal models, 
however, a lack of neutrophil activation can lead to unsolved inflammation caused by 
invading bacteria. 
The reduced recruitment of inflammatory cells, especially neutrophils, to the site of tissue 
injury and inflammation might be an effect of impaired matrix processing and fast 
removal of epithelial cells that, thus, cannot send appropriate chemokine signals or due 
to, for instance, lacking processing of certain chemokines, which are responsible for 
attraction these inflammatory cells. Nevertheless, later on in the chronic process, it 
appears that in MMP-19-deficient mice a persistent delivery of activation and 
chemoattractant signals does not allow to limit and resolve this overwhelming destructive 
reaction of neutrophils and other inflammatory cells.  
 
It was reported that macrophages abundantly express MMP-19 [175] as well as MMP-28 
[172]. MMPs are widely reported to affect leukocyte transmigration due to processing of 
ECM components. Macrophages express several MMPs such as MMP-1, -3, -7, -9, -12, and 
MT1-MMP, which degrade interstitial collagens and basement membrane proteins [268]. 
As it was reported that MMP-19 is expressed in macrophages and that its expression is 
upregulated upon adhesion [189] it is likely that this deficiency could affect the healing 
process. Our current investigations have shown that MMP-19-deficient mice exhibit 
reduced migration (not published) in a transmigration assay (Figure 5-2A). This result was 
confirmed in a mouse model of acute Zymosan-induced inflammation (Figure 5-2B) [264]. 
In contrast, this study does not show significant differences in numbers of macrophages 
in the inflamed colon during acute colitis as well as during the recovery. The reason for 
this discrepancy might be explained by the analyzed time points. The previous studies 
were only focused on much shorter time points, differences were detected 40h after 
induction inflammation with Zymosan (Figure 5-2B), whereas the analysis in case of the 
colitis experiment was performed at later time points (8 days). Differences in the 
migratory kinetic of macrophages from WT and MMP-19 -/- mice were compensated over 
time. However, there is clear sign of dysregulation of macrophage migration in peripheral 
blood and in spleen. Using flow cytometry, an increase in the amount of F4/80 positive 
cells (macrophages) was detected in blood and spleen of DSS-treated wildtype mice. In 
contrast, the MMP-19 -/- mice did not display any changes in numbers of macrophages 
upon DSS treatment. 
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Currently, the reason for this bias is not known; however, one important stimulus could 
be the processing of chemokines, which are responsible for attraction of macrophages 
such as MCP-1 or MIP-1.  
 
 
Figure 5-2: MMP-19 impacts cell migration. MMP-19 -/- macrophages showed reduced 
transmigration in vitro. Peritoneal monocytic cells including macrophages were isolated from WT 
and MMP-19 -/- mice, stained with calcein, and examined for their transmigratory capacity 
through a collagen type IV matrix using transwell systems. Fluorescence was measured before 
and 10h after seeding the cells. The pro-migratory stimulus in the lower chamber used was 
supernatant of 3T3 fibroblasts. Controls were done with unconditioned media (A). MMP-19 -/- 
macrophages showed reduced transmigration in vivo. MMP-19 -/- mice exhibit reduced migration 
of macrophages (F4/80+) to sites of inflammation in an air pouch model (B). **, p < 0.01  
 
 
5.3 Splenomegaly caused by the impaired healing process in MMP-19-deficient mice in 
later stages of colitis 
The spleen consists of two major compartments, the red pulp and the white pulp. The red 
pulp filters blood and its main purpose is the removal of parasites, dying red blood cells, 
and bacteria. It is also the site of haematopoiesis in rodents. The white pulp is the second 
largest lymphatic organ and initiates immune responses to blood-borne antigens [269]. 
Splenomegaly is the enlargement of the spleen and usually associates with anemia or 
congestion of the red pulp as well as severe bacterial infections.  
Strikingly enlarged spleens seen in MMP-19-deficient mice recovering from acute colitis 
and with chronic colitis as well as MMP-19/-28 double-deficient mice in the recovery 
phase. However, splenomegaly is more a consequence rather than a cause of colonic 
inflammation but it mirrors the severity of colitis. Deficiency in MMP-19 leads to 
persistent inflammation in the colon and a destroyed barrier towards the intestinal lumen, 
which allows a constant influx of bacteria in to the tissue. These bacteria translocate into 
the blood and finally reach the spleen, where they are engulfed by neutrophils and 
macrophages. Subsequently, the white pulp will be activated and B lymphocytes start to 
produce antibodies. The more bacteria and/or their contents accumulate in the spleen, 
the more neutrophils and macrophages will be present, too. Eventually, this can lead to 
acute sepsis (complex systemic inflammation due to infection). A stressed spleen cannot 
function properly and could be another reason for the impaired wound healing [270]. The 
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presence of enlarged spleens is consistent with published data where evidences are 
provided suggesting a role for secondary lymphoid tissues, such as spleen, to contribute 
to the initiation and/or perpetuation of ulcerative colitis. Also for the mouse model of 
DSS-induced colitis, which resembles UC, enlargement of the spleen was described. 
Several studies suggest a correlation between spleen size and severity of DSS-induced 
colitis [90; 271]. Splenectomy was found to have a protective effect at early stages in the 
DSS model [272]. 
Taken together, the splenomegaly in MMP-19- and MMP-19/-28 double-deficient mice is 
in line with the persistent inflammation in the colon and the destroyed barrier and 
supports the severity of the disease as well as the impaired healing process in these 
animals.  
 
5.4 Protective role of MMP-19 by mobilization of chemokines?  
MMPs have recently been shown to be important regulators of inflammatory responses, 
mostly by processing of specific proteins, resulting in a gain-of-function activity [273], loss 
of activity or generation of a receptor antagonist [274]. Those proteins include cytokines, 
chemokines and also antimicrobial peptides. For example, IL-1β can be activated by 
several MMPs (MMP-2, -3, and -9) [275] and MMP-7 and -12 have been reported to 
activate latent TNF-α in macrophages [118; 159; 276]. However, MMP activity can also 
result in deactivation: MMP-8 and MMP-9, for instance, have the capacity to cleave 
CXCL9/MIG and CXCL10/IP-10 at their C-terminus, rendering them functionally inactive 
[162]. Another example is processing of CXCL12/SDF-1 by MMP-2 in the central nervous 
system during HIV infection: The cleaved form of CXCL12 is not only chemotactically 
inactive but highly neurotoxic, and induces neuronal apoptosis and inflammation in mice 
[161; 277].  
Cleavage and activation of antimicrobial peptides is reported for MMP-7 [166; 278]. It 
was shown that proteolytic processing of α-defensins results in results in acquisition of 
defensin activity, thus, the ability to kill bacteria. MMP-7-deficient mice have an impaired 
ability to battle enteric pathogens due to a lack of mature defensins.  
In vivo, chemokines are generally immobilized on the ECM or cell membrane through 
interactions with glycosaminoglycans (GAG) [279]. Several MMPs have been identified, 
which have the capacity to resolve these interactions and to release the active soluble 
form of the chemokine. This process, also termed ‘unmasking’ of chemokines [115], has 
been well described for the neutrophil-specific MMP-8 (collagenases 2), which cleaves the 
N-terminus of both CXCL8/IL-8 and LIX to enhance chemotactic potency. Indeed, MMP-8 
null mice showed impaired recruitment of PMNs in an LPS-induced inflammation model, 
indicating the high specificity and relevance of MMP-8 in the immune response [117]. 
Other in vivo studies have demonstrated a role for MMP-2 and MMP-9 in mobilization of 
CCL11/eotaxin, CCL7/MCP-3 and CCL17/TARC [280].  
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Besides cytokines, MMPs can process chemokines making them more or less potent or by 
generating chemoattractant peptides from precursor proteins [121; 281]. A well 
investigated example is CXCL8 (human IL-8) [162] and LIX where the N-terminal part is 
cleaved by MMP9 and 8. This cleavage results in more potent chemoattractant activity 
than the full-length protein. MMPs can also affect chemokine gradients by shedding 
accessory proteins that bind or restrain chemokines, which was observed for MMP-7 
shedding a transmembrane-complex of syndecan-1 and KC [124]. 
In the present study, MMP-19-deficient mice produced extremely high concentrations of 
various cytokines and chemokines, although the amount of inflammatory cells in the 
colon tissue was reduced in comparison to the wildtype mice. Colon explant culture 
supernatants of wildtype and MMP-19 -/- were used in a migration assay using mouse 
macrophages to investigate the chemoattractive activity of the mixture. Macrophages 
were migrating faster to supernatants of MMP-19 -/- colon tissue, concluding the 
released mixture of cytokine and chemokines to be biologically active. However, no 
conclusion could be drawn for a specific molecule, which was not activated by processing 
of MMP-19 as only the total supernatant was analyzed. We suggest that the protective 
effect of MMP-19 in colitis could be explained by a cleavage process leading to an 
activated signalling molecule as described for other MMPs. We propose, MMP-19 cleaves 
KC or LIX (the murine homologues for IL-8) and therefore increases the chemotactic 
activity, leading to an increased recruitment of neutrophils to the site of inflammation. KC 
and LIX are potent chemoattractants for neutrophils in mice, they especially act in early 
stages of inflammation to rapidly bring neutrophils to the site of inflammation. This 
hypothesis is in line with the decreased influx of neutrophils in MMP-19-deficient mice 
(Figure 5-4). Another mechanism of the protective effect of MMP-19 is the cleavage of 
antimicrobial peptides such as defensins, which would result in their activation and a 
result reduce the amount of infiltrating bacteria into the tissue, thus, inflammation. 
 
5.4.1 MM-19 dependent processing of Fractalkine – protective role in IBD? 
This study has also shown by in vitro cleavage assays as well as Western blot analysis of 
colon tissue lysates and colon explant culture (CEC) supernatants that MMP-19 can 
proteolytically cleave fractalkine (FKN, CX3CL1), a chemokine associated with IBD 
pathogenesis (Figure 5-3).  FKN is expressed as a membrane-bound molecule and requires 
shedding from the cell surface to become chemotactically active. ADAM10 and ADAM17 
(TACE) have been shown to mediate constitutive and PMA-induced cleavage of FKN to 
release a soluble form that attracts cells expressing the cognate receptor CX3CR1 such as 
macrophages and neutrophils [282]. The chemokine is up-regulated in a synergistic 
fashion by the pro-inflammatory cytokines TNF-α and IFN-γ, and elevated levels have 
been implicated in various inflammatory diseases such as atherosclerosis, rheumatoid 
arthritis and psoriasis. A study by Muehlhoefer et al has demonstrated that FKN is also 
expressed by intestinal epithelial cells and that a subpopulation of human intestinal 
intraepithelial lymphocytes expressed the receptor CX3CR1 [283].  
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In this study it was shown that colon tissue samples of wildtype mice release substantial 
amounts of a soluble FKN variant in the culture supernatant that was much reduced in 
samples of MMP-19-deficient mice. From this, one may assume an impaired capacity of 
the proteinase deficient mice to attract neutrophils and macrophages to the site of injury, 
a hypothesis that is in line with the diminished numbers of those cells seen in the 
inflamed colon tissue of the MMP-19 -/- animals. 
We therefore propose a beneficial effect of MMP-19 through processing of colon-
expressed FKN and the resulting recruitment of cells important for the wound healing 
process.  Interestingly, it was reported that also the FKN receptor CX3CR1 is expressed on 
intestinal epithelial cells and that FKN can act in an autocrine fashion to induce the 
production of IL-8 in the colon epithelium via the ERK-1/2 signaling pathway [284]. IL-8 in 
turn is the master chemokine for attraction of neutrophils so the protective effect of FKN 
could well be an indirect one through promoting the synthesis of IL-8. This process is 
likely to be impaired in MMP-19-deficient mice as those cannot efficiently produce the 
soluble FKN variant required to induce receptor-mediated signalling (Figure 5-3 and 5-4).  
We also suggest that the cleavage product generated by MMP-19 (Figure 5-3) might be 
more potent in signaling than the longer soluble form which is generated by ADAM17 
(TACE), which cleaves fractalkine close to the membrane [285] and the long glycosylated 
stalk could not probably freely move as the short chemokine domain released by MMP-19. 
MMP-19 might be a proteinase responsible for constitutive shedding of fractalkine as it is 
expressed under normal conditions in many tissues. The cleavage of FKN and attraction of 
macrophages to the site of inflammation in the colon could be therefore faster in 
wildtype mice and is delayed in MMP-19-deficient animals as it has to be induced. The 
soluble CX3CL1 recruits bone-marrow derived monocytes/macrophages to the site of 
inflammation and their subsequent activation. 
 
Figure 5-3: MMP-19 activity generates a soluble form of fractalkine.  
Schematic representation. As Western blot and in vitro cleavage assays suggest (see 4.5.2 and 
4.5.3), endogenous MMP-19 processes colon-expressed fractalkine to release a soluble variant of 
about 22 kDa, which is detectable in the supernatants of colon explant cultures. The remaining 
membrane-bround fractalkine fragment is detectable in colon tissue lysates and has a size of 
about 25 kDa. Opposed to human fractalkine expressed on endothelial cells, colon-expressed 
murine homolog appears to be much less glycosylated as it migrates at a lower molecular mass in 
SDS-PAGE (hFKN, ~90 kDa versus mFKN, ~45 kDa). 
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Figure 5-4: Schematic representation of suggested influence of MMP-19 on the chemoattractant 
KC or LIX.  MMP-19 generates high concentrations of active KC or LIX by either processing the 
chemokine itself, leading to an increase in chemotactic activity (1) or via the processing of CX3CL1 
to its soluble form, which promotes synthesis of KC/LIX (2). Modified from [286]. 
 
 
As MMP19-deificient mice showed profound effects on the development of colitis, and as 
these effects included altered influx of inflammatory cells and biased distribution and 
ratio of macrophages and T-cells, it is likely that MMP-19 also processes some of the 
cytokines and chemokines or accessory proteins. An addition to the release of the 
fractalkine chemotactic domain (or processing the molecule), further work should identify 
the substrates from these extracellular regulatory molecules. In this context, pilot 
experiments have shown that MMP-19 may process syndecan-4 and SDF-1 (not 
published) and could also release VEGF from its ECM stores.  
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5.5 MMP-19 deficiency leads to development of fibrosis in chronic colitis 
Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a 
reparative or reactive process. In case of fibrosis of the intestine, a thickening of the 
bowel wall can be observed due to increased amounts of collagens, mostly collagen type I. 
Fibrosis is one of the major symptoms in Crohn’s disease [287] and can be viewed as an 
excessive healing response to constantly injured tissue. 
We show that development of fibrosis in the MMP-19-deficient mice suffering from 
chronic colitis, whereas wildtype mice were healthy. Accumulation of collagen fibres was 
visualized by Masson Trichrome staining suggesting that MMP-19 -/- animals suffer from 
persistent inflammation throughout the treatment and partially also in the course of the 
recovery phase. The CD-like phenotype of these mice was supported by the fact that high 
concentrations of Th1 cytokines were detected in plasma (IL-1, IL-6) as well as in CEC 
supernatants (TNF-α, IFN-γ, IL-1, IL-6) of the mice. The elevated levels of acute phase 
cytokines like IL-6 in plasma indicate a systemic inflammatory response to chronic DSS-
treatment. We conclude that by the deletion of MMP-19 we established an imbalance 
between MMPs and TIMPs, which is then contributing to collagen deposition and end up 
in fibrosis. In this regard, it is also important that MMP-19 is expressed also in healthy 
epithelium and, thus, its deficiency might already cause certain vulnerability of the barrier 
and predispose mice for exacerbated immune response. 
The development of fibrosis upon multiple cycles of DSS treatment is well known and it is 
dependent on the mouse strain, for example C57BL/6 mice develop chronic colitis, 
whereas Balb/c do not [106]. Chronic DSS colitis shares some common features with CD, 
including activation of T and B cells, induction of T cell-derived cytokines, prominent 
lymphoid aggregates, and fissuring ulcerations [288]. The injury causes activation of 
mesenchymal cells with increased capability for ECM synthesis [289]. In fibrosis, 
mechanisms to degrade ECM are not working physiologically and the number of 
fibrogenic cells is not only maintained but also expand. Mechanisms regulating these 
effects are unknown but may include factors associated with CD, such as Th1 cytokines or 
transmural inflammation [290] or imbalance of MMPs and TIMPs [291].  
Colon explants of MMP-19-deficient mice secreted enormous high concentrations of 
monocyte chemoattractant protein 1 (MCP-1) during the chronic phase of DSS-induced 
colitis. This could be part of the induction of the fibrotic process in MMP-19-deficient 
mice. The process starts with the accumulation of collagens in the inflamed tissue, which 
cannot be degraded in the knockout mice, at least the non-fibrillar collagens or degraded-
fibrillar collagens, and this effect is amplified by the continuous inflammation due to 
impaired healing and the release of high amounts of MCP-1. 
Increased levels of MCP-1 are in agreement with patient studies and revealed an increase 
in MCP-1 in inflammatory bowel disease (IBD), it is especially increased in the submucosa 
of CD patients [292; 293]. Mouse studies demonstrated that overexpression of MCP-1 
induces a fibrogenic response [294] in the colon tissue. The mechanisms regulating MCP-
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1-induced fibrosis include enhanced infiltration of lymphocytes and interaction between 
lymphocytes and fibroblasts/myofibroblasts and upregulation of TGF-b and TIMP-1. 
The development of fibrosis causes problems in the re-epithelialization in the gut as the 
tissue hardens and cells are not able to migrate properly, leading to a decreased ability to 
remodel the architecture of the mucosa. The decreased ability of MMP-19-deficient 
macrophages to migrate and, thus, to remove or repair the provisional ECM could be also 
important in the fibrogenic process. 
 
 
In conclusion, MMP19 -/- mice show higher susceptibility to DSS-induced colitis 
accompanied by strongly reduced proliferation of epithelial cells and decreased influx of 
inflammatory cells important for inflammatory reaction, despite increased concentrations 
of pro-inflammatory cytokines and chemokines. Thus, MMP-19 is involved in stimulating 
acute inflammation in DSS-induced colitis. However, this phenotype is even more 
pronounced in the MMP-19/-28 double-deficient mice. 
Functional loss of MMP-19- activity shows that this MMP plays a crucial role in the 
severity of colitis. However, further studies are required to delineate the precise 
mechanism by which MMP-19 alone or in combination with MMP-28, or another MMP, 
are involved in intestinal inflammations and homeostasis. These future investigations 
have to be performed in order to elucidate the function of MMP-19 and MMP-28 in 
distinct cell types, tissues, and cell signaling processes. Analysis of neutrophil and 
macrophage chemotaxis to various recombinant chemokines may prove useful for further 
identification of chemokines and their receptors as novel substrates. 
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6 Summary 
 
The present study investigates the role of two matrix-metalloproteinases, MMP-19 and 
MMP-28, in intestinal homeostasis and inflammation by means of a mouse model for 
inflammatory bowel disease (IBD). Based on previous experiments, the two proteinases 
have been implicated in cell proliferation and migration, remodelling of extracellular 
matrix, and wound healing. However, their in vivo function has remained largely elusive. 
Acute or chronic colitis was induced in wildtype, MMP-19, and MMP-28 single-deficient 
as well as MMP-19/-28 double-deficient mice by dextran sulfate sodium (DSS). Moreover, 
the wound healing process was analyzed in a recovery phase following the acute colitis. 
Throughout the experiments, parameters of disease development and severity such as 
body weight loss, bleeding, stool consistency, and survival were monitored. These basic 
parameters were followed by histological analysis of colon and spleen tissues and 
pathological assessment of inflammation and symptoms of tissue destruction. Analysis of 
cytokine and chemokine release in plasma and in supernatants of colon explant cultures 
supported the investigations. Flow cytometry analysis was used to access possible bias of 
leukocyte subpopulations in peripheral blood and spleen. Finally, investigations into a 
potentially new MMP-19 substrate were carried out. 
One of the major findings of this study is that in contrast to wildtype mice MMP-19-
deficient mice showed an increased susceptibility to acute and chronic DSS-induced colitis 
accompanied by impaired healing process compared to the wildtype animals. Survival 
rates during acute and chronic colitis were significantly reduced, colonic inflammation 
and tissue destruction were markedly enhanced, and chemokine (e.g. KC) and pro-
inflammatory cytokine (e.g. IL-6, IL-1) concentrations in plasma and colon explant cultures 
were highly elevated. Peripheral blood of MMP-19 -/- mice suffering from acute colitis 
contained significantly increased numbers of granulocytes whereas CD3+ T cells were 
dramatically reduced. During chronic colitis, the mice developed additional symptoms 
such as splenomegaly and colonic fibrosis. In contrast, the MMP-28-deficient mice show 
only moderate signs of disease and behaved similarly to the DSS-treated wildtype group 
in all experiments. Strikingly, the MMP-19/-28 double-deficient mice showed the most 
severe phenotype in acute colitis and during the recovery, which was reflected in very 
poor survival rates and impaired wound healing in the surviving animals.  
Finally, it was demonstrated that MMP-19 processes fractalkine (CX3CL1), a membrane-
bound chemokine that has been associated with IBD and which, in its soluble form, 
attracts monocytes and T cells. In vitro as well as ex vivo studies were performed to reveal 
the capacity of MMP-19 to process fractalkine to a soluble form. This missing proteolytic 
activity in MMP-19-deficient mice might explain the late influx of inflammatory cells in 
the acute phase of colitis. 
In conclusion, this study provides several lines of evidence for a pivotal role of MMP-19 
and MMP-28 in maintenance of intestinal tissue homeostasis. The data suggest that loss-
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of-function of MMP-19 results in an increased susceptibility to colonic inflammation, 
mediated by an exacerbated innate immune response and inability of colonic tissue to 
heal. Mobilization of chemokines to facilitate migration of immune cells crucial for wound 
healing, e.g. macrophages, is a potential mechanism by which MMP-19 could exhibit its 
function. In this respect, the identification of fractalkine as a potential novel substrate of 
MMP-19, could pave the way for further functional studies. 
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7 Zusammenfassung 
 
Die vorliegende Arbeit untersucht die Bedeutung der Metalloproteinasen MMP-19 und 
MMP-28 in entzündlichen Darmerkrankungen mittels eines Mausmodels. Bisherige 
Studien haben gezeigt, dass beide Proteinasen mit Zellproliferation, Erneuerung 
extrazellulärer Matrix und Wundheilung asoziiert sind. Über ihre in vivo-Funktionen ist 
jedoch nur wenig bekannt. 
Akute oder chronische Kolitis wurde in Wildtyp-Mäusen, MMP-19- und MMP-28-einfach 
defizienten sowie MMP-19/-28 doppelt-defizienten Mäusen induziert, indem den Tieren 
eine 2%ige Dextran Natriumsalz (DSS)-Lösung als Trinkwasser verabreicht wurde. Der 
Wundheilungsprozess wurde in einer separaten Phase analysiert, in der sich die Mäuse 
von den Krankheitssymptomen erholen konnten. Im Verlauf der Experimente wurden 
Krankheitsparameter wie Körpergewichtsverlust, Blutungen, Stuhlkonsistenz und 
Mortalität gemessen. Zusätzlich wurden Gewebeschnitte von Darm und Milz auf 
Entzündungszeichen und Läsionen untersucht. Weiterhin wurden Zytokin- und 
Chemokinkonzentrationen im Blutplasma der Tiere sowie in Überständen von 
Darmgewebekulturen bestimmt. Durchflußzytometrie wurde verwendet, um mögliche 
Veränderungen in der Zusammensetzung der Leukozyten im Blut oder der Milz zu 
erfassen. Schließlich wurden Untersuchungen zu einem potentiell neuen Substrat der 
MMP-19 durchgeführt. 
Ein Hauptergebnis der Studie ist, dass im Gegensatz zu Wildtyp-Mäusen, MMP-19-
defiziente Mäuse eine höhere Anfälligkeit aufweisen, an der DSS-induizierten Kolitis zu 
erkranken. Dies wurde in einem verschlechterten Heilungsprozess, signifikant geringeren 
Überlebensraten sowie ausgedehnter Darmentzündung und -schädigung deutlich. 
Weiterhin wurden im Blutplasma sowie den Überständen der Darmgewebekulturen stark 
erhöhte Konzentrationen an Chemokinen (z.B. KC) und entzündungsfördernden Zytokinen 
(z.B. IL-6 und IL-1) gemessen. In dem Blut der an akuter Kolitis leidenden MMP-19 -/- 
Mäusen wurde zudem eine signifikant erhöhte Anzahl von Granulozyten festgestellt, 
wohingegen die Anzahl der T-Zellen dramatisch reduziert war. Im Verlauf der chronischen 
Kolitis entwickelten die Mäuse zusätzliche Krankheitssymptome wie z.B. eine 
Vergrößerung der Milz und Fibrose im Kolon. 
Im Gegensatz zu den MMP-19-defizienten Mäusen wiesen die MMP-28-defizienten Tiere 
nur milde Anzeichen einer Erkrankung auf und verhielten sich während der gesamten 
Experimente im Wesentlichen wie die Wildtyp-Mäuse. Bemerkenswerterweise zeigten die 
MMP-19/-28 doppelt-defizienten Mäusen in der akuten Kolitis den gravierensten 
Krankheitsverlauf, was in reduzierten Überlebensraten und einer stark eingeschränkten 
Wundheilung zum Ausdruck kam. Schließlich konnte gezeigt werden, daß Fraktalkin 
(CX3CL1), ein membranständiges Chemokin, das mit der Entstehung entzündlicher 
Darmerkrankungen assoziiert wird und in seiner löslichen Form chemotaktisch auf 
Monozyten und T-Zellen wirkt, von MMP-19 prozessiert wird. Die Entstehung einer 
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löslichen Form wurde sowohl in vitro als auch ex vivo  nachgewiesen. Dieser Mangel an 
proteolytischer Aktivität in den MMP-19-defizienten Mäusen kann erklären, warum hier 
die Entzündungszellen erst in der späten Phase der akuten Kolitis in den Darm 
einwandern.  
Zusammengefaßt liefert diese Arbeit mehrere Hinweise, dass MMP-19 und MMP-28 eine 
wichtige Rolle in der Aufrechterhaltung eines gesunden Darmmilieus einnehmen. Die 
Daten lassen darauf schließen, dass der Verlust der MMP-19-Aktivität die Anfälligkeit für 
entzündliche Darmerkrankungen erhöht und dies vermutlich in einer Überreaktion des 
angeborenen Immunssystmes und einer eingeschränkten Wundheilung begründet ist. Die 
MMP-vermittelte ‚Mobiliserung’ von Chemokinen, welche die Migration von 
heilungsfördernden Immunzellen wie z.B. Makrophagen ermöglichen, ist ein denkbarer 
Mechansimus für die Funktionsweise von MMP-19. In dieser Hinsicht kann die 
Identifikation von Fraktalkin als mögliches neues Substrat von MMP-19 den Weg für 
weitergehende Studien ebnen. 
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9 Appendix 
 
Table 9-1: Genetic association with Crohn’s disease and ulcerative colitis.  
Adapted from [51]. 
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Table 9-2: List of MMPs and their substrates. 
Matrix metalloproteinases, systematically listed with their trivial description and substrates. 
Families of MMPs are listed by their proteolytic activity: collagenases, gelatinases, stromelysins, 
matrilysins, MT-MMPs, and other MMPs. Adapted from C. Overall’s web page  
(www.clip.uba.ca/archive/mmp_timp_folder/). 
 
Systematic name Trivial description Matrix substrates Non-matrix substrates 
    
Collagenases    
MMP-1 Collagenase-1 collagen type I-III, VII, X, MCP-1, -3, -4, SDF-1, proIL-1β, 
  gelatin, aggrecan, proTNF-α, proMMP-2, 
  nidogen, tenascin, 
IGFBP-2, -3, α2-
macroglobulin,  
  perlecan α1-proteinase inhibitor 
    
MMP-8 Collagenase-2 collagen type I-III, VII, X, MCP-1, L-selectin,  
 neutrophil collagenase gelatin, aggrecan, proTNF-α, proMMP-8, 
  nidogen, tenascin, α2-macroglobulin,  
   α1-proteinase inhibitor 
    
MMP-13 Collagenase-3 collagen type I-III, VII, X, MCP-3, SDF1,  
  gelatin, aggrecan, proTNF-α, proMMP-9, 
  nidogen, tenascin, α1-antichymotrypsin 
    
MMP-18 Collagenase-4 collagen type I-III,  
 xCol4 (only in Xenopus) gelatin  
        
Gelatinases    
MMP-2 Gelatinase A collagen type I, IV, V, VII, X, XI, MCP-3, SDF-1, proIL-1β,  
 72 kDa-gelatinase gelatin, elastin, laminin5, proTNF-α, IGFBP-3, FGFR-1, 
  fibronectin, brevican, proTGF-α1, endothelin-1,  
  decorin, vitronectin, aggrecan 
galectin-3, proMMP-1 and -
13, 
   α2-macroglobulin,  
   α1-proteinase inhibitor 
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MMP-9 
 
Gelatinase B 
 
collagen type I, IV, V, VII, X, XI, 
 
SDF-1, Gro-α, proTNF-α,  
 92 kDa-gelatinase elastin, fibronectin, laminin, 
proTGF-β, IL-2Rα, 
plasminogen, 
  aggrecan, vitronectin 
galectin-3, proMMP-9 and -
13, 
   α2-macroglobulin,  
   α1-proteinase inhibitor 
        
Stromelysins    
MMP-3 Stroelysin-1 collagen II-V, IX, X, proMMP-1, -7, -8, -9, -13 
 Proteoglycanase gelatin, aggrecan, laminin, α2-macroglobulin,  
  
fibronectin, nidogen, 
tenascin, α1-proteinase inhibitor 
  perlecan, elastin, vitronectin, α1-antichymotrypsin 
  fibrin/fibrinogen  
    
MMP-10 Stromelysin-2 gelatin type I, III, IV, V, proMMP-1, proMMP-8 
  fibronectin, proteoglycan  
    
MMP-1 Stromelysin-3 fibronectin, laminin, IGFBP-1, α2-macroglobulin,  
  aggrecan α1-proteinase inhibitor 
        
Matrilysin    
MMP-7 Matrilysin 
non-helical collagen IV, V, IX-
XI, α-defensin, proTNF-α,  
 PUMP-1 laminin, gelatin, fibronectin, plasminogen, FasL, 
  aggrecan, nidogen, tenascin, E-cadherin, β4 integrin,  
  vitronectin, fibrin/fibrinogen proMMP-1, -2, -9, 
   α1-proteinase inhibitor, 
   α2-macroglobulin,  
    
MMP-26 Matrilysin-2 collagen type IV, fibronectin, IGFBP-1, proMMP-9, 
 Endometase gelatin, fibrin/fibrinogen α1-proteinase inhibitor 
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MT-MMPs    
MMP-14 MT1-MMP collagen I-III, gelatin,  
MCP-3, SDF-1, CD44,  proTNF-
α, 
  aggrecan, 
proMMP-2, α2-
macroglobulin,  
  fibronectin, vitronectin α1-proteinase inhibitor, 
   tissue transglutaminase 
    
MMP-15 MT2-MMP proteoglycans proTNF-α, proMMP-2 
   tissue transglutaminase 
    
MMP-16 MT3-MMP collagen type III, fibronectin proTNF-α, proMMP-2 
   tissue transglutaminase 
    
MMP-17 MT4-MMP gelatin, fibrin/fibrinogen proTNF-α, proMMP-2 
    
MMP-24 MT5-MMP gelatin, fibronectin, proMMP-2 
  proteoglycans  
    
MMP-25 MT6-MMP collagen type IV, gelatin,  proMMP-2, proMMP-9 
  
laminin, fibronectin, 
fibrinogen, α1-proteinase inhibitor 
  proteoglycans   
    (chondroitinsulfate)   
other MMPs    
MMP-12 Metalloelastase elastin, fibronectin, laminin, proTNF-α, plasminogen 
 Macrophage elasrase proteoglycans, α1-proteinase inhibitor 
  fibrin/fibrinogen  
    
MMP-19 RASI collagen type IV, gelatin, IGFBP-3, VEGF, plasminogen 
 Stromelysin-4 fibronectin, nidogen tenascin,  
  aggrecan, COMP,  laminin,  
  fibrin/fibrinogen  
MMP-20 Enamelysin amelogenin, aggrecan, COMP not determined 
    
    
APPENDIX 155  
MMP-21 XMMP (Xenopus) not determined not determined 
MMP-22 CMMP (chicken) not determined not determined 
MMP-27 human homologue not determined not determined 
    
MMP-23 CA-MMP gelatin not determined 
 (cystein-array-MMP)   
    
MMP-28 Epilysin casein, NCAM not determined 
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Table 9-3: Chemokines systematically listed including their trivial description. 
Families of chemokines classified by arrangement of cysteins (C) in their sequence are grouped 
(CXC, CX3C, and CC chemokines). Only chemokines mentioned in this work are mentioned. 
 
Systematic name Trivial description 
(human) 
Trivial description 
(mouse) 
CXCL1 Gro-α KC 
CXCL2 Gro-β MIP-2α 
CXCL3 Gro-γ MIP-2β 
CXCL5 ENA-78 LIX 
CXCL8 IL-8 Unknown 
CXCL9 MIG MIG 
CXCL10 IP-10 IP-10 
CXCL11 I-TAC/IP-9 I-TAC 
CXCL12 
CXCL13 
SDF1α 
BLC 
SDF1α 
BLC 
CXCL16 SRPSOX SRPSOX 
   
XCL1 Lymphotactin-α/ATAC Lymphotactin-α 
XCL2 Lymphotactin-β Lymphotactin-β 
   
CX3CL1 
 
Fractalkine Fractalkine/neurotactin 
CCL1 I-309 TAC-3 
CCL2 MCP-1 MCP-1 
CCL3 MIP-1α MIP-1α 
CCL4 MIP-1β MIP-1β 
CCL5 RANTES RANTES 
CCL7 MCP-3 MCP-3 
CCL8 MCP-2 MCP-2 
CCL9 unknown MIP-1γ 
CCL11 Eotaxin Eotaxin 
CCL12 MCP-5 MCP-5 
CCL13 MCP-4 MCP-4 
CCL17 TARC TARC 
CCL19 MIP-3β MIP-3β 
CCL20 MIP-3α MIP-3α 
CCL24 Eotaxin-2 Eotaxin-2 
CCL25 TECK TECK 
CCL27 CTACK CTACK 
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List of primers 
 
Genotyping 
MMP-19 
WT forward: m1-U10, 5’-CCGCATCTTCAATGTGCCC-3’ 
WT reverse: mD1-21, 5’-GATCGCCAGGTTCACTCC-3’ 
KO forward: m1-U3, 5’-AGATGGATGACGCCACAAG-3’ 
KO reverse: neofwd, 5’- CTTCTATCGCCTTCTTGACG-3’ 
 
MMP-28 
WT forward: Epi WT, 5’-GTGAAGATGTCCCATGCCCACAGT-3’ 
KO forward: MMP28 KO For, 5’-GCTGACCGCTTCCTCGTGCTTTAC-3’ 
WT and KO reverse: MMP28 rev common, 5’-AGGGCCCTCTTTCATCTTCCTGATG-3’ 
 
RT-PCR 
mGAPDH 
mGAPDH_RT_F:    5’-AACTTTGGCATTGTGGAAGG-3’  
mGAPDH_RT_R:  5’-GTCTTCTGGGTGGCAGTGAT-3’ 
 
mMMP19 
mMMP19_RT_F3: 5’-ATCTTCAATGTGCCCTCCAC-3’ 
mMMP19_RT_R3: 5’-CCACGCTGCTCCAGTACTTA-3’ 
 
mMMP28 
mMMP28_RT_F3: 5’-CCTGTACGGAAAGCCTCTGG-3’ 
mMMP28_RT_R3: 5’-GTCTGCTCTGGGAGTTGTGG -3’          
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Figure 9-1: Blood scores of all colitis experiments.
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